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Abstract 
 
An ever increasing incidence of diabetes has resulted in an epidemic of chronic 
wounds.  Few therapies effectively promote wound healing, and thus, health care 
budgets are faced with an unsustainable burden and patients with poor quality of life.    
Recently, the isoleucine-glycine-aspartic acid (IGD) tripeptide motif of Migration 
Stimulating Factor (MSF) has been found to be responsible for the wound healing 
properties of this protein.  Modelling studies of the IGD motif of MSF have lead to the 
design and synthesis of a benzodiazepinone core, which displays wound healing 
properties in vitro and in vivo.  This thesis discusses the optimisation of the synthetic 
route to this exciting IGD peptidomimetic and investigations into the activity and the 
method of action of this molecule through scratch assays and qRT-PCR studies.   
 
Analogues of this benzodiazepinone with varying synthetic handles have been 
developed and used to tag the active bicyclic core with desired technologies. In one 
such example, BODIPY tagging and confocal microscopy allowed the investigation of 
fibroblast uptake of the BODIPY IGD peptidomimetic.  An IGD peptidomimetic with a 
triethylene glycol synthetic handle has been developed for increased hydrophilicity 
and is envisioned to be used in the development of a therapeutic hydrogel. 
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1.0 Introduction 
1.1 Wound Healing  
Impaired wound healing is a significant cause of morbidity and mortality for a large 
proportion of the population.  With the ever increasing incidence of diabetes and other 
diseases that blight wound healing it is now believed that 1% of the European 
population are affected by chronic wounds and that 2% of health budgets are devoted 
to their care.[1] [2]    Patients with chronic wounds suffer from a significant decrease in 
quality of life, however, to date the choice of wound healing promoting drugs can be 
described as limited at best. [2] 
1.1.1 Physiological Wound Healing   
There are four overlapping phases of normal healing: haemostasis; inflammation; 
migration proliferation and remodeling (Figure 1.1.1).[3]   
1.1.2 Haemostasis and Inflammation 
Haemostasis involves vasoconstriction and platelet activation, very quickly after the 
injury has occurred a fibrin plug forms and inflammatory cells are activated.  The fibrin 
plug has several components; essentially it is a meshwork of polymerised fibrinogen, 
fibronectin, vitronectin and thrombospondin, amongst others.[4]  Platelets are 
embedded within this meshwork.  The primary role of this plug is to provide a barrier 
to prevent infection and to provide temporary coverage.[3]   
Second to this the platelets trapped within the meshwork secrete a number of growth 
factors, two of the most notable being platelet derived growth factor (PDGF) and 
transforming growth factor (TGF)β1.[5]These growth factors are involved in several 
stages of wound healing, having an early role in cell recruitment and later helping to 
form the extra cellular matrix (ECM).[6]  
The inflammatory response is instigated as fibrinogen polymerises to fibrin, in this 
process fibrinopeptides A and B are formed and they are responsible for recruiting 
inflammatory cells.  At this point white blood cells are able to move into the 
extracellular space (this is stimulated by the expression of selectins by endothelial 
cells and enabled by integrin binding).  Again these white blood cells have many 
functions within the initial stage of wound healing.  Neutrophils and macrophages aid 
in wound debridement, they are also key as they produce growth factors and 
mediators that are essential for the healing process.[3]   
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At this stage wounds are hypoxic in nature, due to vascular damage.  This hypoxia 
acts as a stimulus for further healing, as it increases keratinocyte migration, 
angiogenesis, proliferation of fibroblasts, synthesis of cytokines and the biosynthesis 
of growth factors, such as, PDGF, vascular endothelial growth factor (VEGF), and 
TGFβ1.  The synthesis of growth factors and cytokines continues for 2-3 days.  At 
this stage macrophages collect at the injury site along with fibroblasts and endothelial 
cells which form early granulation tissue.[3, 7]   
1.1.3 Migration, Proliferation and Remodeling  
In the later stages of wound healing the inflammatory response becomes less intense, 
this allows wound closure and contraction to begin.  In this phase of healing ECM 
proteins are formed, angiogenesis occurs, as does contraction and keratinocyte 
migration.  Several of these processes will form the backbone of this discussion.   
 
Figure 1.1.1: Events in physiological Wound Healing.[8] 
.
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1.2 Wound Healing in Relation to Diabetes 
Diabetes is a disease that requires no introduction and whose prevalence is 
increasing at an alarming rate, driven by increasing life expectancy and obesity 
epidemics.  It was estimated that in 2000 there were 151 million cases of diabetes 
worldwide, in 2010 285 million were estimated, and shockingly, by 2030 it is thought 
that there will be a staggering 438 million cases[9-10]   
Diabetes mellitus is a term used to encompass the many kinds of diseases 
characterised by chronic hyperglycaemia and which are caused by a variety of 
underlying factors.  There are many illnesses that diabetic patients are predisposed 
to including the significantly increased risk of developing micro- and macro-vascular 
diseases.[10]   The macrovascular effects of diabetes are numerous, and are the cause 
of significant health problems in the diabetic population.  Significantly, poor peripheral 
vascular circulation contributes to further complications.[10]   
Peripheral vascular disease in diabetes patients is of the same nature as it is in the 
general population, however, it is said to be more aggressive and will occur at a much 
younger age.  The development of this vascular disease is thought to be largely due 
to impaired endothelial cell function.  However, an even more crucial factor appears 
to be the thickening of the basement membrane of capillaries.  This thickening inhibits 
white blood cell migration, compromising the sufferer’s immune response to injury.  
This reduced immune response then leaves any injured limbs, most usually feet, more 
at a higher risk of infection.[10]  This problem is compounded by the reduced ability of 
diabetics to vasodilate in response to injury, leaving the sufferer vulnerable to trauma 
and at a further increased risk of infection.  As a whole, this often leads to a great 
amount of pain and poor quality of life. [11] 
1.2.1 Biological Treatment of Diabetic Foot Ulcers 
One of the most problematic manifestations of diabetes is the infamous diabetic foot 
ulcer.  Diabetic foot ulcers occur in 15% of diabetic patients and are a major cause of 
lower limb amputation.[12]  A diabetic foot ulcer is defined as any skin breakdown in 
the foot of a diabetic.  This is complicated by the fact that non-healing foot ulcers act 
as portals of entry for systemic infection, which given the impaired nature of diabetics 
immune response is a very serious health issue.  A diabetic foot ulcer can then be 
described as a chronic non-healing wound, when it does not undergo the linear wound 
healing events outlined in Figure 1.1.1.[3]    
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With rigorous care including proper dressings, debridement, and off-loading many 
ulcers can heal in time.[13]  However, foot ulcers that display less than 10% closure 
within a three week time period are currently treated with biological therapies.[14]   
Physiologically, diabetic foot ulcers exhibit a decreased expression of growth factors 
and consequently a reduced angiogenic response.[14]  There are two methods of 
applying biological treatments, the first is through cell therapy which involves the 
application of a living human skin equivalent, for example Apligraf®, onto the wound.  
This therapy has been shown to increase the healing rate of diabetic foot ulcers by 
55%.  
The utilization of a human skin equivalent promotes wound healing through many 
mechanisms: promoting angiogenesis, increasing growth factors and cytokines, as 
well as increasing matrix proteins.  Human skin equivalents also provide and 
providing a physical and biological barrier against wound infection. 
Another strategy using biological agents to increase wound healing is the use of 
synthetic growth factors.  The only current example of this technology is Becaplermin 
(Regranex®) which is a growth factor generated from recombinant DNA technology.  
It is a homodimer of the B chain of human platelet-derived growth factor (PDGF-BB), 
and is marketed as a gel with the active ingredient preserved in a sodium 
carboxymethylcellulose based gel.   
1.2.1 Becaplermin (PDGF-BB) 
Becaplermin is sold as Regranex® in a gel form of 100 µg/g.[15]  There are a number 
of growth factors present in the wound healing process. Any drug containing or acting 
on growth factors is likely to be more clinically useful if it has a broader spectrum of 
activity.  This makes the use of a PDGF a good choice for a drug of this kind.   
Platelet-derived Growth Factor is produced by many cells in the wound healing 
process e.g. macrophages, endothelial cells, fibroblasts and keratinocytes.  It acts on 
many of these same cells as a mitogen and induces the production of fibronectin and 
hyaluronic acid.  This particular growth factor works in synergy with others such as 
transforming growth factor (TGF-β), giving it an active role throughout the wound 
healing process.[15] 
In double-blind clinical trials Regranex® performed well, significantly decreasing the 
number of days required for healing, and possibly also having an effect on wound 
size compared to a carboxymethylcellulose gel placebo.  Becaplermin was also found 
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to have an excellent safety profile and good cost effectiveness (which is not to say 
that this is a cheap drug).  However, despite all of these positive attributes Regranex® 
has failed to stand up in actual clinical practice, and consequently, it is not widely 
used.[15] 
There are a few hypotheses as to why this drug is not currently clinically useful.  One 
school of thought is that the gel preparation does not ensure good delivery to the 
wound, while some research suggests that other growth factors present my hinder 
the therapeutic potential of PDGF-BB.[16] Alternatively, it has been suggested that 
clinicians require more information on when to use Becaplermin.[15]  Whatever the 
reason for this disappointing clinical response, it has to be noted that this approach 
to wound healing is a promising one and drugs of this nature are likely to be the 
subject of significant investigation for the foreseeable future.    
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1.3 The Extra Cellular Matrix and Fibronectin 
For many years it was believed that the extra cellular matrix (ECM) was an inert 
scaffold, however, the ECM is much more complex and dynamic than it might at first 
appear to be.  The ECM is essential for the organisation of tissues, stem cell niches 
and cellular microenvironments and it contains many growth factors.  The importance 
of this network is highlighted when we consider that problems with assembly of the 
ECM can lead to scarring, tumorigenesis and fibrotic disease.[6]   
Two structural components of the ECM, the interstitial matrix (stroma) and the 
basement membrane (basal lamina) can be visualized using electron scanning 
microscopy.  The interstitial matrix is a fibrous and porous network of threadlike fibrils 
that surround cells.  The basement membrane, on the other hand, is sheet like in 
nature, and acts as a platform for cells and forms a boundary that separates tissue 
compartments.  Both of these ECM components are made of similar types of proteins, 
such as collagens, proteoglycans and cell adhesive glycoproteins.[6]   
Matrix proteins are crucial for normal cell behaviour to take place; collagens, 
fibronectin and vitronectin allow cell movement which, allow tissues to regain their 
function after injury.  Wound contraction is an efficient way of closing an injured site 
and this is enhanced by the reformation of the ECM.   
1.3.1 Fibronectin 
Fibronectin was discovered by Richard Haynes in the early nineteen seventies.[17]  
At this point in time it was the only known difference in surface chemistry between 
tumour and healthy cells, and its discovery was received with great excitement.   
Although the discovery of was an important find, although it was not the pivotal 
switch turning healthy cells into cancerous forms as was hoped at the time. Today, 
it is considered to be an extremely important milestone in the elucidation of the very 
complex processes associated with tumour proliferation, and integrin signaling.[17]   
1.3.2 Fibronectin in the Extra Cellular Matrix 
Fibronectin can exist as two main types of dimer: the first, plasma fibronectin (pFN), 
is soluble and exists in body fluids.  The second, cellular fibnonectin (cFN), is an 
insoluble multimeric component of the extra cellular matrix.  pFN is produced in the 
liver by hepatocytes and is involved in wound healing in conjunction with fibrin.   
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 Cellular Fibronectin is a large extracellular matrix glycoprotein, of around 440 kDa 
in weight and, amazingly, around three nanometres in width.  cFN is secreted by 
various cells as a globular molecule which has the ability to quickly assemble into 
fibrils, which are the main constituent of the extra cellular matrix along with collagen. 
Not surprisingly, cFN is essential for life as it is assembled into a fibrillar matrix in all 
tissues.[18] This fibrillar matrix connects neighbouring cells and forms mesh works 
around them (Figure 1.3.1).[6]  
cFN also has other crucial functions including cell migration, growth, wound healing 
and embryonic development.  cFN mainly binds to integrins, however importantly, it 
also binds to components of the extracellular matrix (ECM) such as collagen and 
fibrin.   
 
Figure 1.3.1:  Fibronectin Surrounds Cells in Culture.  Fibrils are shown in green, cell nuclei 
are stained blue.[6] 
 
Ten years after the isolation of fibronectin the three-amino-acid sequence that is 
required for fibronectin to attach to cells was discovered.  This tripeptide, RGD, lead 
the way to the discovery of integrins as the link between structural glycoproteins and 
the cytoskeleton.[17] 
1.3.3 The Structure of Fibronectin 
The significant interest that followed the discovery of fibronectin lead to the rapid 
elucidation of its structure.  As previously stated, fibronectin exists as a dimer.  This 
fibronectin dimer is composed of two subunits both weighted from 220-250 kDa.  
  
8 
 
These two subunits are covalently linked by a pair of disulfide bonds near their C-
termini of the monomers.  Each of the two subunits is comprised of three repeating 
types of modules, analogous to beads on a string (Figure 1.4.2).  There are twelve 
type I modules, two type II, and fifteen to seventeen type III modules.  In addition to 
these, each subunit also contains a variable sequence that is not homologous to the 
other parts of FN.  Two of the type III domains are subject to alternative splicing, 
these extra domains (ED-A and ED-B) are only found in cellular fibronectin.  A further 
difference between cFN and pFN is the variable region (V) which is only found in one 
of the subunits of pFN, but is present in nearly all cFN subunits.   
Fibronectin binds to α5β1 and α IIbβ3 integrins through the III8-III10 modules.  The III10 
module houses a critical binding site, the Arg-Gly-Asp (RGD) module.  Excitingly, 
synthetic RGD peptides block integrin mediated cell adhesion to FN.   
 
Figure 1.3.2:  Schematic Diagram of the Modular Structure of the Fibronectin Dimer.[19]   
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1.4. Migration Stimulating Factor 
 
Migration Stimulating Factor (MSF) is a truncated isoform of fibronectin and was first 
isolated from fetal calf serum in 1974.[20]  As such, it is produced from the primary 
fibronectin gene transcript.   
MSF is a motogenic protein, which stimulates the migration of a number of cells 
including epithelial cells, fibroblasts, vascular endothelial cells and pericytes.  MSF is 
also involved in the upregulation of hyaluronan synthesis, proteolysis and the 
upregulation of angiogenesis.[21]   
MSF is commonly expressed by fibroblasts, keratinocytes, and vascular endothelial 
cells in foetal skin.[22]  It is not normally found in healthy adult skin in noteworthy 
amounts, but is expressed during wound healing and is expressed by over 80% of 
human tumours.[22]  As such, it is currently being investigated as a target for 
prevention of novel angiogenesis in tumours.[23]  
The activity of this protein comes from its IGD (Ile-Gly-Asp) tripeptide motifs.  This 
motif is a highly conserved feature of the fibronectin type I modules and is present in 
the third, fifth, seventh and ninth type I modules of MSF (Figure 1.4.1).  Although 
Fibronectin does contain this motif it does not display any MSF like activity.  It is most 
likely that protein folding makes the IGD motifs cryptic.[21] [24] 
 
Figure 1.4.1:  The primary sequence of fibronectin/ MSF type I modules with highlighted 
IGD sequences.[24]   
 
1.4.1 Origin of Biological Activity of the IGD Tripeptide Motif and MSF 
In vitro mutagenesis studies have shown that the motogenic activity displayed by MSF 
is due to the IGD amino acid motif.  However, the biological activity of the IGD motif 
found in fibronectin and MSF is still relatively undefined.  Work by Schor indicated 
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that MSF promotes fibroblast and endothelial cell migration, at least partially, by 
inhibiting protein kinase AKT.[25]  
 
Work within the Schor group found that the IGD peptides stimulated fibroblast 
migration.  IGDS was found to be the most active, followed by IGDQ and then IGD, 
while the scrambled peptides SDGI and RGDS did not display activity.  This work 
found that the observed cell activation and enhanced migration upon treatment with 
IGD-containing peptides occurs within minutes, and involves the tyrosine 
phosphorylation of focal adhesion kinase.  Furthermore, this work found the activity 
is dependent on integrin α5β3 functionality, and is inhibited by signaling through 
integrin α5β1.[24, 26]  
1.4.2 MSF in Relation to Wound Healing 
The cell migratory properties of the IGD motif of MSF make it a good model for a 
therapeutic agent, whose applications would be based in patients with impaired 
wound healing and other diseases requiring the stimulation of cell migration and 
angiogenesis.  The Marquez, Norman and Schor groups recognised that design of an 
IGD peptidomimetic would allow the development of a small molecule with increased 
stability with respect to MSF.  Any peptidomimetic generated could be the structural 
basis for a new family of analogues, allowing optimisation of activity.   
Initially, the dihedral angles of the IGD turn in the fnI-5 and fnI-7 modules of MSF 
were studied via NMR measurements, showing the IGD sequence as a highly 
structured turn (Figure 1.4.2).  The angles were found to be very similar in both cases, 
enhancing the belief that they were good models for peptidomimetics 
It was hypothesized that the highly structured nature of this motif would lend itself to 
easy recognition by the relevant cell receptors.  Consequently, any peptidomimetics 
that mimic this turn would also have the potential to bind to these receptors.[27]   
 
Figure 1.4.2:  Space Filling Representation of the IGD motif on the FnI-7 backbone.[27] 
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1.5 First Generation IGD Peptidomimetics 
AB-Initio level-modeling studies indicated that the IGD tripeptide motif of MSF could 
be closely mimicked by a benzodiazepinone bicyclic ring structure, specifically 
benzodiazepinone 2 (Figure 1.5.1).  To best imitate the aspartic acid residue the 
stereocentre of the peptidomimetic should have an (S)-configuration. The IGD 
peptidomimetic 2 also incorporated an ester functionality, providing a handle through 
which the molecule could be modified, depending on the pharmacological traits 
required.[27] 
 
HN
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Figure 1.5.1:  IGD Peptide Sequence A/1 and Racemic IGD peptidomimetic B/(S)-2. 
 
The proposed benzodiazepinone core is particularly interesting, a number of RGD 
peptidomimetics are also based around this privileged moiety (Figure 1.5.2).  The 
similarity in structure could be indicative of binding to similar biological targets. 
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Figure 1.5.2:  Benzodiazepinone RGD Peptidomimetics. 
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1.5.1 Synthesis of the First IGD Peptidomimetic 
The synthesis of the first IGD peptidomimetic (±)-2 began with the alkylation of nitro-
cresol 5.  The product of this reaction was then brominated under radical conditions 
giving the desired benzylic bromide 6 along with a small amount of the undesired 
double brominated adduct 7 in moderate yield over two steps.  These compounds 
could not be separated at this point and were reacted with methyl amine to give 
amines 8 and 9.  BOC protection of the benzylic amine gave intermediates 10 and 11 
in good yield over both steps.  Subsequent hydrogenation gave aniline 12 as a single 
compound in good yield (Scheme 1.5.1).[27]   
 
Scheme 1.5.1:  Synthesis of Aniline 12.  Reagents and Conditions: (i) 1-bromo-3-methyl 
butane, K2CO3, DMF, RT, 24 h; (ii) NBS, AIBN, CCl4, reflux, 12 h, (43% over two steps); (iii) 
CH3NH2 (40% in H2O), THF, RT, 12 h; (iv) BOC2O, TEA, DMAP, CH2Cl2, 0 °C-RT, 12 h 
(84% over two steps); (v) Pd/C (10%), H2, CH3OH, RT, 3 h (75%). 
 
Aniline 12 was then condensed with dimethyl acetylenedicarboxylate to give dimethyl 
diester 13 in excellent yield.  Reduction of the double bond using palladium and 
hydrogen gave the desired racemic dimethyl diester (±)-14.  Deprotection of diester 
(±)-15, followed by cyclisation afforded the first IGD peptidomimetic (±)-2 as a racemic 
mixture in variable yields (Scheme 1.5.2).[27]   
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Scheme 1.5.2:  Completion of Synthesis of IGD Peptidomimetic (±)-2.  Reagents and 
Conditions: (i) MeO2CCCCO2Me, CH3OH, reflux, 1 h (85%); (ii) Pd/C (10%), H2, CH3OH, RT, 
30 min (58%); (iii) TFA, CH2Cl2, 0 °C, 1 h (96%); (iv) NaOCH3 (25% in CH3OH), RT, 1 h (45-
77%).   
 
The motogenic activity of the newly synthesized IGD peptidomimetic ((±)-2 = BDP1, 
Figure 1.5.3) was assessed alongside 2 amino acid sequences with known activity.  
Human skin fibroblasts were treated with the peptidomimetic or the peptide 
sequences in a 3D collagen gel assay.  Pleasingly, the IGD peptidomimetic (±)-2 was 
found to be as effective as IGDS in stimulating the migration of human skin fibroblasts.  
The control reverse peptide SDGI was devoid of any motogenic activity as 
expected.[27]   
 
  
Figure 1.5.3:  The Motogenic Activity of IGD Peptidomimetic (±)-2.   
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1.6 Synthesis of the First Enantiomerically Pure IGD Peptidomimetic 
Further exploration of the IGD peptidomimetic (±)-2 has been carried out within the 
Marquez group with the synthesis of the IGD peptidomimetics in the enantiomerically 
pure forms.  The route to the (R) and (S)-IGD peptidomimetic esters was developed 
from the original methodology to ensure higher yields throughout the synthesis but 
also to allow the inclusion of the desired chiral functionality.[28]   
The enantiomerically pure synthesis began with the alkylation of benzophenol 16 to 
afford clean 17.  Treatment of ether 17 with nitronium tetrafluoroborate proved very 
temperamental yielding nitrobenzaldehyde 18 in working yield (53%).  Methylamine 
was then reacted with nitrobenzaldehyde 18 under reductive amination conditions to 
give amine 8 in excellent yield over two steps (94%).   Subsequent protection (93%) 
and reduction (100%) gave aniline 11 near quantitative yield (Scheme 1.6.1).[28]   
 
Scheme 1.6.1: Second Route to Aniline 11.  Reagents and Conditions:  (i) DMF, K2CO3, 1-
bromo-3-methyl butane, RT, 1h (96%); (ii) DCM, NO2BF4, -28 °C, 22h (53%); (iii) MeNH2, 
heptane, RT, 2h; (iv) MeOH, NaBH4, 1h, 0 °C (94% over two steps); (v) DMF, TEA, BOC2O, 
2.5 h, RT (93%); (vi) Pd/C (10%), MeOH, H2, 15 h (100%). 
 
It was found that the chiral centre could be introduced through the generation of chiral 
triflate (S)-20 from (S)-(-)-dimethyl malate ((S)-19).  The reaction of triflate (S)-20 with 
aniline 11 proceeded in excellent yield (100%).  Subsequent deprotection (82%) and 
cyclisation (85%) gave the desired benzodiazepinone core (R)-2 (Scheme 1.6.2).[28] 
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Scheme 1.6.2.:  Synthesis of the Enantiomerically Pure (R)-2.  Reagents and Conditions: (i) 
Tf2O, 2,6-lutidine, DCM, 2 h, -78 °C (100%); (ii) Triflate (S)-20, DCM, reflux (100%); (iii) TFA, 
DCM, 20 h, RT (82%); (iv) NaOMe, MeOH, reflux (85%). 
 
For a more complete assessment of the biological and chemical properties of the 
peptidomimetics it was decided to synthesize the corresponding carboxylic acids (R)-
22.  Thus, ester (R)-2 was then converted to the desired carboxylic acid (R)-22 
through treatment with potassium trimethylsilanolate (97%) (Scheme 1.6.3).  The (S)-
IGD peptidomimetic ester was isolated and the enantiomeric excess defined by chiral 
HPLC through comparison with the racemic product.[28]   
 
Scheme 1.6.3:  Saponification of IGD Peptidomimetic (R)-2.  Reagents and Conditions: (i) 
KOSiMe3, Et2O; (ii) 1M HCl (97% over two steps).  
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1.7 In Vitro and In Vivo Testing of IGD Peptidomimetics 
The newly synthesised enantiomerically pure peptidomimetics then underwent 
biological testing to get a clearer picture with regards to the biological activity of each 
enantiomer.  Initially, the peptidomimetics were tested in vitro in the transmembrane 
and 3D collagen gel assays.   
Surprisingly, contrary to what was expected from the modeling studies the (R)- IGD 
peptidomimetic methyl ester ((R)-2)  displayed noteworthy activity on fibroblasts and 
endothelial cells whereas the (S)-IGD peptidomimetic methyl ester ((S)-2) was 
inactive.  The (R)-IGD peptidomimetic acid ((R)-22) was found to have activity but this 
was significantly less than the corresponding ester, and again the (S)-IGD 
peptidomimetic acid ((S)-22) showed no motogenic activity on cells.[28] 
In vivo testing followed with the compounds being tested on the wounds of 
C57BLKs/Bom diabetic mice.  A single wound (10 mm × 10 mm) of standard thickness 
was made on the back of several diabetic mice.  The experimental animals then had 
their wounds treated either with a control preparation or an (R) or (S)-IGD 
peptidomimetic preparation along with an appropriate dressing.  The treatments were 
reapplied on days 2, 4, 7 and 10 after wounding.[28] 
The results were pleasing, the (R)-IGD peptidomimetic methyl ester ((R)-2) was 
shown to promote wound healing in the diabetic mice, having an effect on wound 
closure, wound contraction, re-epithelialisation and cellular maturity where healing 
was increased to 77% ±3 of levels displayed by healthy mice.  Activity was also seen 
in acid ((R)-22), with this molecule allowing for faster healing times and significant 
reduction in wound size compared to the control group, however, this activity was less 
than that observed for the corresponding ester.  This could allow us to conclude that 
the (R)-IGD peptidomimetics promote wound contraction in the diabetic mouse model 
(Figure 1.7.1).[28] 
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(R)-IGD Peptidomimetic Wound  
Day 0 
(R)-IGD Peptidomimetic Wound  
Day 10 
  
Control Wound  
Day 0 
Control Wound  
Day 10 
  
Figure 1.7.1:  Examples of Wound Healing in Test Mice Treated with (R)-IGD 
Peptidomimetic ((R)-2) or Control Treatment.   
 
It was also found that the (S)-IGD peptidomimetic acid ((S)-22) promoted wound 
contraction in the diabetic mouse model, relative to the control groups, although not 
to the same extent as the (R)-IGD peptidomimetics.  It is possible that epimerisation 
of the (S)-IGD acid is the cause of these unexpected results, alternatively, it may be 
acting through an different biological mechanism.[28]  
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2.0 PROJECT AIMS 
2.1. Development and Investigation of Methyl IGD Peptidomimetics 
The initial aim of the project was to optimise the synthesis of the (R)- and (S)-methyl 
IGD peptidomimetics ((R)-2) and ((S)-2) (Figure 2.1.1), in order to generate enough 
material for biological testing.  An improved synthetic route to the IGD 
peptidomimetics would greatly facilitate the generation of future analogues. 
Once the synthesis of (R)-2 and (S)-2 had been optimised, biological testing was 
planned to confirm the relative activity of each enantiomer.  Observation of “wound 
healing” activity would allow us to confidently to harvest samples for Polymerase 
Chain Reaction arrays, with the hope that these tests would divulge the origin of 
activity.  Further to this, each enantiomer would be submitted for toxicology studies. 
 
Figure 2.1.1: Methyl IGD peptidomimetics (R)-2 and (S)-2. 
 
2.2. Functionalised IGD Peptidomimetics 
Analogues of (R)-2 and (S)-2 could also be used to gain new insight into the biological 
mode of action of the IGD peptidomimetics.  Thus, analogues could be designed to 
incorporate a moiety that could facilitate drug delivery.  Each of these goals wa 
envisioned to proceed via common intermediate (R/S)-23/(R/S)-24 or (R/S)-25/ (R/S)-
26 (Figure 2.2.1). 
It was postulated that an alcohol functionality would allow efficient divergence to 
afford a small library of IGD peptidomimetics with varying functionalities.  These 
functional groups would be capable of attaching the mimetic to other structural units 
for development and investigation, such as fluorophores and solid supports.  The alkyl 
chain in the 4 position was designed to allow distance between any potential new 
support and our active IGD mimetic core.   
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Figure 2.2.1: IGD Peptidomimetic Mimetic with Incorporated Alkyl Chain and Alcohol. 
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3.0 Results and Discussion 
3.1. Methyl IGD Peptidomimetic Route Optimisation  
3.1.1 Optimisation of IGD Peptidomimetic Intermediates  
As referred to in the introduction, the original synthesis of the methyl IGD 
peptidomimetics (R)-2 and (S)-2, was let down by one crucial step.[27] Intermediate 18 
(Scheme 3.1.1) was accessible only through nitration of the 2 position of 
benzaldehyde 17 and this strategy presented several issues which made the reaction 
incompatible with the scale-up required to generate sufficient material for the 
subsequent steps of the synthesis.   
The synthesis of 18 starts with alkylation of phenol 16, in excellent yield to generate 
the desired ether 17 (83%).  With the ether 17 in hand the addition of the nitro group 
was explored.  Unfortunately, nitration of ether 17 proved to be extremely challenging.  
Setting aside the cost and sensitivity of the nitrating agent, nitronium 
tetrafluoroborate, the most significant problem comes from the isolation of the desired 
product from the reaction mixture.  The conversion of starting material 17 to a nitrated 
species is good, generally around 75%, however, there is no selectivity shown for the 
desired C2 position and several mono- and di- nitrated isomers are also formed.  This 
problem is compounded by the similar chemical properties of these isomers meaning 
that flash column chromatography is often extremely lengthy and unsuccessful in 
giving pure material.  Thus, the 53% yield previously demonstrated was 
irreproducible, with 26% being the highest yield of 18 observed via this route.  
 
Scheme 3.1.1: The Synthesis of Nitrobenzaldehyde Intermediate.   Reagents and 
Conditions: (i) DMF, K2CO3, 1-bromo-3-methyl butane, 83%; (ii) DCM, NO2BF4, - 20 ºC, 
26%. 
It was apparent that this method of accessing 18 was unsuitable for such an early 
intermediate and alternative strategies were sought.  Initially, it was thought that the 
synthesis of aldehyde 18 by oxidation of the benzylic methyl group of the 
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commercially available 3-methyl-2-nitrophenol may be a convenient route (Scheme 
3.1.2). 
The first step in this alternative strategy was the alkylation of phenol 5, which 
proceeded in excellent yield to give ether 27 (89%) (Scheme 3.1.2).  Selenium 
dioxide was then employed in an endeavour to access nitrobenzaldehyde 18. The 
reaction mixture was heated to 100 ºC for forty eight hours, yet no conversion was 
observed.[29]  It is known that extremely high temperatures are necessary in many 
selenium dioxide reactions, and thus, it was thought that an alternative reagent may 
achieve successful conversion.  A subsequent oxidation attempt was carried out with 
2-iodoxybenzoic acid in dimethylsulfoxide, the reaction mixture was heated to 75 ºC 
for fifteen hours, however, thin layer chromatography and NMR analysis showed only 
starting material.[30]  In a final attempt, oxone and MnSO4.H2O were reacted with 5 
and 27 in an attempt to oxidize the benzylic position, however, despite consumption 
of starting material in each case, no product was observed.[31]    
 
Scheme 3.1.2:  Benzylic Oxidation Strategy for the Synthesis of Nitrobenzaldehyde 18.   
Reagents and Conditions: (i) DMF, K2CO3, 1-bromo-3-methylbutane, 89%; (ii) IBX, DMSO 
(failed); SeO2, dioxane (failed); MnSO4.H2O, Oxone, H2O (failed); (iii) MnSO4.H2O, Oxone, 
H2O (failed). 
It was hypothesised that the electron withdrawing nature of the nitro group may be 
hindering the oxidation of the methyl group and so compound 27 was reduced under 
hydrogenation conditions in good yield (69%) (Scheme 3.1.3).  However, subsequent 
oxidation of the methyl with selenium dioxide in dioxane was unsuccessful, thus, this 
route was abandoned.  
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Scheme 3.1.3:  Attempted Synthesis of Nitrobenzaldehyde 30.  Reagents and Conditions: (i) 
NH4CO2H, MeOH, Pd/C, 69%; (ii) SeO2, dioxane (failed); MnSO4.H2O, Oxone, H2O (failed). 
In an alternative strategy, a double SNAr approach was envisioned starting with 
commercially available 2,6-difluoronitrobenzene (31).  However, no conversion of 
starting material was witnessed upon treatment of 31 with 3-methylbutanol under 
basic conditions (Scheme 3.1.4). 
 
Scheme 3.1.4: SNAr Approach for the Synthesis of Nitrobenzaldehyde 18.  Reagents and 
Conditions: (i) 3-methylbutanol, K2CO3, DMF, 110 °C, (failed); (ii) 3-methylbutanol, NaOMe, 
DMF, 110 °C, (failed). 
Faced with the low selectivity of the nitration and low reactivity of the 2,6-difluoro 
nitrobenzene (31) towards nucleophilic displacement, a new approach was sought.  
The new approach envisioned having the nitro and aldehyde groups in place from the 
start of the synthesis in order to avoid selectivity issues.  Thus, it was decided to 
attempt the demethylation of 3-methoxy-2-nitrobenzaldehyde (32) (Scheme 3.1.5).[32]   
Gratifyingly, treatment of 3-methoxy-2-nitrobenzaldehyde (32) with boron tribromide 
gave 3-hydroxy-2-nitrobenzaldehyde (33) in excellent yield (89%).  Phenol 33 was 
then alkylated using 1-bromo-3-methyl-butane in high yield (83%), giving 18 quickly 
and efficiently in 73% yield over two steps.  This straightforward synthesis allowed 
the multigram preparation of the key intermediate 18, accelerating access to 
subsequent intermediates.   
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Scheme 3.1.5: Improved Route to Nitrobenzaldehyde 18.  Reagents and Conditions: (i) 
BBr3, CH2Cl2 (89%); (ii) DMF, K2CO3, 1-bromo-3-methyl butane (83%). 
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3.2 Methyl IGD Peptidomimetics 
3.2.1 Synthesis of Methyl IGD Peptidomimetics 
The newly developed, efficient and reliable synthesis of intermediate 18 allowed focus 
to shift towards the methyl IGD peptidomimetics (R)-2 and (S)-2 (Figure 3.2.1).  As 
previously discussed, the synthesis of these analogues is necessary to generate 
sufficient material for further biological tests, firstly to reconfirm which enantiomer is 
biologically active, and secondly, to expand our knowledge of the origin of this activity 
via PCR studies.   
 
Figure 3.2.1: Methyl IGD peptidomimetics (R)-2 and (S)-2. 
 
The synthesis of (R)-2 and (S)-2 proceeded from intermediate 18 as in the previous 
approach (Scheme 3.2.1).[27]  Reductive amination of aldehyde 18 using methyl 
amine and sodium borohydride gave the benzylic amine, which upon subsequent 
protection gave compound 8 in 99%.  Hydrogen gas and 10% palladium on activated 
charcoal were then used to reduce the nitro group to the corresponding aniline, 
however, despite previously reported success with these conditions, reaction 
progress was slow.  Increasing the reaction time from three hours to four days, failed 
to achieve total conversion and these conditions were abandoned.  Hydrogen gas 
was substituted with ammonium formate, and the reaction temperature was increased 
to 55 °C.  This gave the desired aniline in quantitative yield after forty eight hours 
stirring.  Subsequent alkylation of aniline 12 with triflate (S)-20 proceeded in 70% to 
afford key intermediate (R)-14.  
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Scheme 3.2.1:  Optimised Synthesis of Intermediate (R)-14.  Reagents and Conditions: (i) 
NH2Me (aq.)(40%), heptane; (ii) NaBH4, MeOH; (iii) Boc2O, NEt3, DCM (99% over three 
steps); (iv) NH4CO2, Pd/C, MeOH (quant.); (v) 2,6-lutidine, (S)-20, DCM (71%). 
 
Deprotection of (R)-14 with trifluoroacetic acid, followed by cyclisation with sodium 
methoxide then gave the desired methyl IGD peptidomimetic ((R)-2) in 85% over the 
two steps (Scheme 3.2.2). 
 
Scheme 3.2.2: Synthesis of (R)-Methyl IGD Peptidomimetic ((R)-2).  Reagents and 
Conditions: (i) TFA, CH2Cl2; (ii) NaOMe (25% wt in MeOH), 65 °C (85%). 
 
These synthetic conditions were applied to the synthesis of the S-enantiomer, with 
the alkylation proceeding in good yield (86%) (Scheme 3.2.3).  The deprotection and 
cyclisation steps occurred in yields analogous to the (R)-IGD peptidomimetic (86%).   
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Scheme 3.2.3: Synthesis of (S)-Methyl IGD Peptidomimetic ((S)-2).  Reagents and 
Conditions: (v) 2,6-lutidine, (R)-20, DCM (86%). (i) TFA, CH2Cl2; (ii) NaOMe (25% wt in 
MeOH), 65 °C (86%). 
 
Using this optimised approach the peptidomimetics (R)-2 and (S)-2 could be 
generated in significant amounts (around 1 g) in a short amount of time 
(approximately two weeks).  With reliable access to the methyl IGD peptidomimetics 
we were able to focus on the biological testing testing of these molecules.   
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3.3 Biological Assessment of Methyl IGD Peptidomimetics 
In order to confirm the biological activity previously seen with the IGD peptidomimetics 
(S)-2 and (R)-2, a reliable method of assessment was needed.  The wound healing 
activity of our peptidomimetic compounds originates from their ability to induce 
migration, motogeniticity or cell proliferation.  Thus cell migration was used as a 
measure of the efficacy of our compounds. 
3.3.1 Time Lapse Studies 
Work proceeded in collaboration with Prof. Matt Dalby and Carol-Anne Smith 
(University of Glasgow).  The Dalby group have studied the migration and adhesion 
ability of cells as they respond to changes in microtopography by timelapse 
microscopy.[33]  It was believed that a similar approach using time lapse microscopy 
may be useful to quantify the migration of cells treated with the (R)- or (S)-methyl IGD 
peptidomimetics. 
Carol-Anne Smith carried out the cell culture and time lapse incubation.  Due to the 
limitation of access to only two microscopes with time-lapse capabilities it was not 
possible to study cells treated with the R enantiomer, the S enantiomer and a control 
simultaneously.  Therefore, the (R)-methyl IGD peptidomimetic was studied alongside 
a control, this was repeated for the (S)-methyl IGD peptidomimetic and a control.  The 
control values were used to normalise the R and S results so that direct comparison 
became possible.   
 
hTERT Fibroblasts were seeded at 5000 cells per 5 mL in complete Dulbecco's 
modified eagle's medium (cDMEM), into two T25 vented culture flasks and incubated 
at 37 °C for 24 hours.  (R)-Methyl IGD peptidomimetic of ((R)-2) was then added to 
the culture flask at the desired concentration as a DMSO solution, while the control 
flask was left unmodified.  Both flasks were incubated at 37 °C and recorded over 
twenty four hours with photographs being taken every two or three minutes.  This 
process was repeated with the (S)-methyl IGD peptidomimetic ((S)-2) and a further 
control. 
 
hTERT fibroblasts were selected due to their ease of handling (longevity in aerobic 
conditions) and their relevance to wound healing.[3]  The initial experiments were run 
with 100 ng/mL concentration of the IGD peptidomimetic as this was the most 
efficacious concentration in previous experiments. [27] 
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ImageJ (version 1.49t) with Manual Tracking plug-in and Axiovert25 Timelapse were 
used to compile the images captured from the timelapse incubations and turned into 
video footage.  The movement of each trackable cell was then followed, generating 
data of the cells XY coordinates in the flask over the twenty four hour period.  This 
approach allowed us to measure the number of micrometres moved by each cell on 
each axis.   
 
Five cells from each of four time lapse videos were tracked.  The data was used to 
generate XY plots of cell movement (Graphs 3.3.1-3.3.4) and plots of distance from 
origin (Graphs 3.3.5-3.3.8).   
 
Graphs 3.3.1-3.3.4: XY Coordinates of Fibroblast Movement (µm) Over 24 h. 
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Graphs 3.3.5-3.3.8: Distance From Origin of Fibroblasts (µm) Over 24 h. 
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Inspection of the Graphs 3.3.1-3.3.4 show no striking differences between the 
experiments, with cells in each experiment travelling a range of distances.  Graphs 
3.3.5-3.3.9 are a useful alternative representation of cell movement.  In these graphs 
we can get a clearer image of the micrometres moved by all cells.  This is useful to 
visualise cells that don’t travel far but may move forwards and backwards relative to 
ther starting positon.  Again, we see no obvious difference in cells movement between 
experiments.   
 
However, upon inspection of the mean cell movement for each experiment (Entry 1, 
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treated with (R)-methyl IGD peptidomimetic ((R)-2) compared to those treated with 
the (S)-Methyl IGD peptidomimetic ((S)-2) and the control experiments.  
While these results were encouraging, they were not statistically significant.  In order 
to increase the likely hood of statistical significance in these results, the number of 
cells tracked would have to be increased. With the number of trackable cells in each 
experiment being small (generally between 5 and 7), each experiment was repeated 
in order to gain enough data.   
However, the new set of results were not as hoped.  The cells treated with the (R)-
methyl IGD peptidomimetic showed a large reduction in cell movement despite 
experimental conditions remaining unchanged (Entry 2, Table 3.3.1).   
In order to encourage a more consistent result, the concentration of the 
peptidomimetics used was increased to 1000 ng/mL and the experiments were 
repeated (Entry 3, Table 3.3.1).  The (R)-IGD peptidomimetic showed a slight 
increase in movement compared to the control, however, the (S)-IGD peptidomimetic 
showed a large decrease in activity.   
Upon examination of the results, we can see there is large variability within the data 
obtained in each experiment (as shown by high standard deviation), even in control 
groups.  This raises the possibility that the values gained may not be reliable 
indications of the motogenic effect of the peptidomimetics.   
Table 3.3.1: Summarised Results of Micrometres moved by each hTERT cell in Timelapse 
Studies. 
 Surface [R/S] 
(ng/mL) 
Cell 
Line 
Mean Cell movement (µm) 
    R  Control R Corrected S Corrected 
Control S 
1 Flask 100  hTERT 901±195 791±132 636±124 791±92 
2 Flask 100  hTERT 489±150 701±334 662±186 701±131 
3 Flask 1000  hTERT 724±245 671±273 490±38 671±284 
 
The small sample size of five cells is not enough to allow to achieve a median 
population and to remove outliers, thus, we have data with large variations within 
groups.  In order to increase the number of cells tracked from each experiment we 
would have to pursue one of two undesirable options.  Firstly, decreasing our 
magnification would increase the number of cells in view, however, this would 
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decrease the accuracy of the measurements.  Alternatively, we could increase the 
cell density within the flask, however, due to likely increased cell interactions this is 
unlikely to be successful in increasing the number of trackable cells.   
 
In order to track enough cells to increase the likelihood of gaining statistically 
significant results we would be required to repeat each experiment around ten times, 
however, with demand on the time lapse microscopes and time constraints this was 
not viable.   Nor would this give us an experiment that could quickly and reliably be 
used to check the activity of any new compounds synthesised.  It was clear at this 
point that a change in experimental design was required. 
 
It was hypothesised that the poor reliability of previous results gained may be due to 
the nature of the flask surface.  Schor and Schor have previously shown IGD 
tripeptides to have “substratum dependant” activity, with cellular stimulation by the 
peptide being noted on native collagen but not denatured collagen.[26]  Thus, it was 
decided to coat culture flasks with rat tail collagen, and to repeat the experiments 
(Entries 1-4, Table 3.3.2).  Unfortunately, upon examination of the results it was clear 
that the data lacked any clear trend, and was still subject to large variations.   
It was decided at this point that no further tests of this kind would be carried out and 
a new method of measuring cell motility would be investigated. 
Table 3.3.2: Mean Micrometres Moved by Each hTERT Cell on Collagen in Timelapse 
Studies.  
 Surface [R/S] 
(ng/mL) 
Cell 
Line 
Mean Cell movement (µm) 
    R Control R Corrected S Corrected 
Control S 
1 Collagen 1000  hTERT 1002±418 765±218 681±84 765±199 
2 Collagen 1000  hTERT 680±178 775±93 - - 
3 Collagen 1000  hTERT 851±162 1100±653 - - 
4 Collagen 1000  hTERT  805±102 797±58 - - 
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3.4 Scratch Assays and RT-qPCR for the Investigation of (R)- and (S)–IGD 
Peptidomimetics 
 
Martin and Wright at Glasgow Caledonian University have reported the use of scratch 
assays to study the efficacy of Gap27.  Gap27 is a connexion mimetic peptide with 
wound healing implications which increases the migration of human keratinocytes 
and dermal fibroblasts.  Dr Martin and Dr Wright were able to conclude that Gap27 
increased cell migration in conditions mimicking healthy and diabetic physiological 
conditions.[34-36]  Further to this, they were also able to investigate what effect Gap27 
treatment has on gene regulation under varying physiological conditions through 
Polymerase Chain Reaction (PCR) arrays.   
 
Working in collaboration with the Wright group we were able to apply these 
techniques in our own investigations.  Initially, scratch assays were used to quantify 
the effects of our (R)- and (S)- IGD peptidomimetics and subsequently, RT-qPCR was 
used to investigate the implications of these molecules on gene expression.  
  
3.4.1 Scratch Assays for the Quantification of Cell Migration  
 
Scratch assays are a convenient and low cost way of measuring cell migration.[37]  
Monolayers of cells are grown to around 80% confluency in a 12 well plate, and an 
artificial wound is created in each well with a pipette tip.  The wound is immediately 
photographed and the denuded area is calculated by measuring the perimeter of the 
scrape (Figure 3.4.1).   
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Figure 3.4.1: (A) Schematic of 12 Well Plate and Scrape Perimeter Measurement (red line); 
(B) An Example of Perimeter Measurement (yellow line) in Fibroblasts 
 
This measurement is repeated after 24, 48 and 72 hours, with the perimeter taking 
into account any cells that have migrated into the denuded area (Figure 3.4.2).  The 
percentage of wound area remaining, with respect to time 0, is calculated for each 
well.  Thus, this is a model for wound healing that yields quantifiable results.   
 
0 Hours 24 Hours 
  
48 Hours 72 Hours 
  
Figure 3.4.2: Scrape Wound Closure Over 72 Hours. 
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3.4.2 Serum Free vs. Complete Media Scratch Assay 
 
In their experiments with Gap27, Wright and Martin used serum free media in order 
to ensure the availability of their mimetic in the cellular environment.  With the concern 
that the lack of observed activity in our previous cell migration experiments could be, 
due to the use of complete media, efforts were concentrated on investigating this 
possibility.  Thus, human dermal fibroblasts were plated in accordance with General 
HDFn Scrape Wounds Procedure (Experimental 5.5, p178) and wells were treated 
with one of four media solutions (Table 3.4.1). 
 
Table 3.4.1:  Composition of Serum Free and Complete Media Treatments. 
 
 Treatments  
Media 
Components 
Serum Free 
Media + 
Compound 
Serum Free 
Media Control 
Complete 
Media + 
Compound 
Complete 
Media Control 
Media sfDMEM sfDMEM cDMEM cDMEM 
DMSO 1 µL/mL 1 µL/mL 1 µL/mL. 1 µL/mL 
[(R)-IGD 
peptidomimetic] 0.1µg/mL - 0.1 µg/mL - 
 
Analysis of scrape wounds results (please see Appendix 6.1, p180 for data) with a 
two-tailed t-test between “serum free media control” and “serum free + compound” 
showed significance at 72 hours (p=0.0086), although no such significance was found 
between the complete media experiments (p=0.6789) (Graph 3.4.1).   
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Graph 3.4.1: HDFn Migration in Complete vs Serum Free Media With and Without (R)-
Methyl IGD Peptidomimetic ((R)-2) 
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These results were highly encouraging.  With an assay that could quantify the cell 
migratory properties of the IGD peptidomimetics in an efficient manner we were able 
to focus our attentions on establishing the optimal treatment dose. 
 
3.4.3 Determination of Optimal Dose 
 
With these promising initial results in hand, experiments to investigate the optimal 
dose for cellular migration were undertaken.  Thus, cells were plated and scrape 
wounds were formed in according to General HDFn Scrape Wounds Procedure and 
wells were treated with 0, 0.1, 1, 10 µg/ mL of either (S)-methyl IGD peptidomimetic 
((S)-2) or (R)-methyl IGD peptidomimetic ((R)-2).   
 
To our surprise, initial plates experienced significant cell death.  Although no 
contamination was observed in the plates, it was thought that this was a likely cause 
of the poor health of the cells.  In order to minimise this issue, filter sterilisation of the 
peptidomimetic containing media was incorporated into the procedure.  However, this 
precaution failed to improve the condition of the cells. 
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 In subsequent plates, it was observed that the well centres were often dry upon 
removal from the incubator.  It is believed that this was caused by the proximity of the 
plates to the incubator fan.  Volume of media treatments per well was increased from 
0.27 µL to 0.50 µL, and this issue was not encountered again.   
 
The effect of each dose was measured 9 times (3 wells x 3 plates) for each 
enantiomer and the results were examined.  The (S)-IGD peptidomimetic failed to 
show significant activity at any dose (Graph 3.4.2) (please see Appendix 6.2, p181 
for data). On the other hand, the (R)-methyl IGD peptidomimetic displayed significant 
activity at 0.1 µg/ mL (3 × 10-7 M) (Graph 3.4.3) (please see Appendix 6.3, p182 for 
data).   
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Graph 3.4.2: Migration in HDF Cells Treated with Varying (S)-Methyl IGD Peptidomimetic 
Doses 
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Graph 3.4.3: Migration in HDF Cells Treated with Varying (R)-Methyl IGD Peptidomimetic 
Doses 
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3.5 Polymerase Chain Reaction Experiments 
 
3.5.1 Polymerase Chain Reaction  
 
Polymerase Chain Reaction experiments transformed biological science when the 
technique was developed in 1983 by Kary Mullis.[38]  This sensitive assay allows a 
piece of DNA to be amplified selectively in the presence of many others.  This Nobel 
prize winning technique has many valuable applications including DNA cloning, 
genetic fingerprinting, diagnosis of hereditary diseases.[39]   
 
To investigate a desired fragment of DNA first the sample is heated to 94-96 °C.  This 
heating induces denaturation to give single stranded DNA (Figure 3.5.1).  The 
subsequent annealing step allows short pieces of DNA with complimentary base pairs 
(primers) to bind to the fragment in question.  The coordination of primers to the DNA 
single strand provides a 3’-OH onto which DNA polymerase can add nucleotides 
(elongation).  Crucially, by selecting the primer in use we can amplify one desired 
piece of DNA and thus by exposing any DNA pool to a strategic range of primers we 
may see what DNA is present.  These three steps are repeated many times, thereby 
amplifying the volume of our DNA of choice.[39]   
  
 
Figure 3.5.1:  Polymerase Chain Reaction Increasing the Number of Copies of a Desired 
Piece of DNA. [39]   
 
A modification of this technique Reverse Transcription PCR (RT-PCR) allows the 
detection of RNA, through the synthesis of cDNA.  This technique is particularly 
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valuable for studying gene expression.  Another variation is quantitative real time PCR 
(qPCR) where DNA is detected as it is formed through the release or activation of 
fluorophores.[40]  Reverse transcriptase real time PCR (RT-qPCR) is the combination 
of both techniques and allows quantitative analysis of the RNA present in a sample, 
and thus, can be used to identify changes in gene regulation.[41]  
 
Many companies offer RT-qPCR services, including the RT-qPCR experiments and 
data analysis (Figure 3.5.2).  Qiagen’s Human Cell Motility PCR Array includes 84 
selected primers for the investigation of gene regulation in relation to cell motility (plus 
12 quality control/ house keeping primers) (Please see Appendix 6.4, p188 for a 
complete list of the genes investigated in this assay).  Through these 84 primers many 
aspects of cell motility are investigated including chemotaxis, common receptors, 
growth factors, cell adhesion, integrin signalling and cellular projection.  This assay 
would be particularly useful to give us information about the origin of activity of our 
peptidomimetics.   
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Figure 3.5.2: General RT2 Profiler PCR Array workflow from sample to result.[42] 
 
3.5.2 RNA Extraction 
 
Having confirmed that the (R)-IGD peptidomimetic ((R)-2) is the active enantiomer 
and having established our optimal dose, it was possible to focus our efforts towards 
obtaining RNA samples for RT-qPCR analysis.  
 
The fibroblasts were treated with either (R)-methyl IGD peptidomimetic ((R)-2) or (S)-
methyl IGD peptidomimetic ((S)-2) and the RNA was extracted from the cells and sent 
off for analysis.  Using the (S)-IGD peptidomimetic as our control would allow us to 
highlight the differences in gene expression that are specifically implicated with the 
activity of the R enantiomer.  
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Cells were cultured as in General HDFn Scrape Wounds Procedure (Experimental 
5.5, p178), with the exception that RNA was harvested after 24 h.   RNA was 
harvested with Qiagen’s RNeasy Mini Kit and RNase-Free DNase Set, following 
“Purification of Total RNA from Animal Cells using Spin Technology” and “Optional 
On-Column DNase Digestion with the RNase-Free DNase Set” protocols as outlined 
in Qiagen’s RNeasy® Mini Handbook Fourth Edition June 2012.  The steps followed 
from these protocols have been outlined in RNA Extraction Protocol (Experimental 
5.6, p179). 
The extracted RNA was analysed on a NanoDrop Spectrophotometer (Table 3.5.1).  
Experiments R4 and S4 were found to contain low quantites of RNA, possibly a result 
of incomplete aspiration of media during RNA extraction.  Samples R1-3 and S1-3 
were found to be of sufficient amounts and quality giving us the required number of 
replicates. The samples were sent to Qiagen to undergo RT-qPCR analysis. 
Table 3.5.1: Analysis of Extracted RNA. 
Test Group Volume [RNA] ng/ µL Control Volume [RNA] ng/ µL 
R1 27 µL 448.8 S1 27 µL 177.7 
R2 27 µL 446.4 S2 27 µL 482.9 
R3 27 µL 469.9 S3 27 µL 568.3 
R4 27 µL 23.4  S4 27 uL 66.0 
3.5.3 Human Cell Motility RT-qPCR Array Results 
The scatter plot provided in the Qiagen report is a quick way to visualise up or down 
regulation of each studied gene (Figure 3.5.3).  The central line indicates unchanged 
gene expression, genes above the line are upregulated, while those below are 
downregulated.  From this plot we can see that two genes (highlighted in red) have 
been upregulated, Insulin Like Growth Factor 1 (IGF1) and Alpha Actinin 3 (ACTN3).   
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Figure 3.5.3:  Scatter Plot of Gene Regulation.[42] 
 
Representing the data as a volcano plot (Figure 3.5.4) allowed us to visualise the 
statistical significance of the observed gene expression and the fold regulation of the 
genes.  Based on this analysis it can be determined that the two genes that have 
been upregulated (highlighted in red) vary in their statistical significance.  IGF1 has 
an undesirable p value of 0.332608, whereas, ACTN3 has a very low value of p = 
0.001347.   
IGF1 
ACTN3 
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Figure 3.5.4:  Volcano Plot of Statistical Significance vs Fold Gene Expression.[42] 
 
In summary, the array shows the over expression of two genes in the samples treated 
with (R)-methyl IGD peptidomimetic ((R)-2) compared to (S)-methyl IGD 
peptidomimetic ((S)-2), no genes were under expressed.  ACTN3 has been 
overexpressed by over three fold, and has a very low p value.  IGF1 was upregulated 
by over two fold, however, the reliability of this result may be in question due to the 
high p value (Table 3.5.2). 
 
Table 3.5.2: Summary of Upregulation of Gene Expression. 
Gene Over-Expressed Fold Regulation p-value 
ACTN3 3.1246 0.001347 
IGF1 2.1865 0.332608 
 
  
IGF1 
ACTN3 
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3.6 Implications of RT-qPCR Results 
3.6.1 Insulin Like Growth Factor 1  
The insulin like growth factor 1 gene (IGF1) encodes the homonymous protein Insulin 
Like Growth Factor 1 (Figure 3.6.1).[43]  The biological activity of this protein is well 
documented, with involvement in childhood growth and, crucially for our purposes, 
tissue repair. 
  
 
Figure 3.6.1:  Insulin Like Growth Factor-1.[44] 
 
During normal wound healing IGF1 is upregulated, and it plays a key role in 
reepithelialisation and the formation of granulation tissue, significantly, this activity is 
delayed or inhibited in diabetic patients.[45]  Reduced levels of IGF1 are implicated in 
the microvascular complications of diabetic patients.[46]  Further to this, in ex-vivo 
organ culture, healthy and diabetic tissues subjected to adenoviral overexpression of 
IGF-1 (Ad-IGF-1) show enhanced angiogenesis and wound healing in healthy and 
diabetic tissues.[47]    
Further to this IGF-1 regulates the expression of other proteins implicated in wound 
healing.  Vascular Endothelial Growth Factor (VEGF) and Hypoxia-Inducible Factor 
1 (HIF-1) are regulated by IGF-1 and are particularly implicated in wound healing due 
to their effect on tissue repair, angiogenesis and cell proliferation.[48]   
The high p value (0.332608) displayed with the upregulation of this gene casts doubt 
on the reliability of these results, and thus, it would be rash to conclude that the activity 
of the (R)-IGD peptidomimetic can be attributed to this observation.  However, this is 
an important find and it would be wise to do further tests to investigate the impact of 
the regulation of this gene on our observed activity.   
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3.6.2 Alpha Actinin 3 
The alpha actinin 3 gene (ACTN3) encodes Alpha Actinin 3 protein, also known as 
Alpha-Actinin skeletal muscle isoform 3 or F-actin cross-linking protein (Figure 3.6.2).  
As these names suggest, this protein is expressed by ACTN3 in skeletal muscle 
where its role is crosslinking actin containing filaments.  The Alpha-Actinin-3 (ACTN3) 
gene has been most studied for its implications in athletic prowess, with different 
athletic abilities being linked to the normal expression or defunct nature of this 
gene.[49]   
 
Figure 3.6.2: Alpha Actinin 3. [49] 
 
For our purposes the role of ACTN3 are a little less defined, there are many 
implications of the alpha actinin family of genes in cellular migration but less 
specifically relating to ACTN3 alone.  
The alpha actinin family are implicated in forming the cross linked actin cytoskeleton 
network that supports filopodia and lamellipodia (leading protrusions in migrating 
cells).[50]  The alpha actinin family are also involved in binding other proteins, such as 
viniculin and titin which are involved in focal adhesions (links between the internal 
actin cytoskeleton and the ECM).[51]  Alpha actinin links signalling proteins such as, 
phosphatidylinositol 3-kinase, PKN and Rho effector kinase to transmembrane 
receptors including β-integrins.[50] [52] It is possible that these interactions may 
responsible for the wound healing activity displayed by the (R)-IGD Peptidomimetic.   
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3.7 IGD Peptidomimetics with Synthetic Handles 
3.7.1 Background of Functionalised IGD Peptidomimetics  
Returning to the original modelling studies of the IGD tripeptide motif of MSF, we can 
see that the bicyclic ring system of the benzodiazepinone is essential to give our 
peptidomimetic the correct confirmation.  It is also true that any alteration in the 1,2 
or 3 positions of this bicyclic ring system would be likely to have significant 
implications for activity.  However, looking at Figure 3.7.1 we can see that it is 
possible that alteration of the N-methyl group may be possible without a loss of 
activity.[27]   
                              
Figure 3.7.1: Model of the IGD Tripeptide Motif (A), Benzodiazepinone core (B). 
 
Previously within the Marquez group Dr Phillip McGivern synthesised a small library 
of IGD peptidomimetics with a phenyl functionality attached to the benzodiazepinone 
core with varying alkyl chain lengths (Figure 3.7.2).  Biological testing of these 
analogues by trans-membane assay showed no reduction in motogenic activity, thus, 
providing evidence to the suitability for modification of this position.  
n = 1, (±)-34, n = 2 (±)-35, n = 3 (±)-36
NH
N
O
O CO2Me
n
 
Figure 3.7.2: IGD Peptidomimetics with N-Alkyl Phenyl. 
 
Dr. McGivern’s results, although preliminary, demonstrated that modification of the 
nitrogen substituents was indeed possible.  Two classes of analogue were 
envisioned, one that could give information about the mode of action of the IGD 
N-methyl group 
47 
 
peptidomimetic core and one that could be used for drug delivery (Figure 3.7.3).  With 
little information about the optimal length of any alkyl chain, n was designed to be one 
or three, to allow sufficient distance between the benzodiazepinone core and any new 
functionality whilst avoiding aggregation and coiling of the linker unit.   
 
Figure 3.7.3: IGD Peptidomimetics Functionalised for Investigation (35) or Delivery (36). 
 
In order to maximise the utility and versatility of the linker unit, it became desirable to 
synthesise a range of IGD peptidomimetics each containing a functionality that could 
be used in bond formation (Figure 3.7.4).  Thus, it was envisioned that accessing 
acids 37/38 or amines 39/40 and alkynes 41/43 or azide 44/45 would allow further 
derivatisation via amide coupling or Huisgen cyclisation.[53]   
 
Figure 3.7.4:  Desired Functionalised IGD peptidomimetics. 
 
The generation of the desired analogues was envisioned to proceed through 
divergence from alcohols 24/26 (Scheme 3.7.1).  It was hoped that oxidation of 
alcohols 24/26  would allow access to aldehyde 48/49 and acid 37/38.  An Ohira-
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Bestmann olefination could be employed to access alkyne 41/43 from aldehyde 
48/49.  Alkyne 41/43 could be used in Huisgen cyclisations, while the aldehyde unit 
49/49 could potentially be used in reductive amination.  Alternatively, tosylation of 
alcohol 24/26, would provide a good leaving group which could then be used to 
generate azide 44/45 and subsequently amine 39/40.  
 
Scheme 3.7.1:  Retrosynthetic Route of Functionalised IGD Peptidomimetics Diverging from 
Alcohols 24/26. 
 
Having established a reliable route to access multigram quantities of intermediate 18, 
it was possible to adapt our efforts towards an efficient synthesis of alcohols 24/26.  
The route was envisioned to proceed in an analogous manner to the synthesis of the 
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methyl IGD peptidomimetics ((R)-2 and (S)-2, Figure 2.1.1. p30) (Scheme 3.7.2).  
Thus, the synthesis would require the introduction of the linker arm via the reductive 
amination of aldehyde 18, followed by reduction and N-alkylation using triflate 20.[27]  
The alcohol would be unmasked after cyclisation, allowing the desired diversification 
with the n carbon chain providing the required space between the IGD core and any 
desired functional group. 
 
Scheme 3.7.2: Envisioned Route to IGD Peptidomimetics 24/26. 
3.7.2 Synthesis of Functionalised IGD Peptidomimetics  
3-Aminopropanol and 5-aminopentanol were chosen as precursors for the reductive 
amination.  The synthesis of amine 54 (Scheme 3.7.3) began with the protection of 
3-aminopropanol, with tert-butyldiphenylmethylsilyl chloride to generate silyl ether 58 
in good yield (85%).[54]  5-Aminopentanol was protected in an analogous manner 
giving silyl ether 59 in slightly lower yield (65%).   
Nitrobenzaldehyde 18 underwent reductive amination with the free amine 58 giving 
benzylic amine 54 in excellent yield (94%).  These conditions were reproduced for 
the reaction of the 5-amino-pentanol derived amine 59 and nitrobenzaldehyde 18 and 
gave the desired amine 55 in near quantitative yield (98%).  
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Scheme 3.7.3:  Synthesis of Silyl Ethers 55 and 55.  Reagents and Conditions: (i) TBDPSCl, 
DCM, 0 ºC, n = 1, 85%, n = 3, 65%; (ii) Heptane, CHCl3; (iii) MeOH, NaBH4, n = 1, 94%, n = 
3, 98%. 
The newly formed benzylic amines 54 and 55 were protected as BOC carbamates 60 
and 61 respectively in quantitative yields.  With the protected amines in hand, the 
reduction of the nitro group to the corresponding aniline was initially attempted using 
10% palladium on activated charcoal under a hydrogen atmosphere.  The use of 
hydrogen gas was found to give incomplete conversion, and ammonium formate was 
used to drive the reaction to completion (Scheme 3.7.4). 
Ammonium formate was found to be a slow but reliable method of hydrogenation, 
requiring increased time and higher temperatures than conditions reported for the 
generation of the corresponding methyl analogue, however, intermediates 52 and 53 
can be accessed under these conditions in excellent yield without the need for 
purification.  Attempts to improve rate of reaction, by changing the solvent to ethyl 
acetate proved to be counter productive, and methanol had to be added to the 
reaction mixture to drive the reaction to completion.   
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Scheme 3.7.4:  Protection and Hydrogenation to give 52 and 53.  Reagents and Conditions:  
(i) Di-t-butyldicarbonate, Et3N, DCM, n = 1, quantitative, n = 3, quantitative; (ii) NH4CO2H, 
Pd/C, methanol, n = 1, 78%, n = 3, 90%. 
With the anilines in hand, the next step was the introduction of the chiral diester unit.  
Following a parallel approach to synthesis of the methyl IGD peptidomimetics, (S)-
triflate ((S)-20), was generated by coupling (S)-(-)-dimethyl malate with 
trifluoromethylsulfonic anhydride in quantitative yield (Scheme 3.7.5).   
 
Scheme 3.7.5:  Formation of Activated Malate (S)-20.  Reagents and Conditions: (i) triflic 
anhydride, 2,6- lutidine, DCM, (quant). 
The newly formed malate proved to be slightly moisture sensitive and had to be used 
promptly.  Gratifyingly, immediate coupling of the chiral triflate ((S)-20) with anilines 
52 and 53 gave the desired secondary amines (R)-50 and (R)-51 in excellent yields 
(Scheme 3.7.6).   
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Scheme 3.7.6:  Formation of Chiral Intermediates (R)-50 and (R)-51.  Reagents and 
Conditions: (i) 2,6- lutidine, DCM, n = 1, 68%, n = 3, 73%. 
The efficient coupling of triflate (S)-20 with anilines 52/53 allowed us to get access to 
the precursor for the tetrahydrobenzodiazepinone cores for both chain lengths in 
excellent yields (n = 1, 50%, n = 3, 64%) over the five step sequence from 
nitrobenzaldehyde 18.  Significantly, this synthesis can be scaled up and requires 
minimal purification. 
   
53 
 
3.8 Benzodiazepinone Cyclisation 
3.8.1 Examples of Benzodiazepinone Formation 
Outwith work carried out in the Marquez group, there are several literature examples 
of formation of benzodiazepinones with a chiral centre at the 2-position.   
Synthesis of fibrinogen receptor antagonist 3 took place via the cyclisation of 
intermediate 62.  This approach used sodium methoxide in methanol to afford the 
cyclisation, this is the method most frequently used in the literature for the synthesis 
of the benzodiazepine core of benzodiazepinone derived RGD mimetics (Scheme 
3.8.1).[55]  
 
Scheme 3.8.1: Synthesis of 3.  Reagents and Conditions: (i) NaOCH3, CH3OH, reflux (70%).  
A related example employed triethylamine and toluene to achieve the cyclisation of 
compound 65 en route to complete the synthesis of 2-benzazepine 64 (Scheme 
3.8.2).[56]  
 
Scheme 3.8.2: Synthesis of 64.  Reagents and Conditions: (i) Et3N, toluene, reflux (98%). 
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Miller reported the synthesis of enantiomerically pure SB214857 (4, Scheme 3.8.3) 
through the intramolecular displacement of an activated aryl fluoride.[56]  The 
carboxylic ester 67 is sufficiently activated to allow this reaction to proceed giving 68 
in moderate yield (47%) as a single enantiomer along with the elimination product 69 
(27%). 
 
Scheme 3.8.3:  Key Cyclisation in Route to SB214859 (4).  Reagents and Conditions: (i) 0.1 
M 67 in DMSO, 125 °C (47% of 68, 28% of 69).   
3.8.2 Formation of the Benzodiazpinone Core: Propyl Analogues 
With the synthesis of the IGD peptidomimetic framework complete, the key cyclisation 
step was attempted. Treatment of Boc amine (R)-50 with trifluoroacetic acid cleanly 
removed the BOC group to yield the TFA salt (R)-70.  Sodium methoxide was then 
used to try to induce cyclisation as in previous syntheses, however, no cyclisation 
occurred and the free amine ((R)-72) was isolated in reasonable yield (76%) (Scheme 
3.8.4).   
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Scheme 3.8.4:  Isolation of Amine (R)-72.  Reagents and Conditions: (i) trifluoroacetic acid, 
DCM, (88%); (ii) NaOMe (2.0 eq.), MeOH, 70 ºC, 76%. 
As discussed previously, the majority of benzodiazepine cyclisations are carried out 
with sodium methoxide in methanol.[55, 57-58]  In an attempt to achieve cyclisation of salt 
(R)-70, the equivalents of sodium methoxide employed was increased.  
Thus, the amount of sodium methoxide was increased from 2 to 5 equivalents, 
however, this lead to degradation of starting material.  In subsequent attempts the 
number of equivalents was reduced to 3, with a short reaction time (5 minutes).  Thin 
layer chromatography at this point indicated that the starting material had been 
consumed, however, flash column chromatography failed to isolate any product from 
a complex reaction mixture (Scheme 3.8.5).   
 
Scheme 3.8.5: Attempted Synthesis of (R)-71.  Reagents and Conditions: (i) NaOMe (5.0 
eq.), MeOH, 70 ºC (degradation); (ii) NaOMe (3.0 eq.), MeOH, 22 ºC (degradation). 
In order to gain further insight into these reactions it was decided to isolate the 
secondary amine (R)-72 before subjecting it to further reactions.  Hence, after 
treatment of (R)-50 with trifluoroacetic acid, strong cation exchange silica was used 
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to in an attempt to generate the free amine (R)-72.  The SCX silica was washed with 
methanol to remove non-amine impurities and then flushed with 7 M ammonia in 
methanol solution.  However, unexpectedly and to our satisfaction, the major product 
isolated was the desired protected tetrahydrobenzodiazepinone (R)-71 in reasonable 
yield (48%) (Scheme 3.8.6).   
 
Scheme 3.8.6:  Synthesis of Protected Tetrahydrobenzodiazepinone (R)-71. Reagents and 
Conditions: (i) SCX Column, 7 M NH3/MeOH, (R)-70 48%. 
Interestingly, a simultaneous reaction using one equivalent of sodium methoxide 
yielded amine (R)-72 (30%) and cyclised alcohol (R)-24 (18%).  To our delight, 
solvation of the free amine (R)-72 in 7 M ammonia in methanol solution gave the 
protected tetrahydrobenzodiazepinone (R)-71 in quantitative yield (Scheme 3.8.7).   
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Scheme 3.8.7:  Synthesis of Protected and Deprotected Tetrahydrobenzodiazepinones (R)-
24 and (R)-71. Reagents and Conditions: (i) NaOMe (1.0 eq.), MeOH, amine (R)-72 30%, 
alcohol (R)-24 18%; (ii) NH3/MeOH, quantitative. 
As summarised in Table 3.8.1 after optimisation of the reaction conditions, it became 
possible to access the protected tetrahydrobenzodiazepinone (R)-71.  Thus, it 
became possible to generate the desired benzodiazepinone alcohol (R)-24  in 23% 
from amine (R)-72  or 12% overall yield from 18.   
Table 3.8.1:  Summary of Yields, Products and Reaction Conditions for Cyclisations and 
Deprotections. 
Starting 
Material 
Reaction and Conditions Yields and Products 
Salt (R)-70 NaOMe (1.0 eq.), 22 ºC (R)-72 (30%), (R)-24 (18%) 
Salt (R)-70 NaOMe (2.0 eq.), 70 ºC, (R)-72 (76%) 
Salt (R)-70 NaOMe (5.0 eq.), 70 ºC Degradation 
Salt (R)-70 NaOMe (3.0 eq.), 22 ºC Degradation 
Salt (R)-70 SCX Column, 7 M NH3/MeOH (R)-71 (48%). 
Amine (R)-72 7 M NH3/MeOH (R)-71 (quant.) 
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The protected tetrahydrobenzodiazepinone (R)-71 was then taken on and 
deprotected using TBAF (Scheme 3.8.8). The reason for the low yield is not apparent, 
however, a number of low yields using TBAF were reported throughout the Marquez 
group at this time, thus, it is possible that the yield could be improved upon 
optimisation.   
 
Scheme 3.8.8:  Deprotection of Benzodiazepinone (R)-71.  Reagents and Conditions: (i) 
TBAF, THF (30%).   
 
3.8.3 Formation of the Benzodiazpinone Core: Pentyl Analogues 
Having successfully synthesised alcohol (R)-24, the ammonia/methanol and strong 
cation exchange conditions were applied to the synthesis of the five carbon chiral 
intermediate (R)-26 (Scheme 3.8.9).  Thus, trifluoroacetic acid deprotection, followed 
by purification with a SCX column and subsequent flash column chromatography 
provided us with benzodiazepinone (R)-26 as the free alcohol (46%), with a small 
amount of uncyclised, deprotected amine (R)-73  9%.  
Upon further optimisation of the deprotection cyclisation process, the ammonia 
methanol eluent from the SCX column was allowed to stand for an increased time (2 
hours) before being concentrated in vacuo.  This minor, yet important modification 
increased the yield of alcohol (R)-26  to 56% with no side products being obtained. 
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Scheme 3.8.9:  Cyclisation and Deprotection.  Reagents and Conditions: (i) trifluoroacetic 
acid, DCM; (ii) SCX, 7 M NH3/MeOH, (R)-26 (46%), (R)-73 (9%). 
It was clear that the use of trifluoroacetic acid for the carbamate deprotection was not 
an intuitive deprotection strategy when working with TBDPS protected compounds.  
In an attempt to improve yields, and avoid unwanted deprotections, the carbamate 
deprotection was carried out with 5% hydrochloric acid in ethyl acetate, and the 
resultant mixture was dissolved in ammonia methanol solution.  This method yielded 
alcohol (R)-26 (39%) and of acetate (R)-74 (50%), suggesting that the labile nature 
of the TBDPS group under acidic conditions is responsible for the low yields rather 
than fluoride ions in the TFA (Scheme 3.8.10).   
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Scheme 3.8.10:  Deprotection and Cyclisation of (R)-51 Using Hydrochloric Acid.  Reagents 
and Conditions: (i) 5% HCl in EtOAc; (ii) 7 M NH3 in MeOH, (R)-26 (39%), (R)-74 (50%). 
Since it was evident that a stepwise strategy would not be possible, it was decided to 
focus on a telescopic approach that would combine as many steps as possible.  It 
was found that increasing the reaction time of the trifluoroacetic acid deprotection 
from 18 to 32 hours before purification with SCX silica and 2 hours in 7 M ammonia 
methanol solution yielded the desired alcohol (R)-26 in 95% without the need for 
subsequent column chromatography (Scheme 3.8.11).  This improved methodology 
allowed access to alcohol (R)-26  in 61% yield from nitrobenzaldehyde 18.  
 
Scheme 3.8.11:  Deprotection and Cyclisation of (R)-51 Using Trifluoroacetic Acid.  
Reagents and Conditions: (i) TFA in CH2Cl2; (ii) SCX silica, 7 M NH3 in MeOH (95%). 
This improved and optimized synthetic route was then applied to the synthesis of the 
(S)-IGD peptidomimetic ((S)-26) (Scheme 3.8.12) giving the desired alcohol in 77% 
yield from aniline (53).   
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Scheme 3.8.12: Synthesis of (S)-IGD Peptidomimetic (S)-26.  Reagents and Conditions: (i) 
(S)-20, 2,6-lutidine, CH2Cl2; (ii) TFA, CH2Cl2 ; (iii) SCX, 7 M NH3/MeOH (77%). 
 
The newly developed conditions for benzodiazepinone cyclisations were then also 
applied to the synthesis of methyl IGD peptidomimetic (R)-2.  Deprotection of (R)-14 
proceeded with trifluoroacetic acid, and strong cation exchange conditions were 
employed to promote cyclisation giving the desired methyl IGD peptidomimetic ((R)-
2) in 90% over the two steps, a slight improvement of the 85% yield previously seen 
upon deprotection and subsequent cyclisation with sodium methoxide (Scheme 
3.8.13).   
 
Scheme 3.8.13: Synthesis of (R)-Methyl IGD Peptidomimetic ((R)-2).  Reagents and 
Conditions: (i) TFA, CH2Cl2; (ii) SCX, 7 M NH3/MeOH (90%). 
 
These synthetic conditions were applied to the synthesis of the (S)-methyl-
enantiomer ((S)-2).  N-Alkylation proceeded in good yield (86%) and deprotection and 
cyclisation occurred in yields analogous to the (R)-methyl IGD peptidomimetic (88%) 
(Scheme 3.8.14).   
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Scheme 3.8.14: Synthesis of (S)-Methyl IGD Peptidomimetic ((S)-2).  Reagents and 
Conditions: (i) TFA, CH2Cl2; (ii) SCX, 7 M NH3/MeOH (88%). 
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3.9 Diverging from IGD Peptidomimetic Alcohols 24 and 26 
Having successfully formed benzodiazepinone cores with both the 3 and 5 carbon 
chain handles, our efforts were focused on diverging from the primary alcohols 24 
and 26.  Manipulation of the hydroxyl groups and the generation of other functional 
groups would allow us to tag our IGD peptidomimetic core with technologies which 
would be used to gain information about their mode of action or used for drug delivery.   
3.9.1 Diverging from Propyl IGD Peptidomimetic Alcohol 24  
Thus, small amount of alcohol (R)-24 gained through our synthetic approach was 
subjected to tosylation conditions.  Tosylation of (R)-24 (Scheme 3.9.1) gave poor 
conversion with only a small amount of impure tosylate (R)-46 being isolated.  
The lower yields in the synthesis of alcohol (R)-24  compared to the longer chain 
analogue ((R)-26) and the difficulty in modifying the alcohol group encouraged efforts 
to be directed towards the synthesis of the five carbon chain analogues and thus, no 
further experimentation took place with the three carbon chain analogues. 
 
Scheme 3.9.1: Attempted Tosylation of Alcohol (R)-24.  Reagents and Conditions: (i) TsCl, 
NEt3, CH2Cl2. 
3.9.2 Diverging from Pentyl IGD Peptidomimetic Alcohol 26 
In contrast to the 3 carbon chain analogue, reaction of the 5 carbon chain analogue 
proved to be extremely reliable with tosylation of alcohol (R)-26 proceeding to give 
tosylate (R)-47 in excellent yield (quant.) (Scheme 3.9.2).  Tosylate (R)-47 was then 
reacted with sodium azide to give the desired azide (R)-45 (78%).  The corresponding 
amine ((R)-40) was then synthesised through  hydrogenation using 10% palladium 
on activated charcoal and hydrogen gas in methanol (78%).   
This efficient approach to the 5-carbon chain analogues allowed access to tosyl, azide 
and amine derived IGD peptidomimetics from commercially available 3-methoxy-2-
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nitrobenzaldehyde (18) in reliable yields of 47, 47, 37% respectively over 10, 11 or 12 
steps. 
 
Scheme 3.9.2: Synthesis of Amine (R)-40 from Alcohol (R)-26.  Reagents and Conditions: 
(i) TsCl, NEt3, CH2Cl2 (quant.); (ii) NaN3, DMF (78%); (iii) H2, Pd/C, MeOH (78%). 
By comparison tosylation of (S)-alcohol ((S)-26) was achieved in good yield albeit 
lower than the (R)-counterpart (72%).  Tosyl group displacement with sodium azide 
yielded the desired azido-derivative (S)-45 in excellent yield (87%).  Hydrogenation 
of azide (S)-45 afforded the desired amine ((S)-40) in good yield (70%) giving (S)-
IGD peptidomimetic amine (S)-40 in 23% yield over twelve steps from commercially 
available materials (Scheme 3.9.3). 
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Scheme 3.9.3:  Synthesis of (S)-IGD Mimetic ((S)-40).  Reagents and Conditions: (i) TsCl, 
NEt3, CH2Cl2 (72%); (ii) NaN3, DMF (87%); (iii) H2, Pd/C, MeOH (70%). 
 
With access to tosyl ((S)-47), azido ((S)-45) and amine ((S)-40) analogues 
established, efforts were directed towards the synthesis of the carboxylate units.  
Thus, attempts were made towards achieving the oxidation of alcohol (S)-26. 
Initial efforts towards the transformation of the alcohol (R)-26 to acid (R)-38 employed 
tetrapropylammonium perruthenate (TPAP) and N-methylmorpholine oxide.  
However, this was unsuccessful, with crude NMR analysis showing no trace of the 
desired aldehyde (Scheme 3.9.4).[59]  It was observed that the TPAP used was dark 
in colour and thus, may not have been of sufficient quality to promote reaction.  Time 
constraints allowed no further attempts towards the synthesis of (R)-38, however, it 
is possible that repetition of this experiment with fresh TPAP could have been 
successful. 
Alcohol (R)-26 was then subjected to Swern conditions, with the crude NMR analysis 
suggesting that a small amount of oxidation to the desired aldehyde may have 
occurred, however, significant degradation and multiple IGD peptidomimetic 
compounds were also detected.[60]  TEMPO and BAIB were used in the hope of a 
more clean transformation, however, once again proton NMR analysis suggested that 
small amounts of (R)-49 may have formed but were minimal compared to starting 
material and other undesired side products.[61]   
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It was thought that perhaps the lack of reaction observed may be a result of 
incompatible functionality between the secondary amine and the oxidants.  Iwabuchi 
has recently discussed the “non-productive interaction” between the oxoammonium 
species present in nitroxyl radical catalysts and amine containing substrates (Figure 
3.9.1).[62] 
 
Figure 3.9.1:  Oxoammonium Catalysis and Nonproductive Interaction between 
Oxoammonium and Amine. 
 
Iwabuchi however, reports the use of AZADO and copper (I) to selectively oxidise 
alcohols in the presence of primary, secondary and tertiary amines (Figure 3.9.2).  
Iwabuchi suggests that the copper catalyst coordinates to the oxygen forming a 
copper alkoxide preferentially to a copper amide, and thus, effective oxidation can 
occur.  
 
Figure 3.9.2: Coordination of Copper to Amino Alcohol Allowing Oxidation in the Presence 
of an Amine. 
 
Unfortunately, upon treatment of primary alcohol (R)-26 with AZADO, copper chloride 
and a seventy two hour reaction time, crude 1H NMR showed no desired aldehyde 
signal.  It is possible that persistence and a comprehensive screen of conditions may 
allow access to either the aldehyde or the carboxylic acid in the future, but to date no 
oxidation product could be isolated. 
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Scheme 3.9.4: Proposed Route to Aldehyde (R)-49 and Acid (R)-38.  Reagents and 
conditions: (i) TPAP, NMO, MeCN, H2O (failed). (i) DMSO, SOCl2, (OCCl)2, DCM, (failed); 
TEMPO, BAIB, DCM (failed); AZADO, CuCl, DMAP, Bipyridine, MeCN (failed). 
 
The difficulty found in attempting to oxidise alcohol (R)-26 prompted us to consider 
new approaches for its transformation.  Attempts were made at introducing an alkyne 
functionality through alkylation of alcohol (R)-26 (Scheme 3.9.5).  Initially alkylation 
was attempted with propargyl bromide, however, despite the use of extensive 
experimentation no reaction was observed.[63] 
 
Scheme 3.9.5: Attempted Alkylation of Alcohol (R)-26.  Reagents and conditions: (i) TBAI, 
NaI, BrCH2CCH, 2,6- lutidine, THF (failed); TBAI, NaI, BrCH2CCH, KOH, THF, 50 °C (failed); 
TBAI, NaI, BrCH2CCH, K2CO3,THF (failed). 
 
Propargyl alcohol was then deprotonated in an attempt to couple with tosylate (R)-47 
it through a displacement reaction.  Disappointingly, 1H NMR analysis indicated the 
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presence of the tosyl group in the product, while also showing the absence of the 
methyl ester (Scheme 3.9.6).  
 
Scheme 3.9.6:  Attempted Displacement of Tosyl Group. Reagents and conditions: (i) NaH, 
HCCCH2OH, THF (failed). 
 
This prompted us to consider carrying out the reaction in the presence of the free 
carboxylic acid, in order to avoid side reactions.  Saponification of ester (R)-47 to the 
corresponding carboxylic acid (R)-76 with potassium trimethylsilane occurred in 50% 
yield (Scheme 3.9.7).  Subsequent displacement of the tosyl group of (R)-76 was 
attempted with propargyl alcohol anion.  1H NMR analysis suggested that the tosyl 
group had been removed, however, no product was isolated despite repeated 
attempts.  Interestingly, characterisation of carboxylic acid (R)-76 by 13C NMR 
demonstrated the compound’s poor stability, which could account for the difficulties 
encountered during the synthesis and isolation of (R)-77. 
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Scheme 3.9.7: Saponification of (R)-47 and Attempted Displacement.  Reagents and 
conditions: (i) KOSiMe3, Et2O, then HCl (aq.) (50%); (ii) NaH, HCCCH2OH, THF (failed). 
 
In conclusion, tosyl, azide and amine-containing IGD peptidomimetics were 
synthesized efficiently and in good yields.  Significantly, this approach allows the 
possibility of using these analogues in amide couplings and Huisgen cyclisations, 
opening up many potential coupling partners.  At this point our efforts were directed 
towards applying these analogues alongside various technologies to gain further 
knowledge of the origin of the biological activity of IGD peptidomimetic, and to 
investigate potential modes of delivery.    
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3.10 IGD Peptidomimetic Immobilisation  
The logical development of a drug with wound healing properties and topical 
application would be its incorporation into a medical device such as a bandage or 
other wound dressing.  Ligand immobilisation could be a useful method for the future 
development of the IGD peptidomimetic.  Further to this, the potential angiogenic 
properties of these mimetics may allow scope as part of a biologically active implant.   
Furthermore, an immobilised ligand could be used to study binding to various cell 
types that overexpress (or do not express) particular cell surface receptors.  Biological 
studies of this kind would be particularly interesting with cells that express different 
integrins.[64] 
Foillard reported the immobilisation of a multivalent, RGD containing peptide on to a 
NovaSyn® TG resin in an effort to evaluate the effects of clustered vs individual RGD 
peptide ligands on integrin α5β3  binding. [65]  NovaSyn® TG carboxy resin is an 
appropriate choice of solid support as it has many features that would be desirable 
for any future biological testing.  This resin is commercially available as 130 µM beads 
are comprised of a composite of low cross-linked polystyrene and 3000-4000 
molecular weight polyethylene glycol, of which the ends are functionalised with 
carboxylic acid groups (Figure 3.10.1, A).   The hydrophilic nature of the polyethylene 
glycol chains allow the immobilised ligand to sit at some distance from the core of the 
bead in aqueous solution, which is a necessary feature for any cell work.  These 
beads are non toxic and non magnetic, allowing for in vitro work and NMR analysis.  
The loading of the carboxylic acid functionality is described as 0.20-0.30 mmole/g 
resin (Figure 3.10.1, B).  
 
Figure 3.10.1:  NovaSyn TG carboxy resin. A. Cross-linked hydroxyethylpolystyrene 
polyethylene glycol. B. Schematic of Bead.  
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Foillard decorated the beads in three ways (Figure 3.10.2), compounds 78 and 79 
contained one and four recognition elements.[65]  Compound 80 bore a nonsense 
RβAD peptide that served as a control for biological tests.   
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Figure 3.10.2:  Synthesised Immobilised Ligands. 
The ability of the cells to bind to the resin through RGD-α5β3 was then assessed using 
Human Embryonic kidney cells (HEK 293) which express a high level of α5β3 integrins 
(Figure 3.10.3).  The cells were incubated with the three resins for thirty minutes at 
37 °C.  Both resins exhibiting the RGD functionality were found to bind to the cells, 
80 did not.  At very low densities (2 nmol/gresin) only the clustered resin 79 was 
effective in binding to the cells.  The resin beads were also found to be capable of 
capturing α5β3 – expressing cells from a biological mixture.  
a)  b)  
Figure 3.10.3: Optical Microscopy Images of Cell Adhesion to Resin Beads.  HEK 293 were 
treated with 0.2 mmol/gresin a) Resin 78 b) Resin 79, incubated for 30 mins at 37 °C and then 
fixed and stained with methylene blue. 
Work of a similar nature would require the development of facile chemistry that could 
be carried out on a solid support.  The robust synthesis of the amine IGD 
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peptidomimetic (40) provided us with an ideal platform from which to start, with an 
amide coupling as a natural choice for our preliminary work in this area. 
Thus, the coupling of the IGD mimetic (R)-40 and the carboxylic acid bead was 
attempted with HBTU and DIPEA (Scheme 3.10.1).  Upon filtration it was observed 
that the beads were no longer free flowing.  Microscopy showed that very few 
spherical beads remained, the majority having formed amalgams of damaged beads.  
It was hypothesised that this damage was the result of collisions caused by the 
internal stirrer bar.  The experiment was repeated, this time with a source of external 
stirring.  This approach was successful in allowing the beads to couple to the 
peptidomimetic and retain their integrity.  Dr Michael Hansen (Max Planck Institute) 
was able to confirm the new amide bond by Magic angle spinning, liquid state, proton 
NMR (for 1H NMR spectrum please see Appendix 6.4, p 183-184).  
Scheme 3.10.1: Attachment of Amine (R)-40 to Bead.  Reagents and Conditions: (i) HBTU, 
DIPEA, CH2Cl2. 
The polystyrene nature of these beads results in significant swelling upon treatment 
with solvent, leaving dichloromethane molecules within the bead.[66]  This property 
was noted by Foillard as the beads were swollen in DCM before reaction, but it was 
not discussed any further.  This particular property must be recognised as an area of 
concern in biological testing.  It is entirely possible that solvent (or other small 
molecules from synthesis) could leach from the bead into any biological assay and 
interfere with results obtained.   
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While this approach remains a useful indication of cell-ligand interactions, but it would 
be sensible to exercise caution when attempting to quantify any results gained.  It 
would also be important to ensure that all beads had been exposed to the same 
chemicals when comparing two or more functionalised beads.  If we take the example 
of DMSO as a solvent or reagent, small amounts leaching from beads to cells could 
have a large impact on the health of treated cells. 
Please see p 81 for further discussion of this work.  
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3.11 Synthesis of BODIPY IGD Peptidomimetic via an Amide Coupling  
3.11.1 BODIPY FL 
Fluorescent molecules are extremely useful for the investigation of ligands and 
receptors.  Their inherent properties are useful in showing the location of receptors 
present in low concentrations, as well as the reversibility of ligand binding, and binding 
affinity.[67]  
The BODIPY family are a range of fluorophores that span the visible spectrum.  Their 
versatility and desirable spectral characteristics affords their increasing use in the 
literature.  The BODIPYs have a common 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
chromophore (82, Figure 3.11.1), the electrical neutrality of this core allows increased 
cell permeability compared to charged fluorophores.[68] 
BODIPY FL (83) is considered to be a replacement for fluorescein (84) due to its 
enhanced properties including, a red shift in fluorescence emission at high 
concentrations.  This is particularly useful for example in in vitro studies, allowing easy 
detection of areas of high concentration of BODIPY FL-ligand conjugate within cells.  
Further to this, BODIPY FL has an increased photostability compared to 
fluorescein.[68] 
 
Figure 3.11.1:  BODIPY Core 82, BODIPY FL (83) and Fluorescein (84). 
3.11.2 Synthesis of a BODIPY Tagged IGD Peptidomimetic 
A fluorescent peptidomimetic analogue was designed with the intention to determine 
the peptidomimetic’s cellular localisation, as it was hoped that this would give an 
insight into the mechanism of action.  Retrosynthetically, the fluorescent IGD 
peptidomimetic (Scheme 3.11.1) was envisioned as originating from the IGD amine 
(R)-40 and BODIPY FL (83) which is well known for its favourable properties in 
biological testing.  
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Scheme 3.11.1: Target Fluorescent IGD Peptidomimetic (R)-85. 
 
The synthesis of BODIPY FL (83) was carried out following the route developed by 
Malan.[69]  Thus, pyrrole-2-carboxaldehyde (86) was reacted with methyl 
(triphenylphosphoranylidene)acetate in a Wittig reaction to give the desired 
conjugated ester alkene 87 in moderate yield (49%), as a single geometric isomer.  
Hydrogenation of ester 87 proceeded in quantitative yield to afford the desired ester 
88.  The coupling partner 3,5-dimethyl-pyrrole-2-carbaldehyde (90) was synthesised 
from 3,5-dimethyl-pyrrole (89), in excellent yield (83%) through Vilsmeier–Haack 
conditions.   
Coupling of ester 88 with aldehyde 90 in the presence of phosphorous oxychloride 
gave a crude intermediate which upon treatment with boron trifluoride diethyl etherate 
and Hünig’s base gave the BODIPY derivative 91 in 44% yield.  Subsequent 
hydrolysis of ester 91 with hydrochloric acid gave the BODIPY FL free acid (83) in 
50% yield (Scheme 3.11.2).  The optimisation of this hydrolysis, was attempted by 
the Marquez group and other academic groups, however, yields remain moderate.[70]   
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Scheme 3.11.2:  Synthesis of BODIPY FL (83).  Reagents and Conditions:  (i) 
Ph3PCHCO2Me, CH2Cl2 (49%); (ii) Pd/C, MeOH, H2, 40 °C (quant.); (iii) POCl3, DMF (83%); 
(iv) POCl3, CH2Cl2 then BF3·OEt2 , DIPEA (44%); (v) THF, H2O, HCl (50%). 
With BODIPY FL (83) in hand, it was now possible to attempt the coupling to the IGD 
mimetic (R)-40 (Scheme 3.11.3).  Thus, coupling of acid 83 and amine (R)-40 with 
HBTU and N,N-diisopropylethyldiamine yielded a one to one mixture (dark red) of the 
desired adduct (R)-85  with the urea byproduct.  Extensive, repeated purification by 
flash column chromatography yielded a clean sample of the key IGD-peptidomimetic 
BODIPY derivative (R)-85.   
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Scheme 3.11.3:  Synthesis of Benzodiazepine (R)-85.  Reagents and Conditions: (i) HBTU, 
DIPEA, CH2Cl2 (37%). 
With the fluorescent IGD BODIPY derivative in hand visualisation studies were 
attempted using mouse embryoic fibroblasts (MEF) in collaboration with Dr Niall 
Fraser (MVLS, University of Glasgow). 
Mouse embryonic fibroblasts were cultured in DMEM (Gibco) with 10% FBS, 
penicillin/streptomycin and L-glutamine (2mM) in a 5% CO2 atmosphere at 37 oC. 
Cells were seeded onto cover slips in 6 well plates (Corning) and incubated in serum 
free DMEM before treatment with 4 nM serum free media solution of BODIPY IGD 
peptidomimetic (R)-85.  Pictures were taken with a Zeiss Axio Imager M1 
fluorescence microscope at × 400 magnification (Figure 3.11.2). 
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Figure 3.11.2: Poor Contrast in Mouse Embryonic Fibroblasts Treated with BODIPY IGD 
Peptidomimetic (R)-85. 
 
Upon inspection of the confocal images, two main observations were made: firstly, 
the fluorophore had been internalised by the cells and secondly, that the contrast 
between the cells and the media was poor.  Internalisation of the probe was not 
expected but not concerning, however, the internalisation coupled with the high 
concentrations of fluorophore remaining in the media suggested that hydrolysis of the 
amide functionality was taking place (Scheme 3.11.4).  Previous work within the 
Marquez group has noted the indiscriminate distribution of free BODIPY tags in media 
and cellular environments. 
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Scheme 3.11.4:  Potential Hydrolysis of Fluorescent IGD peptidomimetic (R)-85. 
 
The observed potential hydrolysis of the amide link under physiological conditions 
may also have serious implications for the immobilised IGD peptidomimetic ligand. 
Thus, it was reasoned that in order to rule out this possibility, a more biologically 
stable analogue must be generated before any further biological experiments take 
place.  
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3.12 Synthesis of BODIPY IGD Peptidomimetic via Meso Substitution  
3.12.1 8-(Methyl-thio)-BODIPY 
Thioether containing BODIPY 92 cores allow for the direct addition of alcohols and 
amines to the BODIPY unit under copper catalysed mild conditions, through an “SNAr-
like” reaction as reported by Cabrera (Scheme 3.12.1).[71]  Mechanistically, the soft 
copper ion of copper(I)-thiophene-2-carboxylate coordinates to the sulfur, and 
weakens the C-S bond facilitating the attack of the alcohol.  It was postulated by the 
authors that the strong (45-55 kcal/mol) S-CuTC bond is the driving force for this 
reaction.   
 
Scheme 3.12.1: Synthesis of Hemicyanine and Merocyanine.  Reported Reagents and 
Conditions: (i) CuTc, Na2CO3, MeOH, MeCN, 55 °C (73%) (ii) CuTc, Na2CO3, MeNH2, 
MeCN, 55 °C. 
 
It was thought that a thioester substituted BODIPY 92 could be treated with either an 
IGD peptidomimetic amine or alcohol to give a suitable fluorescent analogue.  
Significantly, it was expected that an amine or ether linkage would prove to be more 
stable to hydrolysis than the previously developed amide (R)-85 (Scheme 3.12.2). 
 
Scheme 3.12.2: Substitution Route to IGD Peptidomimetic Fluorophore.   
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The synthesis of thiomethyl BODIPY 92 proceeded as outlined by Biellmann starting 
from pyrrole (Scheme 3.12.3).[72]  Coupling of pyrrole with thiophosgene afforded 
thioketone 97 in low yield (43%).  Subsequent reaction of thioketone 97 with methyl 
iodide gave the interemediate salt which was treated with diisopropylethyl amine and 
boron trifluoride to give the desired thiomethyl BODIPY 92 in 6% yield.   
 
Scheme 3.12.3:  Synthesis of BODIPY 92.  Reagents and Conditions: (i) PhMe, SCCl2, 
Et2O, 10% MeOH (aq.) (43%); (ii) DCM, MeI, then Et3N, BF3.Et2O (6%). 
Unfortunately, treatment of 92 with copper thiophene-2-carboxylate, sodium 
carbonate and alcohol (S)-26 showed little progress thermally at 55 °C.  Microwave 
heating to 150 °C did show consumption of BODIPY 92, however no fluorescent 
product could be isolated (Scheme 3.12.4).   
Amine (S)-40  was then used as the nucleophile in a subsequent reaction in the hope 
of achieving the desired coupling.  Excitingly, mixing amine (S)-40  with BODIPY 92 
at room temperature saw spot to spot conversion (40%).  Disappointingly, upon 
purification it was found that (S)-95 was very weakly fluorescent compared to the 
parent BODIPY (92) and would not be suitable for biological testing.  Although the 
poor fluorescence of compound (S)-95 is disappointing, this result is not entirely 
unexpected, with examples of meso substituted BODIPYs with altered fluorescence 
being known in the literature. [55[71] 
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Scheme 3.12.4: Displacement of Methylthio Group.  Reagents and Conditions: (i) BODIPY 
92, CuTC, NaCO3, MeCN (40%).   
 
The electron donating properties of an amine substituent will increase the LUMO 
energy of the system without affecting the HOMO.  This increase is manifested as a 
larger Stokes shift.  As expected, amine substituents display a more pronounced 
effect than their oxygen counterparts.  In this case, we parallel this trend, we see a 
hypsochromic shift induced by meso position heteroatoms again with the amine 
compound being affected more than their oxygen counterparts.  It is possible that this 
is the cause of our poor fluorescence.  Another theory is that intramolecular charge-
transfer (ICT) can be problematic for BODIPY groups conjugated with secondary or 
tertiary amines in polar solvents.  With these points in mind it seemed likely that 
successful synthesis of a fluorescent IGD compatible with biological testing in 
aqueous solutions would have to follow a different pathway. 
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3.13 Synthesis of BODIPY IGD Peptidomimetic via Huisgen Cyclisation  
3.13.1 Alkyne BODIPY 
Having completed the synthesis of the azide IGD peptidomimetic ((R/S)-45), the 
coupling of our bioactive core to a BODIPY was envisioned to proceed via a Huisgen 
cyclisation (Figure 3.13.1).  The structure of the alkyne BODIPY coupling partner was 
not defined at this point, but must have no labile bonds between the alkyne and the 
BODIPY core, and must not have diminished fluorescence. 
 
Figure 3.13.1: General structure of desired fluorescent labelled IGD mimetic. 
 
BODIPY alkynes such as 98 made via meso substitution could potentially suffer from 
the reduced fluorescence issues as previously seen.  Although there are several 
BODIPY alkynes known in the literature, many of these would not be suitable as the 
alkyne functionality is attached to the BODIPY core through a potentially labile bond 
such as an amide or ester (99) (Figure 3.13.2).  Alkyne BODIPY 100 is a rarer 
example of a molecule with no labile bonds between the alkyne functionality and the 
BODIPY core, and consequently alkyne 100 was our chosen cyclisation partner.   
 
Figure 3.13.2:  Examples of Alkyne Containing BODIPYs. 
 
The synthesis of alkyne BODIPY 100 began with 6-heptynoic acid (101) in a one pot 
procedure following Overklefff’s procedure.[73]  The reaction of 6-heptanoic acid with 
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oxalyl chloride generated the desired acid chloride 102 (Scheme 3.13.1).  
Subsequent reaction of acid chloride 102 with 2,4-dimethylpyrrole and boron 
trifluoride generated alkyne BODIPY 100 as an impure red/green oil.  Overkleff 
reports that flash column chromatography (10% acetone in petroleum ethers) and 
recrystallization (unspecified conditions) should afford alkyne 100.  However, in our 
hands multiple rounds of flash column chromatography failed to give clean alkyne.   
 
Scheme 3.13.1: Synthesis of Alkyne BODIPY 100.  Reagents and conditions: (i) (OCCl)2, 
DMF, PhMe; (ii) 2,4-dimethyl pyrrole, DCE; (iii) BF3·Et2O, DIPEA. 
 
The impure alkyne 100 was taken forwards to the cyclisation with the azido IGD 
peptidomimetic ((R)-45) (Scheme 3.13.2).  1H NMR studies suggest that it is possible 
that a click product formed (lack of alkyne peak and CH2 alpha to N3 shifted), however, 
due to low yields and impure alkyne starting material it was not possible to isolate any 
of the desired product.  
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Scheme 3.13.2: Huisgen Cyclisation with Impure Alkyne 100.  Reagents and conditions: (i) 
DIPEA, CuI, PhMe. 
 
3.13.2 Substitution Approach to Alkyne Synthesis 
The difficulties in accessing an appropriate alkyne containing BODIPY, prompted us 
to attempt to design and develop a novel alkyne containing BODIPY (104) (Figure 
3.13.3).  It was reasoned that the incorporation of the alkyne at the C3 position would 
provide us with the desired emission wavelength. 
 
Figure 3.13.3: Desired Alkyne Containing BODIPY 104. 
 
Our synthesis began with the reduction of pyrrole 88, with lithium aluminium hydride 
to give alcohol 105 in excellent yield (83%).  Alcohol 105 was then tosylated in good 
yield (77%) to access novel tosylate 106 (Scheme 3.13.3). Treatment of tosylate 106 
with lithium acetylide showed spot to spot conversion by TLC, however, no product 
was isolated.  It was hypothesised that the likely high volatility of 107 could be the 
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cause of this lack of material, and the desired product may have been lost upon rotary 
evaporation during reaction work up.   
 
Scheme 3.13.3: Attempted Synthesis of Alkyne Pyrrole 107.  Reagents and conditions: (i) 
LiAlH4, diethyl ether (83%); (ii) TsCl, NEt3, DCM (77%); (iii) LiCCH, THF (0%). 
 
In order to circumnavigate the potential volatility issue, tosyl pyrrole 106 was treated 
with pyrrole carbaldehyde 89 under BODIPY forming conditions. Gratifyingly, this 
generated the desired novel tosyl BODIPY 108 in good yield (67%) (Scheme 3.13.4).   
 
Scheme 3.13.4: Synthesis of Tosyl BODIPY 108.  Reagents and conditions:  (i) POCl3, 
DCM, then DIPEA, BF3·Et2O (67%). 
 
Tosyl BODIPY 108 provided us with a shelf stable platform that could be used to 
provide late stage divergence in BODIPY synthesis (Scheme 3.13.5). To test the 
suitability of the tosylate BODIPY in displacement reactions, it was initially treated 
with sodium azide and DMF.  Excitingly, this reaction was successful in producing the 
azide in a 50% yield without the need for optimisation. 
 
Scheme 3.13.5: Substitution of Tosyl Group.  Reagents and conditions:  (i) NaN3, DMF 
(50%). 
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Unfortunately, the displacement of the tosyl functionality with an alkyne unit proved 
more challenging (Scheme 3.13.6).  Displacement attempts with lithium acetylide 
(90% ethylene diamine complex), saw poor conversion of starting material to any new 
fluorescent spots (Table 3.13.1, entries 1-7).  A degree of success was achieved by 
using 5 eq. of lithium acetylide at 40 ºC, which showed a new fluorescent spot, with a 
higher Rf than the starting material by TLC.  This product was isolated by flash column 
chromatography, and was found to have no signals indicative of a tosyl group, 
however, the 4 mg of material was not pure enough to allow reliable characterisation.  
However, all other optimisation attempts failed to yield any of the desired adduct. 
Switching to ethylnyl magnesium bromide in an effort to displace the tosyl group 
(Table 3.13.1, entries 8-12) gave very little conversion.  Increasing the amounts of 
nucleophile to 10 and 15 eq. showed conversion of starting material into a new 
compound by thin layer chromatography.  This new spot also had a higher Rf than 
the starting material, however, IR analysis indicated that this molecule did not contain 
an alkyne unit.  The new spot was analysed by mass spectrometry, and was found to 
be a monobrominated derivative which was not investigated further. 
Sodium hydride was then used to deprotonate trimethyl silyl acetylene to generate a 
stock solution which was then used to attempt to displace the tosyl group.  Again a 
new high Rf fluorescent spot was seen by TLC, however, this was minimal compared 
to amounts of starting material in the reaction mixture.  A wide range of reaction 
conditions (-78 °C - 45 °C) were also tested, however, none were found to give good 
results.  Adding more than 2 eq. of the base above 0 °C caused degradation of the 
starting material.   
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Table 3.13.1: Reaction of Tosyl BODIPY with Alkyne Nucleophiles. 
Nucleophile Entry Solvent Eq. Condtions Reaction 
LiCCH 
(Ethylene 
diamine 
Complex) 
 
1 MeCN 2 22 ºC 18 h Poor Conversion 
2 MeCN 4 22 ºC 18 h Degradation 
3 MeCN 10 22 ºC 18 h Degradation 
4 DMSO 2 22 ºC 18 h Degradation 
5 THF 2 40 ºC 1.5 h Poor Conversion 
6 THF 5 40 ºC 3 h 4 mg “product” isolated 
7 THF 10 22 ºC 18 h Poor Conversion 
HCCMgBr 
 
8 Et2O 1.2 40 ºC 2 h Poor Conversion 
9 THF 1.2 40 ºC 18 h Poor Conversion 
10 THF 2 50 ºC 1 h Poor Conversion 
11 THF 10 50 ºC 1 h Brominated BODIPY isolated 
12 THF 15 50 ºC 18 h Brominated BODIPY isolated 
TMSCCNa 
 
13 THF 1.2 22 ºC 18 h Poor Conversion 
14 THF 1.2 45 ºC 18 h Poor Conversion 
15 THF 3 22 ºC 18 h Degradation 
16 THF 5 -78 ºC 2 h Degradation 
 
 
Scheme 3.13.6: Reaction of Tosyl BODIPY with Alkyne Nucleophiles.  Reagents and 
conditions:  Please see Table 3.13.1. 
 
Despite all efforts to access 104 via a nucleophilic displacement, no successful 
conditions were found.  Thus, it was decided to investigate other methods of 
accessing an alkyne containing BODIPY.   
3.13.3 Heptadiyne Bridge 
The difficulty found in synthesising an alkyne containing BODIPY or IGD 
peptidomimetic lead to the idea that the simplest solution may be to exploit 
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functionalities already accessible.  The reliable synthesis of IGD azide 45 and 
BODIPY azide 109 encouraged the development of a pragmatic, “double click”, route.  
Thus, synthesis of an IGD containing fluorophore was envisioned to proceed with two 
successive click reactions, initially alkyne BODIPY 110 would be synthesised and 
then further reacted with IGD peptidomimetic (R)-45 (Scheme 3.13.7).  Azide 
BODIPY (109) has a shorter synthesis than azide IGD ((R)-45) (6 steps vs. 9 steps 
from commercially available materials), therefore 109 was chosen to undergo the 
initial click reaction in order keep the route as convergent as possible. 
 
Scheme 3.13.7:  Proposed Route to BODIPY tagged IGD mimetic MM-IGD-FL1. 
 
Azide BODIPY 109 was synthesised as previously published by the Marquez group 
by converting alcohol 105 into the corresponding azide through mesylation and 
subsequent displacement with sodium azide (53%) (Scheme 3.13.8).  Azide 111 was 
then treated with 3,5-dimethyl-pyrrole-2-carbaldehyde, phosphorous oxychloride and 
boron trifluoride to give azido BODIPY 109 in 43% yield.[74]   
 
Scheme 3.13.8: Synthesis of Azide BODIPY 109.  Reagents and Conditions: (i) MsCl, NEt3, 
THF then NaN3, EtOH (53%); (ii) DCM, POCl3, BF3.OEt2, DIPEA, 5-dimethyl-pyrrole-2-
carbaldehyde (43%).  
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With azide BODIPY 109 in hand, the key reaction with 1,6-heptadiyne was attempted 
(Scheme 3.13.9). Initial attempts in dimethylformamide with copper iodide and 
triethylamine, showed no reaction after 18 h at 100 °C.  Using bases other than 
triethylamine achieved more success, giving the desired alkyne (110) in 57% yield.  
This moderate yield of this reaction may be attributed to the incomplete conversion of 
starting material as well as the formation of the iodo triazole (112).  
 
Scheme 3.13.9: Synthesis of an Alkyne Containing BODIPY 110 Via Click Conditions.  
Reagents and Conditions: (i) CuI, DIPEA, THF, 1,6 heptadiyne (57%). 
 
Alternative copper sources were screened in an effort to avoid this iodine insertion 
product and promote complete conversion of starting material.  Copper thiophene-2-
carboxylate gave complete consumption of the BODIPY starting material, giving the 
desired product and the corresponding dimer, however, purification issues prohibited 
further work with this copper source (Scheme 3.13.10).[75]   
Copper acetate monohydrate was successful in synthesising the desired product in 
moderate yield (54%) using a THF/water mixture.[76]  Copper sulfate in the more polar 
solvent system of t-butanol and water gave the desired product in low yield (29%), 
together with a large amount of dimer 113.[77] Unfortunately, the high polarity of dimer 
113 proved a challenging issue which prevented the determination of the isolated 
yield. However, it is worth noting that these conditons the dimer seemed to form 
preferentially to the desired product, possibly due to the polar system used.  Copper 
sulphate and sodium ascorbate in tetrahydofuran and water also promoted the 
complete consumption of starting material 109 giving alkyne 110 in low yield (5%) 
together with dimer 113 as the major product, but it is possible that this reaction would 
be improved through an increase in the equivalents of 1,6-heptadiyne used.  These 
results are summarised in Table 3.13.2. 
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Scheme 3.13.10:  Mono- and Di- Click Condensation Products.  Reagents and Conditions: 
(i) CuTC, Toluene, 110 °C (110 60% (impure)); (i) Cu(OAc)2·H2O, NaAsc, THF, H2O, (110 
54% + 113); (i) Cu(SO4)·5H2O, NaAsc, tBuOH, H2O, (110 29% + 113 (major)); (i) 
Cu(SO4)·5H2O, NaAsc, THF, H2O (110 5% + 113 (major)).  
 
Table 3.13.2:  Summary of Reaction Conditions Screened in Alkyne 110 Synthesis.   
Eq of 
alkyne 
Cu 
source 
Base Solvent, Temp 
(°C) 
109 
Consumed 
110 By 
prod
5 CuI NEt3 DMF, 100 No 0% - 
15 CuI DIPEA THF, 55 No 57% 112 
3 CuTC - Toluene, 110 
 
Yes 60% 
 (impure) 
113 
6 Cu(OAc)2 
.H2O 
NaAsc THF/H2O, 50 Yes 54% 113 
6 CuSO4 NaAsc tBuOH/H2O, 50 Yes 29% 113 
(M j1.2 CuSO4 NaAsc THF/H2O, 70 Yes 5% 113
M j 
The small amounts of BODIPY alkyne 110 gained from the above reactions were 
taken forward to the final coupling step where copper iodide and 
diisopropylethylamine were employed (Scheme 3.13.11).  The small scale of this 
reaction and the extensive purification required resulted in no clean product being 
isolated, however, two characteristic triazole protons were visible in 1H NMR spectra.  
This partial evidence suggested that the desired product was being synthesised and 
it was a very encouraging result.   
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Scheme 3.13.11: Synthesis of MM-IGD-FL-1 from BODIPY Alkyne 110.  Reagents and 
Conditions:  (i) DIPEA (4.0 eq.), CuI (1.0 eq.), THF.   
 
The variable yields, incomplete conversion, byproduct formation and purification 
difficulties in the synthesis of alkyne BODIPY 110 encouraged experimentation 
towards the synthesis of an IGD peptidomimetic alkyne derivative  despite the 
potentially longer linear route.  Thus, the synthesis of alkyne (R)-114 was attempted 
with two different copper sources.   
Reaction of azido-IGD peptidomimetic (R)-45 with 1,6-heptadiyne in the presence of 
copper iodide and DIPEA gave the desired alkyne (R)-114 in good yield (57%), 
together with the residual starting material and dimer (R)-115 (Scheme 3.13.12).  
Increasing the amount of 1,6-heptadiyne from 3 eq. to 10 eq. was unsuccessful in 
increasing yields of the desired alkyne (R)-114 (51%).   
Switching the catalyst to copper sulfate and sodium ascorbate successfully promoted 
the complete consumption of azide (R)-45, however, yield of desired (R)-114 did not 
increase.  Interestingly, significant amounts of dimer were still isolated despite the 
very large excesses of 1,6-heptadiyne being used (Table 3.13.3).     
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Scheme 3.13.12:  Synthesis of Alkyne Containing IGD peptidomimetic (R)-114.  Reagents 
and Conditions: (i) CuI, DIPEA, THF (51-57%); Cu(SO4)·5H2O, NaAsc, THF, H2O (46-61%). 
 
Table 3.13.3: Synthesis of Alkyne Containing IGD (R)-114. 
Alkyne eq. Cu Source Base Solvent (R)-45 
present 
(R)-114 Dimer
Observ
3 CuI DIPEA THF Yes 57% Yes 
10 CuI DIPEA THF Yes 51% Yes 
10 CuSO4 NaAsc THF/H2O No 46% Yes 
13 CuSO4 NaAsc THF/H2O No 61% Yes 
20 CuSO4 NaAsc THF/H2O No 46% Yes 
 
Despite comparable yields to those seen in the synthesis of alkyne BODIPY 110, the 
relative ease of purification of alkyne (R)-114 encouraged the use this route in the 
synthesis of a fluorescent analogue (Scheme 3.13.13).   
Thus, the synthesis of MM-IGD-FL-1 was initially attempted in the presence of copper 
iodide. Unfortunately, despite complete consumption of alkyne (R)-114, and no 
observation of an iodine insertion product, extensive purification resulted in a low 
isolated yield of the desired compound (9%). 
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Subsequent cyclisation attempts using copper sulphate (1.2 eq.) and sodium 
ascorbate (2.4 eq.) were challenging, as significant degradation of starting materials 
was observed under the reaction conditions.  Furthermore, the polarity of the 
cyclisation product meant that flash column chromatography and preparative thin 
layer chromatography were both required to access the clean product MM-IGD-FL1 
(30%).  Optimisation however, was achieved by minimising the reaction time and by 
the inclusion of an aqueous work up, which significantly facilitated the product 
purification.  Using these improvements, the desired compound MM-IGD-FL1 was 
accessed through preparative thin layer chromatography (48%).  This synthesis is the 
most successful effort to gain access to a BODIPY tagged IGD mimetic to date.  The 
fluorescent probe was synthesised in 11% over 11 steps (longest linear sequence) 
from commercially available materials.  The same route was followed to generate the 
matching (S)-IGD peptidomimetic derivative MM-IGD-FL2 in reasonable yield from 
(S)-45 (48%). 
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Scheme 3.13.13: Synthesis of MM-IGD-Fl-1 and MM-IGD-Fl-2. Reagents and Conditions: (i) 
1,6-heptadiyne, CuI, DIPEA, THF, (9%); Cu(SO4)·5H2O, NaAsc, DIPEA, THF, H2O (48%); 
(ii) Cu(SO4)·5H2O, NaAsc, DIPEA, THF, H2O (48%).   
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3.14 Confocal Microscopy with MM-IGD-FL1 and MM-IGD-FL2 
With a reliable synthesis of the (R) and (S)- IGD peptidomimetic fluorophores in place, 
we were able to build upon our fruitful collaboration with Dr Catherine Wright by 
focusing our efforts on confocal microscopy. 
Human Neonatal Fibroblasts were cultured as in General Protocols for Splitting and 
Maintaining Human Fibroblast Cultures (Experimental 5.4, p 179)  onto 2 chamber 
Nunc™ Lab-Tek™ II cover slides.  Cells were incubated with serum free media for 
one hour before treatment with 0.1 µg/mL solutions of MM-IGD-FL1, MM-IGD-FL2 or 
a control, media only, solution.  Images were then captured at 10 mins, 30 mins, 2 
hours, 5 hours and 24 hours.   
To our delight, microscopy at 10 minutes showed the internalisation of both (R) and 
(S)- fluorophores (Figure 3.14.1).  Interestingly, although not quantitative, images 
consistently show higher concentrations of internalised MM-IGD-FL1 than MM-IGD-
FL2.  This may be the result of increased uptake MM-IGD-FL1 with respect to its 
enantiomer, however, it could also be due to increased efflux or greater metabolism 
of the (S)- enantiomer.  
(A) 
 
(B) 
 
 
 
Figure 3.14.1: Fluorophores at ten minutes (460 x 460 µm) (A)  Cells treated with MM-IGD-
FL-1; (B) Cells treated with MM-IGD-FL-2. 
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Inspection of the images at a greater magnification highlights pin-pricks of more 
intense fluorescence on cell extremities (Figure 3.14.2).  This is particularly 
interesting as it is indicative of a possible endocytic mechanism of uptake.   
(A) 
  
(B) 
  
Figure 3.14.2: Fluorophores at ten minutes (230 x 230 µm).  (A)  Cells treated with 
MM-IGD-FL-1; (B) Cells treated with MM-IGD-FL-2. 
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Images at five hours showed particularly noticeable differences between the cellular 
levels of MM-IGD-FL1 and MM-IGD-FL2 (Figure 3.14.3). 
(A) 
 
(B) 
   
(C) 
 
 
(D) 
 
Figure 3.14.3: Cells Treated with IGD Peptidomimetic Fluorophores at Five Hours.  (A) MM-
IGD-FL-1 (460 x 460 µm); (B) MM-IGD-FL-2 (460 x 460 µm); (C) MM-IGD-FL-1 (230 x 230 
µm); (D) MM-IGD-FL-2 (230 x 230 µm). 
Fluorescence at 24 hours is diminished but we are still able to visualise the cells 
(Figure 3.14.4). 
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(A) (B) 
 
   
Figure 3.14.4:  Cells Treated with IGD Peptidomimetic Fluorophores at Twenty Four Hours 
(230 x 230 µm). (A) MM-IGD-FL1; (B) MM-IGD-FL2. 
Confocal microscopy with the IGD peptidomimetic fluorophores MM-IGD-FL1 and 
MM-IGD-FL2, has been particularly valuable.  We can now say with confidence that 
the compounds are rapidly internalised, most likely through endocytosis.  It is known 
that fibroblasts take up fibronectin coated collagen via phagocytosis during 
remodelling of granulation tissue, which may be relevant to our observations.[78-79]  
This in turn may support an intergrin based interaction.[80-81]  We can also conclude 
that cellular concentration of the active enantiomer, MM-IGD-FL1 is higher than MM-
IGD-FL2.   
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3.15 Iodine Containing IGD Peptidomimetic 
Based on the success of our click reaction, we became interested in the application 
of a similar approach for the development of potential new PET imaging agents.  A 
PET imaging agent could be used when carrying out in vivo studies allowing 
visualisation of areas of high uptake and metabolism of our IGD peptidomimetics.   
In 2013 Arstad outlined the use of an electrophilic iodine source to give 5-iodo-1,2,3-
triazoles in a one-pot synthesis of 125iodine containing molecular probes.[82]  This 
functionality is advantageous in radioactive tracers as it lends high in vivo stability to 
deiodination.  Arstad also reported the generation of a radioactive species using 125I 
labelled sodium iodide and copper chloride as an alternative to copper iodide and N-
iodosuccinimide (Scheme 3.15.1). 
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Scheme 3.15.1: (i) CuI, NIS, TEA, DMF; (ii) [125I]NaI, CuCl2, TEA, CH3CN/H2O.  
 
In our hands treatment of ((S)-45) with copper iodide and N-iodosuccinimide 
successfully generated the desired iodo-derivative ((S)-117) in 30% yield.  Sodium 
iodide and copper chloride on the other hand, only afforded the dehalogenated 
analogue (S)-116 in 41% yield (Scheme 3.15.2). 
 
Scheme 3.15.2: (i) CuI, NEt3, DMF, NIS, phenylacetylene ((S)-117, 30%); (ii) NaI, CuCl2, 
TEA, MeCN/H2O, Phenylacetylene ((S)-116, 41%).  
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Despite the promising results obtained with copper iodide and NIS which showed 
that it was possible to incorporate an iodine atom into the triazole via click reaction, 
time constraints together with the difficult logistics associated with the incorporation 
of a 125I unit meant that this work could not be taken any further at this point.   
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3.16 Difunctionalised BODIPY Tagged IGD Peptidomimetic 
The development of a BODIPY group containing two synthetic handles has been a 
goal of the Marquez group for some time.  A bisfunctional fluorescent tag could be 
used in solid support work to circumnavigate the need for specialist NMR studies, as 
the presence of fluorescence would indicate successful binding (Scheme 3.16.1). 
 
Scheme 3.16.1:  Proposed Incorporation of a difunctionalised BODIPY 118 onto a Solid 
Support. 
 
To maximise the utility of the fluorescent unit, it would be beneficial if the two 
functional groups had orthogonal reactivity.  Thus, our new BODIPY target 118 was 
designed with these parameters in mind (Scheme 3.16.2).   
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Scheme 3.16.2: Proposed Route to Difunctionalised BODIPY 118.   
 
Our initial approach towards the synthesis of the difunctionalised BODIPY 118 
proceeded via our previously synthesised tosyl pyrrole 106.  Synthesis of formylated 
tosylate 121 was attempted by treatment of pyrrole 106 with phosphorous oxychloride 
and DMF, however, upon treatment no tosyl peaks were visible by 1H NMR.  Mass 
spectrometry confirmed the formation of chloro-pyrrole 122 (Scheme 3.16.3).   
 
Scheme 3.16.3: Synthesis of Undesired Chloride 122.  Reagents and Conditions: (i) DMF, 
POCl3, 50 °C (67%). 
 
In an alternative approach to the synthesis of the bis-functionalised BODIPY, it was 
decided to proceed via formylated azido pyrrole 111 (Scheme 3.16.4).  Formylation 
of azido-pyrrole was initially attempted with standard 1.1 equivalents of phosphorous 
oxychloride, however, no reaction was observed.  Increasing the phosphorous 
oxychloride to 15 equivalents successfully afforded formylated pyrole 123 in good 
yield.   
Gratifyingly, coupling of formylated azido-pyrrole 123 with tosyl-pyrrole 106 under 
standard BODIPY forming conditions proceeded to generate the desired target 
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BODIPY 118 in good yield.  Interestingly, the azido tosyl BODIPY was not the sole 
BODIPY product from the reaction, both diazide and ditosyl species were also 
observed as minor products. 
 
Scheme 3.16.4: Synthesis of Difunctionalised BODIPYs 124, 118 and 125.  Reagents and 
Conditions: (i) DMF, POCl3, 40 °C (70%); (ii) DCM, DIPEA, BF3·OEt2 124 (16%), 118 (54%), 
125 (29%). 
  
The formation of BODIPYs 124 and 125 raises an interesting mechanistic feature of 
the synthesis of the dipyrromethane scaffold.  Wu and Burgess describe a 
condensation–decarbonylation mechanism of pyrrole-2-carbaldehydes to yield 
dipyrrins and subsequently BODIPY dyes.[83] It is possible that the formation of diazide 
BODIPY 124 could be explained though an analogous mechanism, as shown below 
(Scheme 3.16.5). In the proposed Burgess mechanism, azafulvene 126 is 
synthesised by reaction of 89 with phosphorous oxychloride.  Sequential attack from 
a second equivalent of 126 and then a chloride ion results in loss of carbon monoxide 
and 2 equivalents of hydrochloric acid giving dipyrrinium 129. 
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Scheme 3.16.5: Dimerisation of Azido pyrrole 124. 
 
It is possible that this mechanism accounts for the (at least partial) synthesis of 
diazide 124, however, it does not account for the formation of ditosyl BODIPY 125.  
The synthesis of this product implies that the transfer of the meso carbon is occurring.  
This “scrambling” of dipyrromethane scaffolds is well documented, particularly in the 
syntheses of porphyrins.  Smith discusses the origin of this scrambling in “Porphyrins 
and Metalloporphyrins”: under acidic conditions.  In the presence of acid, the 
protonation takes place (Scheme 3.16.6), subsequent electron donation by the most 
electron rich nitrogen results in fragmentation. The new species which can then 
recombine to give three different products.[84] 
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Scheme 3.16.6: The Origin of “Scrambled” Fragments in Porphyrin Synthesis. 
  
This mechanism rationalises the synthesis of difunctionalised BODIPYs 118, 124 and 
125, the acidic environment provided by phosphorous oxychloride generates 
fragments 131 and 136 which can combine with 106 and 123 (Scheme 3.16.7) to 
give the three observed novel BODIPYs. 
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Scheme 3.16.7:  Suggested Mechanism of Meso Substitent Scrambling in Disubstituted 
BODIPYs. 
 
In an attempt to desymmetrise the homo-dimer generated, ditosyl BODIPY 125 was 
treated with sodium azide to increase the amount of desired product accessible 
through this route (Scheme 3.16.8).  Initially ditosyl BODIPY 124 was used in excess, 
however, poor conversion prompted the addition of higher equivalents of sodium 
azide resulting in the formation of 124 and 118.  The small amounts of desired 124 in 
the reaction mixture discouraged further attempts at this transformation. 
 
Scheme 3.16.8:  Ditosyl BODIPY 125 as Reagents and Conditions: (i) NaN3, EtOH. 
 
With a small amount of 118 in hand synthesis of click product 137 was attempted with 
copper iodide.  Good conversion of IGD peptidomimetic was seen by TLC, however, 
the small scale of the reaction and lengthy purification required did not allow full 
characterisation of (R)-119, however, mass spectroscopy indicates a successful 
coupling (HRMS (ESI) calcd for C51H65F2N10NaO7SB [(M+Na)+]: m/z 1032.4748, 
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found m/z, 1032.4698) (Scheme 3.16.9).  Time constraints did not allow for 
completion of this potentially very useful tool, however, the groundwork has been laid 
for future development. 
 
Scheme 3.16.9: Synthesis of a Difunctionalised BODIPY Tagged IGD Peptidomimetic   
Reagents and Conditions: (i) CuI, DIPEA, THF (36%). 
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3.17 Triethylene Glycol IGD Peptidomimetic 
3.17.1 Tripeptide Containing Hydrogels 
The intuitive delivery route for our IGD peptidomimetics as wound healing agents is 
topical application. Topical delivery would allow the drug to be placed in close 
proximity to the site of action while minimising required dosages, premature 
metabolism and unwanted distribution and side effects within the body.[85]   
A topical delivery method would require the IGD peptidomimetic to be incorporated 
into some form of interactive dressing.  There are several forms of dressing that are 
widely used to interact with wound beds including, collagen gels, hydrofoams, and 
most importantly, hydrogels.[86]   
Recently, Ulijn reported the formation of nanofibrous hydrogel comprised of Fmoc - 
RGD 137 (Figure 3.17.1).[87]   Arene-arene interactions allow the individual molecules 
to arrange into cylindrical nanofibres composed of interlocking beta-sheets.   
 
 
Figure 3.17.1:  Fmoc-RGD 137 and AFM image of hydrogel shows an overlapping mesh of 
nanofibres.  [87] 
 
Crucially, the twisted nature of these sheets presents the RGD functionality to the 
surface of the cylinder (Figure 3.17.2).[87]  This feature of the hydrogel is particularly 
desirable as it may allow easier interaction between the active moiety and the relevant 
cellular receptors.  The importance of this feature can be further emphasized by 
considering the case of Regranex® in which poor bioavailability of the PDGF growth 
factor in the carboxymethylcellulose gel may be, at least partially, to blame for its lack 
of activity outside of clinical trials.[16]   
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Figure 3.17.2:  RGD moieties (in red) on the surface of fibrils within the hydrogel.[87] 
 
Work carried out by Dr Anna Mette Hansen within the Marquez group found that 
analogous hydrogels can also be formed from the Fmoc-IGD molecule 138.  Studies 
of these novel gels are on-going, however, early results are encouraging as 
transmission electron microscopy has shown them to have the desired fibrous nature 
(Figure 3.17.3). 
  
 
Figure 3.17.3:  Structure of Fmoc- IGD 138 and TEM image of Fmoc-IGD hydrogel. 
 
We hypothesised that an analogous hydrogel with the IGD peptidomimetic could be 
a valuable drug delivery method.  As previously discussed, the nature and length of 
the alkyl chain used in our IGD peptidomimetic has not been optimised. It is possible 
that the all carbon alkyl chain, designed to put distance between IGD core and 
immobilised technologies, will be less effective than a hydrophilic equivalent due to 
the potential of hydrophobic coiling.  With this in mind, an ethylene glycol based 
synthetic handle was designed in order to enable the synthesis of a molecule with 
significant distance between the active IGD peptidomimetic core and any introduced 
functionality while reducing the hydrophobicity of an all carbon chain (Scheme 
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3.17.1).  The synthesis of this compound was envisioned to follow a similar route to 
the alkyl chain analogues. 
Alcohol (R)-145/(R)-146 would be derived from the aniline 147/148 and would be 
followed by the synthesis of the corresponding amine.  Focus would then be directed 
towards the synthesis of carbamate (R)-140/(R)-142 which is envisioned to be the 
hydrogel building block. 
 
 
Scheme 3.17.1:  :  Retrosynthesis of Fmoc-(R)-IGD mimetic hydrogel building block  
 
With this in mind, efforts were focused on the synthesis of the polyethylene glycol 
linker.  Initial attempts were carried out with tetraethylene glycol (151) (Scheme 
3.17.2).  Mesylation of glycol 151 proceeded at room temperature with 
methanesulfonyl chloride and triethylamine.  Unfortunately, reaction of the crude 
mesylate with sodium azide gave no trace of the desired product.  It was hypothesised 
112 
 
that the lack of success in this reaction could be attributed to the quality of the 
methanesulfonyl chloride used.  This procedure was repeated with fresh 
methanesulfonylchloride, to give the crude mesylate, but again, no product could be 
detected.  
In an attempt to synthesise the more stable intermediate, tetraethylene glycol (151) 
was reacted with para-toluenesulfonyl chloride and sodium hydroxide (Scheme 
3.17.2).[88]  Disappointingly, this reaction also failed to generate any of the desired 
product. 
 
Scheme 3.17.2:  Attempted Synthesis of Azide 152 and Tosylate 153.  Reagents and 
Conditions: (i) MsCl, Et3N, THF; NaN3, EtOH (ii) TsCl, NEt3, DCM. 
Faced with a lack of success using tetraethylene glycol, it was decided to switch to 
triethylene glycol based on the work of Jeong and O’Brien.  Thus, triethylene glycol 
was treated with methanesulfonyl chloride and triethylamine, for eighteen hours 
followed by addition of sodium azide and ethanol (Scheme 3.17.3).[89]  Thin layer 
chromatography highlighted one product with a higher Rf than the starting alcohol 
154, which was then found to be the cyclisation product 156. 
To reduce the possibility of self cyclisation of intermediate (155) the reaction was 
repeated, allowing mesylate 155 only ten minutes to form before the reaction mixture 
was concentrated and taken onto the azide formation.  This approach was successful 
in forming the desired azide albeit in low yield (17%).  The aqueous work up used to 
remove the sodium azide residues was believed to be responsible for the low yield of 
this reaction. Indeed, the removal of the aqueous work up step resulted in a vastly 
improved yield (81%).  Flash column chromatography was time consuming due to 
close running impurities, however, this was circumnavigated by carrying the crude 
product onto the subsequent protection (61%).  The reduction of the protected azide 
proceeded with ammonium formate.  Purification of amine 149 also required 
significant optimisation, however, it was possible to isolate 149 in 45% yield from 
alcohol 154. 
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Scheme 3.17.3: Synthesis of Amine 149.  Reagents and Conditions: (i) MsCl, Et3N, THF, 
overnight; (ii) MsCl, Et3N, THF (10 mins); (iii) NaN3, EtOH 70 °C (157, 81%); (iv) TBDPSCl, 
DCM, NEt3 (61%) then Pd/C, NH4CO2, MeOH (91%). 
 
Reductive amination of aldehyde 18 with the amine 149 proceeded cleanly and in 
good yield with sodium cyanoborohydride (70%) (Scheme 3.17.4).  Subsequent 
protection of benzylic amine 158 proceeded in 80% yield, this relatively average 
protection yield could be explained by the instability of the reductive amination 
product.  Hydrogenation and subsequent N-alkylation proceeded in 36% yield over 
two steps.  Finally, deprotection and cyclisation of (S)-159  were effective in 
synthesising the desired IGD peptidomimetic (S)-145 in 62% yield over two steps, 
thus, completing the synthesis of the IGD peptidomimetic with a ethylene glycol based 
synthetic handle.  Unfortunately, handling error led to the loss of this compound 
before full characterisation could take place, however, mass spectrometry showed 
the desired mass.     
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Scheme 3.17.4: Synthesis of IGD Peptidomimetic with Ethylene Glycol Chain.  Reagents 
and conditions:  (i) 149, heptane, NaBH3CN, 80 °C; (ii) Boc2O, DCM, NEt3; (iii) Pd/C, 
NH4CO2, MeOH; (iv) (R)-20, 2,6-lutidine, DCM; (v) TFA, DCM; (vi·) SCX, 7 M NH3/MeOH, 
MeOH (62%). 
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4.0 Future Directions and Conclusions 
4.1 Methyl IGD Peptidomimetics 
In conclusion, the synthesis of the methyl IGD peptidomimetics has been optimised 
with the development of a novel route to key intermediate 18.  This new route is able 
to generate multigram amounts of material quicky and efficiently with minimal 
purification (Scheme 4.1.1). 
 
Scheme 4.1.1:  Route to Methyl IGD peptidomimetic via intermediate 18. 
 
The biological activity of (R)-methyl IGD peptidomimetic has been corroborated via 
scratch assays.  Work will continue to build upon the knowledge gained from the qRT-
PCR experiments carried out.  The results gained showed the upregulation of ACTN3 
and IGF1 in human dermal neonatal fibroblasts treated with (R)-methyl IGD 
peptidomimetic compared to those treated with the (S)-enantiomer.   
Further qRT-PCR work would be valuable for this project.  The repetition of the 
Human Cell Motility microarray with cells treated with the (R)-Methyl IGD 
peptidomimetic and (S)-Methyl IGD peptidomimetic could allow more confidence to 
be given to the displayed upregulation of the IGF1 gene.  Arrays could be undertaken 
with cells treated with (R)-Methyl IGD peptidomimetic vs media only treatments, which 
may show more dramatic results.  A particularly interesting future direction may be 
the analysis of gene regulation in diabetic fibroblasts treated with the (R)-Methyl IGD 
peptidomimetic.  Further to this, arrays carried out with keratinocytes or endothelial 
cells may be valuable.  This work could form the basis of a further collaboration with 
the Wright group.   
Both (R) and (S)-Methyl IGD peptidomimetics have also been submitted to the 
Fraunhofer Institute for in vitro toxicology studies.  Efforts are also under way to 
assess the blood clearance of the compounds in mice.   
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4.2 Pentyl IGD Peptidomimetics 
The development of our optimised synthetic route also allowed the synthesis of 
alcohols (R/S)-24 (n = 1) and (R/S)-26 (n = 3) from intermediate 18 (Scheme 4.2.1).  
Yields were particularly good with (R)-26 being synthesized in 61% from intermediate 
18.  The synthesis of tosylate (R/S)-47, azide (R/S)-45, amine (R/S)-40 and alkyne 
(R/S)-114 were also achieved starting from the hydroxyl derivative.. 
 
Scheme 4.2.1:  Synthesis of Alcohol Alkyl Chain Containing IGD Peptidomimetics and 
Analogues. 
 
4.3 BODIPY Tagged IGD Peptidomimetics 
Functionalised IGD peptidomimetics were used to synthesise fluorescent tagged 
analogues (Figure 4.3.1).  Amide (R)-85 showed internalisation of the IGD 
peptidomimetic into mouse embryonic fibroblast, however, in order to have 
confidence in this result synthesis and testing of MM-IGD-FL1 and MM-IGD-FL2 was 
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undertaken.  Testing of MM-IGD-FL1 confirmed the internalisation of the molecule in 
human dermal neonatal fibroblasts, and indicated a possible endocytosis mechanism.   
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Figure 4.3.1:  BODIPY tagged IGD Peptidomimetics. 
 
4.4 Difunctionalised BODIPY Tagged IGD Peptidomimetics 
In order to obtain stable and useful molecular probes, several novel BODIPY species 
were synthesised (Figure 4.4.1) during these investigations. It is likely that 
difunctionalised species 118 will be the most valuable in synthesising a fluorescent 
IGD peptidomimetic that can be further tagged onto a solid supports or other delivery 
vehicles.  
118 
 
 
Figure 4.4.1: Novel BODIPYs and Incorporation of (R)-45 onto a Solid Support 
 
4.5 Triethylene Glycol IGD Peptidomimetic  
Having established a reliable synthesis of an IGD peptidomimetic with increased 
hydrophilicity (S)-145 (Scheme 4.5.1) work should proceed towards the synthesis of 
the corresponding amine (S)-143.  Focus would then be directed towards the 
synthesis of the desired hydrogel building block (S)-140.   
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Scheme 4.5.1:  Further Development of Alcohol (S)-145. 
4.6 Biotinylated IGD Peptidomimetic 
The biotinylation of small molecules, used in conjunction with avidin/streptavidin pull 
down and SDS-PAGE experiments, is an incredibly useful tool for the indentification 
relevant cellular binding sites.[90]  In future work, efforts should be directed towards the 
biotinylation of azide (R/S)-45 as a priority (Scheme 4.5.1).[91]  Biotinylated IGD 
peptidomimetic (R/S)-160 would be a very exciting compound and could be 
instrumental in helping to elucidate the biological target of the peptidomimetics. 
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Scheme 4.5.1: Retrosynthetic Analysis of Biotinylated IGD Peptidomimetic. 
.  
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5.0 EXPERIMENTAL 
5.1. Chemistry General Information 
Reactions involving air sensitive reagents and anhydrous solvents were performed in 
glassware dried in an oven (130 °C).  These reactions were carried out with the 
exclusion of air using an argon atmosphere.  Tetrahydrofuran, diethyl ether, and 
dichloromethane were purified through a Pure Solv 400-5 MD solvent purification 
system.  Solvents were evaporated under reduced pressure at 40 °C using a Büchi 
Rotavapor.Column chromatography was performed under pressure using silica gel 
(Fluoro Chem Silica LC 60A) as the stationary phase and HPLC grade solvents as 
eluent.  Reactions were monitored by thin layer chromatography.  TLC was performed 
on aluminium sheets pre-coated with silica gel (Merck Silica Gel 60 F254).  The plates 
were visualised by the quenching of UV fluorescence (λmax254 nm) and/ or by staining 
with anisaldehyde. 
Proton magnetic resonance (1H-NMR) spectra were recorded on a Bruker DPX 
Avance400 instrument at 400 MHz or at 500 MHz using Bruker DPX Avance500.  
Chemical shifts (δ) are recorded as parts per million and are referenced to the 
appropriate residual solvent peak.  Signals in NMR spectra are described as singlet 
(s), doublet (d), triplet (t), quartet (q), multiplet (m), broad (br) or a combination of 
these terms which refer to the spin-spin coupling pattern observed.  13C NMR were 
recorded at 100 MHz or at 125 MHz using Bruker DPX Avance500.  DEPT 135, DEPT 
90 and two-dimensional (COSY, HSQC) NMR spectroscopy were used in novel 
compounds to assist in the assignment of signals in the 1H and 13C NMR spectra.  
Structures have been given an arbitrary numbering system to enable 1H and 13C NMR 
assignment. 
IR spectra were obtained employing a Golden Gate™ attachment that uses a type IIa 
diamond as a single reflection element so that the IR spectrum of the compound (solid 
or liquid) could be detected directly (thin layer) without any sample preparation 
(Shimadzu FTIR-8400).  Only significant absorptions are reported in wavenumbers 
with the following terms to describe intensity: w (weak), m (medium) or s (strong).  
High resolution mass spectra were recorded by the analytical services at the 
University of Glasgow on a JEOL JMS-700 mass spectrometer by electrospray and 
chemical ionisation operating at a resolution of 15000 full widths at half height.  
Melting points were recorded on a Stuart Scientific Melting Point SMPI apparatus and 
are uncorrected.   
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5.2 Reaction Procedures and Compound Analysis 
2-Methyl-6-(3-Methylbutoxy)nitrobenzene 
 
3-Methyl-2-nitrophenol (2.00 g, 13.1 mmol, 1.0 eq.) was dissolved in 
dimethylformamide (50 mL) giving a light yellow solution.  Potassium carbonate (3.62 
g, 26.2 mmol, 2.0 eq.) and 1-bromo-3-methyl butane (4.70 mL, 39.3 mmol, 3.0 eq.) 
were added to the solution which was allowed to stir at room temperature for 48 h.  
The reaction mixture was quenched with water (50 mL), diluted with ethyl acetate 
(100 mL) and allowed to stir for 20 min.  The phases were separated and the aqueous 
layer was extracted with ethyl acetate (3 × 50 mL).  The combined organic layers 
were washed with water (50 mL), brine (50 mL), dried (Na2SO4), filtered and 
evaporated in vacuo giving the title compound as a brown oil (2.59 g, 11.6 mmol, 
89%). 
1H NMR (CDCl3, 400 MHz) δ: 7.29 (1H, t, J = 8.1 Hz, C(5)H), 6.88 (1H, d, J = 8.4 Hz, 
C(4)H), 6.83 (1H, J = 7.7 Hz, C(6)H), 4.08 (2H, t, J = 6.6 Hz, C(7)H2), 2.30 (3H, s, C(12)H3), 
1.80 (1H, apparent septet, J = 6.7 Hz, C(9)H), 1.66 (2H, q, J = 6.7 Hz, C(8)H2), 0.95 
(6H, d, J = 6.7 Hz C(10)H3 + C(11)H3).  13C NMR (CDCl3, 100 MHz) δ: 150.3 (C(1)), 142.3 
(C(2)), 130.8 (C(3)), 130.6 (C(5)), 122.3 (C(4)), 110.9 (C(6)), 67.8 (C(7)), 37.5 (C(8)), 24.9 
(C(9)), 22.4 (C(10) + C(11)), 16.9 (C(12)).  HRMS (EI+) calcd for C12H17NO3 [M+]: m/z 
223.2719, found m/z 223.2727.  νmax (CDCl3)/cm-1: 2957.0 (m), 1612 (w), 1583 (m), 
1529.6 (s), 1086 (s). 
2-Methyl-6-(3-Methylbutoxy)aniline 
 
Nitro-benzene 27 (1.00 g, 4.48 mmol, 1.0 eq.), was dissolved in methanol (30 mL).  
Ammonium formate (2.83 g, 44.8 mmol, 10 eq.) and 10% palladium on activated 
charcoal (30 mg) were added to the mixture which was allowed to stir at 50 ºC for 16 
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h.  The reaction mixture was filtered through celite, and washed with methanol (60 
mL).  The combined organics were evaporated in vacuo giving the title compound 
(0.73 g, 3.81 mmol, 85%). 
1H NMR (CDCl3, 400 MHz): 6.70-6.62 (3H, m, C(4)H + C(5)H + C(6)H), 4.01 (2H, t, J = 
6.6 Hz, C(7)H2), 3.75 (2H, br. s, NH2), 2.18 (3H, s, C(12)H3), 1.85 (1H, apparent septet, 
C(9)H), 1.70 (2H, q, J = 6.7 Hz, C(8)H2), 0.96 (6H, d, J = 6.6 Hz, C(10)H3 + C(11)H3).  13C 
NMR (CDCl3, 100 MHz): 146.4 (C(1)), 134.3 (C(2)), 122.6 (C(3)), 122.4 (C(4)), 117.6 
(C(5)), 109.0 (C(6)), 66.7 (C(7)), 38.2 (C(8)), 25.2 (C(9)), 22.7 (C(10) + C(11)), 17.2 (C(12)).  
HRMS (CI) calcd for C12H20NO [M+H+]: m/z 194.2969, found m/z 194.2980.  νmax 
(CDCl3)/cm-1: 3475 (w), 3381 (w), 2955 (s), 1616 (m), 1489 (s).  
3-(3’-Methylbutoxy)benzaldehyde 
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3-Hydroxybenzaldehyde (15.0 g, 123 mmol, 1.0 eq.) was dissolved in anhydrous 
dimethylformamide (600 mL) under argon giving a light yellow solution.  Potassium 
carbonate (33.9 g, 246 mmol, 2.0 eq.) was added to the solution and the resulting 
mixture was allowed to stir for 25 min giving a yellow cloudy mixture.  1-Bromo-3-
methyl butane (44.1 mL, 368 mmol, 3.0 eq.) was added to the mixture which was 
allowed to stir for 24 h giving a cream cloudy mixture.  The reaction mixture was slowly 
added to water (600 mL) (Caution: exotherm).  Ethyl acetate (400 mL) was added 
and the biphasic mixture was allowed to stir for 20 min.  The phases were separated 
and the aqueous layer was extracted with ethyl acetate (2 × 400 mL).  The combined 
organic layers were washed with water (400 mL), brine (400 mL), dried (Na2SO4) and 
concentrated in vacuo giving the title compound as a light coloured oil (19.6 g, 102 
mmol, 83%).   
1H NMR (CDCl3, 400 MHz):  9.89 (1H, s, C(7)HO), 7.38-7.36 (2H, m, C(5)H + C(6)H), 
7.31 (1H, m, C(2)H), 7.11-7.09 (1H, m, C(4)H), 3.97 (2H, t, J = 6.8 Hz, C(8)H2), 1.80-
1.74 (1H, apparent sept., J = 6.8 Hz, C(10)H), 1.65-1.60 (2H, apparent q, J =  6.6 Hz,  
C(9)H2), 0.89 (6H, d, J = 6.9 Hz, C(11)H3 + C(12)H3).  13C NMR (CDCl3, 125 MHz): 192.3 
(C(7)), 159.7 (C(1)), 137.7 (C(3)), 130.0 (C(5)), 123.4 (C(4/6)), 122.0 (C(4/6))), 112.7 (C(2)), 
66.7 (C(8)), 37.8 (C(9)), 24.7 (C(10)), 22.9 (C(11) + C(12) ).  LRMS (EI+) calcd for C12H16O2 
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[M+]: m/z 192.12, found m/z 192.16.  νmax (CDCl3)/cm-1: 2956 (m), 1696 (s), 1260 (s), 
909 (m), 751 (s).  
3-Hydroxy-2-nitrobenzaldehyde[32] 
 
3-Methoxy-2-nitrobenzaldehyde (0.50 g, 2.76 mmol, 1.0 eq.) was dissolved in 
anhydrous dichloromethane (10 mL) and cooled to 0 ºC.  A solution of boron 
tribromide (1 M in dichloromethane, 8.4 mL, 8.4 mmol, 3.0 eq.) was added dropwise 
to the solution, the reaction mixture was allowed to warm to room temperature and 
stirred for 1 h.  The reaction mixture was syringed into ice water (100 mL).  The 
phases were separated and the aqueous phase was extracted with chloroform (3 × 
25 mL).  The combined organic layer was dried (Na2SO4), filtered and concentrated 
in vacuo giving the title compound as a dark brown solid (0.42 g, 2.5 mmol, 89%). 
1H NMR (CDCl3, 400 MHz) δ:  10.35 (1H, s, C(7)H), 10.25 (1H, s, OH), 7.60 (1H, t, J 
= 7.6 Hz, C(5)H), 7.31 (1H, dd, J = 8.5, 1.4 Hz, C(6)H), 7.25 (1H, dd, J = 7.4, 1.4, C(4)H).  
13C NMR (CDCl3, 125 MHz) δ: 187.9 (C(7)), 155.0 (C(3)), 136.6 (C(5)), 136.6 (C(2)), 135.0 
(C(1)), 124.3 (C(6)), 121.5 (C(4)).  HRMS (CI+) calcd for C7H6NO4 [M+H+]: m/z 168.1289, 
found m/z 168.1291.  νmax (CDCl3)/cm-1: 3218 (s), 1678 (s), 1529 (s), 1313 (s).  M.P. 
156-158 ºC.[92]  
3-(3-Methylbutoxy)-2-nitrobenzaldehyde  
 
From 3-Hydroxy-2-nitrobenzaldehyde: 
3-Hydroxy-2-nitrobenzaldehyde (3.40 g, 20.0 mmol, 1.0 eq.) was dissolved in 
anhydrous dimethylformamide (100 mL) under argon giving a light brown solution.  
Potassium carbonate (5.52 g, 40.0 mmol, 2.0 eq.) was added to the solution and the 
resulting mixture was allowed to stir for 25 min giving a yellow cloudy mixture.  1-
Bromo-3-methyl butane (7.20 mL, 60.0 mmol, 3.0 eq.) was added to the mixture which 
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was allowed to stir for 24 h.  The reaction mixture was slowly added to water (600 
mL) (Caution: exotherm).  Ethyl acetate (400 mL) was added and the biphasic mixture 
was allowed to stir for 20 min.  The phases were separated and the aqueous layer 
was extracted with ethyl acetate (2 × 400 mL).  The combined organic layer was 
washed with water (400 mL), brine (400 mL), dried (Na2SO4) and concentrated in 
vacuo giving the title compound as a light yellow oil (3.90 g, 16.5 mmol, 82%).   
From 3-(3-Methylbutoxy)benzaldehyde: 
3-(3-Methylbutoxy)-benzaldehyde (4.82 g, 25.1 mmol, 1.0 eq.) was dissolved in 
anhydrous dichloromethane (150 mL) under argon and the mixture was cooled to -25 
ºC.  Nitronium tetrafluoroborate (5.00 g, 37.6 mmol, 1.5 eq.) was added in one portion 
and the light yellow solution was allowed to stir at -25 ºC for 5 h.  The reaction mixture 
was quenched with water (100 mL), the phases were separated and the aqueous 
layer was extracted with ethyl acetate (3 × 60 mL).  The combined organic layer was 
washed with brine (60 mL), dried (Na2SO4) and concentrated in vacuo.  The crude 
mixture was purified by column chromatography (0-15% ethyl acetate in petroleum 
ether) giving the title compound as a yellow, oily solid (1.54 g, 6.5 mmol, 26%).   
1H NMR (CDCl3, 400 MHz): 9.85 (1H, s, C(7)HO), 7.30 (1H, t, J = 8.2 Hz, C(5)H), 7.40 
(1H, dd,  J = 7.7, 1.0 Hz, C(6)H), 7.27 (1H, dd, J = 8.3, 1.0 Hz, C(4)H), 4.06 (2H, t, J = 
6.5 Hz, C(8)H2), 1.82 (1H, apparent septet, J = 6.87 Hz, C(10)H), 1.62 (2H, apparent q, 
J =  6.47 Hz,  C(9)H2), 0.86 (6H, d, J = 6.92 Hz, C(11)H3 + C(12)H3).  13C NMR (CDCl3, 
125 MHz): 187.0 (C(7)), 150.6 (C(3)), 140.3 (C(2)), 131.3 (C(5)), 128.0 (C(1)), 122.0 (C(6)), 
119.7 (C(4)), 68.5 (C(8)), 37.3 (C(9)), 24.8 (C(10)), 22.5 (C(11) + C(12)). HRMS (EI+) calcd 
for C12H15O4N [M+]: m/z 237.2554, found m/z 237.2560. νmax (CDCl3)/cm-1: 2958 (m), 
1770 (m), 1546 (s), 1286(s), 908 (s). 
(S)-2-Trifluoromethanesulfonyloxy-succinic acid dimethyl ester[27] 
 
Dimethyl-(S)-(-)-malate (1.70 mL, 11.8 mmol, 1.0 eq) was dissolved in anhydrous 
dichloromethane (25 mL).  2,6-Lutidine (2.60 mL, 22.4 mmol, 1.9 eq.) was added and 
the solution was allowed to stir at -78 ºC for 20 min.  Trifluoromethanesulfonic 
anhydride (5.90 g, 17.7 mmol, 1.5 eq.) was dissolved in dichloromethane (25 mL) and 
added dropwise to the solution which was allowed to stir at -78 ºC for 1 hour.  The 
reaction mixture was quenched with water (50 mL) and was allowed to warm to room 
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temperature.  The phases were separated and the organic phase was washed with 
copper sulfate (aq. sat.) (3 × 50 mL), dried (Na2SO4) and concentrated in vacuo giving 
the title compound as a light coloured oil (3.66 g, 11.8 mmol, quantitative).   
1H NMR (CDCl3, 400 MHz) δ: 5.50 (1H, t, J = 5.9 Hz, C(2)H), 3.88 (3H, s, C(6)H3), 3.77 
(3H, s, C(5)H3), 3.07 (2H, d, J = 5.9 Hz, C(3)H3)  13C NMR (CDCl3, 125 MHz) δ: 167.9 
(C(1)), 166.5 (C(3)), 118.6 (C(7)), 78.5 (C(2)), 53.7 (C(5/6)), 52.6 (C(5/6)), 36.6 (C(3)).  νmax 
(CDCl3)/cm-1: 1743.7 (s), 1419.7 (s), 1203.6 (s), 1141.9 (s). 
(R)-2-Trifluoromethanesulfonyloxy-succinic acid dimethyl ester[27] 
 
(R)-20 was synthesised via the method described above in quantitative yield. 
3-(tert-Butyldiphenyl silanyloxy)-propylamine [54]  
 
3-Aminopropanol (1.50 mL, 19.6 mmol, 2.5 eq.) was dissolved in dichloromethane 
(30 mL) and the mixtue was cooled to 0 ºC.  t-Butyldiphenylsilyl chloride (2.00 mL, 
7.80 mmol, 1.0 eq.) was dissolved in dichloromethane (5 mL) and slowly added to the 
solution.  Triethylamine (1.20 mL, 11.8 mmol, 1.5 eq.) was added, and the reaction 
mixture was allowed to warm to room temperature and stir for 3 h.  The reaction 
mixture was then acidified with 1 M hydrochloric acid (aq.) solution (25 mL) and the 
phases were separated.  The organic layer was washed with sodium bicarbonate (aq. 
sat.) (25 mL), brine (25 mL), dried (Na2SO4), and concentrated in vacuo giving the 
title compound (2.08 g, 6.62 mmol, 85%). 
1H NMR (CDCl3, 400 MHz): 7.60-7.57 (4H, m, 4 × C(5)H), 7.34-7.26 (6H, m, 4 × C(6)H 
+ 2 × C(7)H), 3.65 (2H, t, J = 6.0 Hz, C(3)H2), 2.75 (2H, t, J = 6.8 Hz, C(1)H2), 1.74 (2H, 
broad singlet, NH2), 1.64-1.58 (2H, apparent quintet, J = 6.5 Hz, C(2)H2), 0.97 (9H, s, 
3 × C(9)H3).  13C NMR (CDCl3, 100 MHz): 135.7 (4 × C(5)), 133.8 (2 × C(4)), 129.6 (2 × 
C(7)), 127.7 (4 × C(6)), 61.9 (C(3)), 39.3, (C(1)), 36.0 (C(2)), 26.9 (3 × C(9)), 19.2 (C(8)).  
LRMS (FAB+) calcd for C19H27NOSi [(M+H)+]: m/z 314.5, found m/z 314.2.  νmax 
(CDCl3)/cm-1: 3071 (w), 2930 (m), 1589 (m), 1105 (s), 730 (s), 699 (s). 
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3-(tert-Butyldiphenyl silanyloxy)propyl-[3-(3-methylbutoxy)-2-nitrobenzyl]-amine  
 
Nitrobenzaldehyde 18 (0.85 g, 3.60 mmol, 1.0 eq.) was dissolved in heptane (20 mL) 
and amine 68 (1.68 g, 5.40 mmol, 1.5 eq.) was added.  The reaction mixture was 
allowed to stir for 48 h, concentrated in vacuo and dissolved in methanol (20 mL).  
Sodium borohydride (0.20 g, 5.40 mmol, 1.5 eq.) was added and the solution was 
allowed to stir for 12 h.  The reaction mixture was quenched by the addition of water 
(20 mL), ethyl acetate (20 mL) was added and the phases separated.  The aqueous 
layer was extracted with ethyl acetate (2 × 20 mL).  The combined organic layer was 
washed with brine (20 mL), dried (Na2SO4), and concentrated in vacuo.  The resulting 
mixture was purified by flash column chromatography (0-20% ethyl acetate in 
petroleum ether) giving the title compound as a yellow oil (1.76 g, 3.40 mmol, 94%).     
1H NMR (CDCl3, 400 MHz) δ: 7.59-7.57 (4H, m, 4 × C(12)H), 7.36-7.26 (7H, m, 4 × 
C(13)H + 2 × C(14)H + C(5)H), 6.95 (1H, d, J = 8.0 Hz, C(6)H), 6.84 (1H, d, J = 8.6 Hz, 
C(4)H), 3.99 (2H, t, J = 6.8 Hz, C(17)H2), 3.66-3.63 (4H, apparent t, J = 4.9 Hz, C(10)H2 
+ C(7)H2), 2.64 (2H, t, J = 7.4 Hz, C(8)H2), 1.74-1.57 (6H, m, NH + C(18)H2 + C(19)H + 
C(9)H2), 0.95 (9H, s, 3 × C(16)H3), 0.87 (6H, d, J = 6.8 Hz, C(20)H3 + C(21)H3).  13C NMR 
(CDCl3, 125 MHz) δ: 150.3 (C(3)), 141.5 (C(2)), 135.6 (4 × C(12)), 133.8 (2 × C(11)), 133.7 
(C(1)), 130.8 (C(5)), 129.6 (2 × C(14)), 127.6 (4× C(13)), 121.1 (C(6)), 112.0 (C(4)), 67.9 
(C(17)), 62.3 (C(10)), 49.2 (C(7)), 46.5 (C(8)), 37.6 (C(18)), 32.6 (C(9)), 26.9 (C(19)), 24.9 
(C(20) + C(21)), 22.5 (3 × C(16)), 19.2 (C(15)).  LRMS (FAB+) calcd for C19H27NOSi 
[(M+H)+]: m/z 535.3, found m/z 535.1.  νmax (CDCl3)/cm-1: 2962 (s), 1684 (m), 1533 
(m), 1112 (m), 907 (s), 730 (s). 
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3-[(tert-butyldiphenylsilyl)oxy]propyl -[3-(3-methyl-butoxy)-2-nitro-benzyl]-carbamic 
acid tert-butyl ester  
 
Amine 64 (2.10 g, 3.93 mmol, 1.0 eq.) was dissolved in anhydrous dichloromethane 
(100 mL), triethylamine (1.10 mL, 7.86 mmol, 2.0 eq.) was added and the solution 
was allowed to stir for 25 min.  Di-tert-butyl dicarbonate (1.11 g, 5.09 mmol, 1.3 eq.) 
was added to the reaction mixture which was then allowed to stir for 16 h.  The 
reaction mixture was quenched with water (75 mL), and diluted with dichloromethane 
(75 mL).  The phases were separated and the aqueous layer was extracted with ethyl 
acetate (2 × 75 mL).  The combined organic layer was then washed with brine (75 
mL), dried (Na2SO4) and concentrated in vacuo.  The crude mixture was purified by 
flash column chromatography (0-10% ethyl acetate in petroleum ether) giving the title 
compound as a light coloured oil (2.59 g, 3.93 mmol, quantitative). 
1H NMR (CDCl3, 400 MHz) δ: 7.66-7.65 (4H, m, 4 × C(15)H), 7.36-7.26 (7H, m, C(5)H 
+ 4 × C(16)H + 2 × C(17)H), 6.96-6.93 (2H, m, C(4)H + C(6)H), 3.99 (2H, CH2, t, J = 6.8 
Hz, C(20)H2), 3.66-3.63 (4H, apparent t, J = 4.9 Hz, C(13)H2 + C(7)H2), 2.63 (2H, t, J = 
7.4 Hz, C(11)H2), 1.74-1.57 (5H, m, C(12)H2 + C(21)H2 + C(22)H), 1.37 (9H, s, 3 × C(10)H3) 
0.95 (9H, s, 3 × C(19)H3), 0.86 (6H, d, J = 6.8 Hz, C(23)H3 + C(24)H3).  1H NMR (CDCl3, 
400 MHz, 55 ºC) δ: 7.60-7.58 (4H, m, 4 × C(15)H), 7.37-7.25 (7H, m, C(5)H + 4 × C(16)H 
+ 2 × C(17)H), 6.85 (2H, dd, J = 16.1, 8.4 Hz, C(4)H + C(6)H), 4.36 (2H, s, C(7)H2), 4.03 
(2H, t, J = 6.4 Hz, C(20)H2), 3.63 (2H, t, J = 6.4 Hz, C(13)H2), 3.27 (2H, m, C(11)H2), 1.80 
- 1.68 (3H, m, C(12)H2 + C(22)H), 1.61 (2H, q, J = 6.8 Hz, C(21)H2), 1.37 (9H, s, 3 × 
C(10)H3), 1.00 (9H, s, 3 × C(19)H3), 0.89 (6H, d, J = 6.8 Hz, C(23)H3 + C(24)H3).13C NMR 
(CDCl3, 100 MHz, 55 ºC) δ: 155.5 (C(3)), 150.5 (C(8)), 141.4 (C(2)), 135.5 (4 × C(15)), 
133.9 (2 × C(14)), 132.1 (C(1)), 130.7 (C(5)), 129.5 (2 × C(17)), 127.6 (4 × C(16)), 119.6 
(C(6)), 112.4 (C(4)), 80.0 (C(9)), 68.2 (C(20)), 61.9 (C(13)), 46.0 (C(7)), 44.8 (C(11)) 37.7 
(C(21)), 31.1 (C(12)), 28.3 (3 × C(10)), 27.4 (3 × C(19)), 26.9 (C(23/24)), 26.9 (C(23/24)), 24.9 
(C(22)), 19.1 (C(18)).  νmax (CDCl3)/cm-1: 2956 (m), 1740 (s), 1691 (s), 1534 (s), 1112 
(m), 909 (s). 
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[2-Amino-3-(3-methyl-butoxy)-benzyl]-[3-[(tert-butyldiphenylsilyl)oxy]propyl]-
carbamic acid tert-butyl ester  
 
Nitrophenol 80 (0.45 g, 0.71 mmol, 1.0 eq.) was dissolved in anhydrous methanol (20 
mL).  Ammonium formate (0.45 g, 7.1 mmol, 10 eq.) was added to the solution.  
Palladium on activated charcoal (30 mg) was added and the mixture was heated to 
35 ºC.  After 48 h, the reaction mixture was filtered through celite and washed with 
ethyl acetate (150 mL).  The filtrate was washed with water (150 mL) and the phases 
were separated.  The aqueous phase was extracted with ethyl acetate (2 × 50 mL), 
the combined organic layer was then washed with brine, dried (Na2SO4) and filtered 
giving the title compound as a light red oil (0.32 g, 0.55 mmol, 76 %). 
1H NMR (CDCl3, 400 MHz, 55 ºC) δ:  7.64-7.62 (4H, m, 4 × C(15)H), 7.40-7.32 (6H, m, 
4 × C(16)H + 2 × C(17)H), 6.71 (1H, apparent d, J = 8.0 Hz, C(5)H), 6.62 (1H, apparent 
d, J = 7.5 Hz, C(6)H), 6.52 (1H, t, J  = 7.8 Hz, C(4)H), 4.51 (2H, broad s, NH2), 4.36 (2H, 
s, C(7)H2), 3.99 (2H, t, J  = 6.6 Hz, C(20)H2), 3.63 (2H, t, J  = 6.2 Hz, C(13)H2), 3.25-3.21 
(2H, m, C(11)H2), 1.84 (1H, n, J  = 6.8 Hz, C(22)H), 1.76-1.67 (4H, m, C(21)H2 + C(12)H2), 
1.43 (9H, s, 3 × C(10)H3), 1.05 (9H, s, 3 × C(19)H3), 0.96 (6H, d, J = 6.6 Hz, C(23)H3 + 
C(23)H3 ).  13C NMR (CDCl3, 100 MHz) δ: 156.3 (C(8)), 146.3 (C(3)), 136.2 (C(2)), 135.5 
(4 × C(15)), 133.7 (2 × C(14)), 129.6 (2 × C(17)), 127.6 (4 × C(16)), 123.4 (C(1)), 120.8 (C(6)), 
115.8 (C(5)), 110.6 (C(4)), 79.8 (C(9)), 66.6 (C(20)), 61.9 (C(13)),  47.4 (C(7)), 42.9 (C(11)), 
38.2 (C(21)), 30.7 (C(12)), 28.4 (3 × C(10)), 26.9 (C(22)), 25.1 (C(23) + C(24)), 22.6 (C(18)), 
19.2 (3 × C(19)). LRMS (CI+) calcd for C36H53N2O4Si [M+H+]: m/z 605.9, found m/z 
605.7.  νmax (CDCl3)/cm-1: 2959 (m), 1668 (m), 1472 (m), 1106 (m).  
 
 
 
 
130 
 
(R)-Dimethyl 2-(2-((tert-butoxycarbonyl(3-(tert-butyldiphenyl 
silanyloxy)propyl)amino)methyl)-6-(isopentoxy)phenylamino)succinate 
 
Aniline 62 (0.85 g, 1.40 mmol, 1.0 eq.) was dissolved in anhydrous dichloromethane 
(20 mL), 2,6-lutidine (0.32 mL, 2.80 mmol, 2.0 eq.) was added and the solution was 
allowed to stir at room temperature for twenty minutes.  Triflate (S)-20 (0.70 g, 2.38 
mmol, 1.7 eq.) was dissolved in anhydrous dichloromethane (20 mL) and was added 
dropwise to the solution.  The reaction mixture was heated to 45 ºC and stirred for 16 
hours.  The reaction mixture was then quenched with water (40 mL) and the phases 
were separated.  The aqueous phase was extracted with dichloromethane (40 mL), 
and the combined organic layer was then washed with copper sulfate solution (aq. 
sat.) (3 × 40 mL), dried (Na2SO4), filtered and concentrated in vacuo.  The crude 
mixture was purified by flash column chromatography (0-10% ethyl acetate in 
petroleum ether) giving the title compound as a clear oil (0.72 g, 0.96  mmol, 69%). 
1H NMR (CDCl3, 400 MHz, 55 ºC) δ: 7.62-7.60 (4H, m, 4 × C(15)H), 7.40-7.31 (6H, m, 
4 × C(16)H + 2 × C(17)H), 6.81-6.74 (2H, m, C(4)H + C(5)H), 6.70-6.68 (1H, dd, J = 7.0, 
1.6 Hz, C(6)H), 4.65-4.61 (3H, m, C(7)H2 + C(20)H), 4.33 (1H, d, J = 15.4 Hz, NH), 3.98 
(2H, t, J = 6.9 Hz, C(26)H2), 3.63 (8H, C(29)H3 + C(30)H3+ C(13)H2), 3.20 (2H, m, C(11)H2), 
2.82-2.79 (2H, m, C(23)H2), 1.83 (1H, nonet, J = 6.7 Hz, C(28)H), 1.75-1.69 (4H, m, 
C(27)H2 + C(12)H2), 1.42 (9H, s, 3 × C(10)H3), 1.02 (9H, s, 3 × C(19)H3), 0.96 (6H, d, J = 
6.6 Hz, C(29)H3 + C(30)H3 ).13C NMR (CDCl3, 100 MHz, 55 ºC) δ:  173.2 (C(21)), 171.0 
(C(24)), 155.9 (C(8)), 151.0 (C(3)), 135.5 (4 × C(15)), 134.0 (2 × C(14)), 129.5 (2 × C(17)), 
129.2 (C(2)), 127.5 (4 × C(16)), 122.0 (C(6)), 121.9 (C(1)), 121.3 (C(5)), 111.7 (C(4)), 79.6 
(C(9)), 67.1 (C(26)), 62.1 (C(13)), 56.4 (C(21)), 51.7 (C(22)), 51.4 (C(25)), 46.8 (C(7)), 43.5 
(C(27)), 38.2 (C(23)), 38.1 (C(11)), 31.0 (C(12)), 28.4 (3 × C(10)), 26.9 (C(29) + C(30)),  25.2 
(C(28)), 22.5 (C(18)), 19.1 (3 × C(19)). [α]D:1.41 (c = 1.0, CHCl3, 25.8 ºC).  HRMS (CI+) 
calcd for C42H61N2O8Si [M+H+]: m/z 749.4197, found m/z 749.4202.  νmax (CDCl3)/cm-
1: 2930.9 (m), 1739.9 (s), 1674.3 (s), 1472.7 (s), 1167.0 (s). 
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(R)-Methyl 2-(9-(3-methylbutoxy)-4-(3-(tert-Butyl-diphenyl-silanyloxy)propyl)-3-oxo-
2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate  
 
Amine (R)-60 (0.20 g, 0.27 mmol, 1.0 eq.) was dissolved in anhydrous 
dichloromethane (2 mL) and trifluoroacetic acid (2 mL) and the solution was allowed 
to stir for 16 h.  Analysis by thin layer chromatography indicated that the salt had 
formed.  The reaction mixture was concentrated in vacuo, the reaction mixture was 
loaded onto a strong cation exchange silica column which was washed with methanol 
(20 mL), and flushed with 7 M ammonia in methanol solution (20 mL).  The ammonia 
in methanol fraction was concentrated in vacuo giving the title compound as a light 
yellow oil (0.08 g, 0.13 mmol, 48%).  
1H NMR (CDCl3, 500 MHz) δ: 7.52 (4H, apparent t, J = 6.8 Hz, 4 × C(17)H), 7.33-7.25 
(6H, m, 4 × C(18)H + 2 × C(19)H), 6.59 (1H, d, J = 6.6 Hz, C(9)H), 6.46 (1H, app. t, J = 
7.9 Hz, C(7)H), 6.40 (1H, d, J = 7.4 Hz, C(8)H), 5.27 (1H, d, J = 16.3 Hz, C(5)H), 4.93-
4.90 (1H, m, C(2)H), 4.32 (1H, d, J = 4.3 Hz, NH), 3.88-3.84 (2H, m, C(22)H2), 3.71 (1H, 
d, J = 16.5 Hz, C(5)H), 3.60 (3H, s, C(12)H3), 3.57-3.47 (4H, m, C(13)H2 + C(15)H2), 2.91 
(1H, dd, J = 15.9, 6.9 Hz, C(10)H), 2.56 (1H, dd, J = 15.9, 6.9 Hz, C(10)H), 1.70 (1H, 
apparent septet, J = 6.7 Hz, (C(24)H), 1.66-1.60 (2H, m, C(14)H2), 1.58 (2H, app. q, J = 
6.5 Hz, C(23)H2), 0.94 (9H, s, 3 × C(21)H3), 0.85 (6H, apparent dd, J = 6.7, 1.3 Hz, 
C(25)H3 + C(26)H3). 13C NMR (CDCl3, 125 MHz) δ: 171.8 (C(3)), 169.3 (C(11)), 146.6 (C(9)), 
135.6 (4 × C(17)), 135.0 (C(9a)), 133.8 (2 × C(16)), 129.7 (2 × C(19)), 127.7 (4 × C(18)), 
121.2 (C(6)), 119.9 (C(5a)), 116.9 (C(7)), 110.5 (C(8)), 66.8 (C(22)), 61.3 (2 × C(15)), 52.0 
(C(5)), 51.9 (C(2)), 51.6 (C(12)), 45.2 (C(13)), 38.0 (C(23)), 36.2 (C(10)), 31.2 (C(14), 26.9 (3 
× C(21)), 25.2 (C(24)), 22.7 (C(25)), 22.6 (C(26)), 19.2 (C(20)).  HRMS (CI+) calcd for 
C36H49N2O5Si [(M+H)+]: m/z 617.3411, found m/z 617.3406.  νmax (CDCl3)/cm-1: 2955 
(m), 2929 (s), 1738 (s), 1658 (s), 1105 (s), 1089 (s), 701 (s). 
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(R)-Methyl 2-(9-(3-methylbutoxy)-4-(3-hydroxypropyl)-3-oxo-2,3,4,5-tetraydro-1H-
benzo-1,4-diazepin-2-yl)acetate  
 
Silyl ether (R)-71 (80 mg, 0.13 mmol, 1.0 eq.), was dissolved in tetrahydrofuran (2 
mL).  Tetrabutylammonium fluoride (1 M THF, 0.16 mL, 0.16 mmol, 1.2 eq.) was 
added to the reaction mixture which was allowed to stir for 16 h.   The reaction mixture 
was concentrated in vacuo and purified by flash column chromatography (0-1% 
methanol in ethyl acetate) giving the title compound as an oil (15 mg, 0.04 mmol, 
30%). 
1H NMR (CDCl3, 400 MHz) δ: 6.73 (1H, dd, J = 7.9, 1.3 Hz, C(6)H), 6.61 (1H, apparent 
t, J = 7.8 Hz, C(7)H), 6.56 (1H, dd, J = 7.5, 1.1 Hz, C(8)H), 5.50 (1H, d, J = 16.3 Hz, 
C(5)H), 5.13 (1H, dt, J = 10.9, 5.8 Hz, C(2)H), 4.40 (1H, d, J = 4.7 Hz, NH),4.00 (2H, t, 
J = 6.7 Hz, C(16)H2), 3.79 (1H, d, J = 16.5 Hz, C(5)H), 3.76 (3H, s, C(12)H3), 3.72 (1H, 
m, C(13)H), 3.64 (1H, m, C(13)H), 3.39 (2H, m, C(15)H2), 3.09 (1H, dd, J = 16.0, 8.1 Hz, 
C(10)H), 2.71 (1H, dd, J = 16.0, 6.0 Hz, C(10)H), 1.83 (1H, apparent septet, C(18)H), 1.69 
(5H, m, OH + C(14)H2 + C(17)H2), 0.99 (6H, dd, J = 6.6, 2.4 Hz, C(19)H3 + C(20)H3).  13C 
NMR (CDCl3, 100 MHz) δ: 171.5 (C(3)), 170.9 (C(11)), 146.6 (C(9)), 134.7 (C(9a)), 121.1 
(C(6)), 119.3 (C(5a)), 116.9 (C(7a)), 110.5 (C(8a)), 67.0 (C(16)), 57.8 (C(15)), 52.0 (C(12)), 
51.9 (C(5)), 51.5 (C(12)), 44.1 (C(13)), 37.8 (C(17)), 36.1 (C(10)), 30.5 (C(14)), 25.2 (C(18)), 
22.7 (C(19/20)), 22.6 (C(19/20)). HRMS (CI+) calcd for C20H31N2O5 [(M+H)+]: m/z 
379.2233, found m/z 379.2236.  νmax (CDCl3)/cm-1:  2951 (m), 1734 (s), 1647 (s), 1486 
(m), 905 (s), (728). [α]D: 6.88 (c = 1.0, CHCl3, 25.9 ºC). 
 
5-(tert-Butyldiphenyl silanyloxy)-pentylamine [54] 
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5-Aminopentanol (2.57 g, 25.0 mmol, 2.5 eq.) was dissolved in anhydrous 
dichloromethane (50 mL) and the solution was cooled to 0 ºC.  t-Butyldiphenylsilyl 
chloride (2.60 mL, 10.0 mmol, 1.0 eq.) was dissolved in anhydrous dichloromethane 
(10 mL) and slowly added to the solution.  Triethylamine (2.10 mL, 15.0 mmol, 1.5 
eq.) was added, the reaction mixture was allowed to warm to room temperature and 
stir for 3 h.  The reaction mixture was then acidified with 1 M hydrochloric acid (aq.) 
solution (25 mL) and the phases were separated.  The organic layer was washed with 
sodium bicarbonate (aq. sat) (25 mL), brine (50 mL), dried (Na2SO4), and 
concentrated in vacuo giving the title compound as a clear oil (2.20 g, 6.47 mmol, 
65%). 
1H NMR (CDCl3, 400 MHz) δ: 7.67-7.65 (4H, m, 4 × C(7)H), 7.43-7.35 (6H, m, 4 × C(8)H 
+ 2 × C(9)H), 3.66 (2H, t, J = 7.0 Hz, C(5)H2), 2.68 (2H, t, J = 7.0 Hz, C(1)H2), 1.88 (2H, 
broad s, NH2), 1.59-1.54 (2H, m, C(2)H2), 1.45-1.35 (4H, m, C(3)H2 + C(4)H2), 1.05 (9H, 
s, 3 × C(11)H3).  13C NMR (CDCl3, 125 MHz) δ:  135.6 (4 × C(7)), 134.0 (2 × C(6)), 129.5 
(2 × C(9)), 127.6 (4 × C(8)), 63.8 (C(5)), 42.0 (C(1)), 33.7 (C(2)), 32.3 (C(4)), 26.9 (3 × C(11)), 
23.1 (C(3)), 19.2 (C(10)).  HRMS (CI+) calcd for C21H32NOSi [(M+H)+]: m/z 342.2253, 
found m/z 342.2249.  νmax (CDCl3)/cm-1: 3050 (w), 1605 (m), 1472 (m), 1427 (m), 1105 
(s), 1092 (s), 699 (s).  
5-(tert-Butyldiphenyl silanyloxy)pentyl-[3-(3-methylbutoxy)-2-nitro-benzyl]-amine  
 
Nitrobenzaldehyde 18 (0.97 g, 4.08 mmol, 1.0 eq.) was dissolved in heptane (60 mL) 
and amine 69 (2.10 g, 6.16 mmol, 1.5 eq.) was added.  The reaction mixture was 
allowed to stir for 48 h, concentrated in vacuo and dissolved in methanol (60 mL).  
Sodium borohydride (0.23 g, 6.16 mmol, 1.5 eq.) was added and the solution was 
allowed to stir for 12 h.  The reaction mixture was quenched by the addition of water 
(20 mL), ethyl acetate (20 mL) was added and the phases separated.  The aqueous 
layer was extracted with ethyl acetate (2 × 60 mL).  The combined organic layers 
were washed with brine (20 mL), dried (Na2SO4), and concentrated in vacuo.  The 
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resulting mixture was purified by flash column chromatography (0-20% ethyl acetate 
in petroleum ether) giving the title compound as a yellow oil (2.29 g, 4.07 mmol, 98%).     
1H NMR (CDCl3, 400 MHz) δ: 7.70-7.68 (4H, m, 4 × C(14)H), 7.47-7.35 (7H, m, 4 × 
C(15)H + 2 × C(16)H + C(5)H), 7.07 (1H, d, J = 7.6 Hz, C(6)H), 6.85 (1H, d, J = 8.2 Hz, 
C(4)H), 4.10 (2H, t, J = 6.4 Hz, C(19)H2), 3.76 (2H, s, C(7)H2), 3.68 (2H, t, J = 6.4 Hz, 
C(12)H2), 2.58 (2H, t, J = 6.9 Hz, C(8)H2), 1.82 (1H, apparent septet, J = 6.9 Hz, C(21)H), 
1.62-1.55 (4H, m, C(9)H2 + C(11)H2), 1.50-1.37 (5H, m, NH + C(10)H2 + C(20)H2), 1.07 
(9H, s, 3 × C(18)H3), 0.97 (6H, d, J = 6.5 Hz, C(22)H3 + C(23)H3).  13C NMR (CDCl3, 125 
MHz) δ: 150.8 (C(3)), 142.0 (C(2)), 135.6 (4 × C(14)), 134.1 (2 × C(13)), 133.6 (C(1)), 130.8 
(C(5)), 129.5 (2 × C(16)), 127.6 (4 × C(15)), 121.2 (C(6)), 112.1 (C(4)), 67.9 (C(19)), 63.82 
(C(12)), 49.4 (C(7)), 49.3 (C(8)), 37.5 (C(20)), 32.4 (C(11)), 29.7 (C(9)), 26.9 (3 × C(18)), 24.9 
(C(21)) 23.4 (C(10)), 22.5 (C(22) + C(23)),19.2 (C(17)).  HRMS (CI+) calcd for C33H47O4N2Si 
[(M+H)+]: m/z 563.3305, found m/z 563.3304.  νmax (CDCl3)/cm-1: 2930 (m), 1589 (m), 
1389 (m), 1105 (s), 727 (s), 907 (s), 702 (s).  
[2-Amino-3-(3-methyl-butoxy)-benzyl]-{5-[(tert-butyldiphenylsilyl)oxy]pentyl}-
carbamic acid tert-butyl ester  
 
Nitobenzene 55 (2.58 g, 4.58 mmol, 1.0 eq.) was dissolved in anhydrous 
dichloromethane (100 mL), triethylamine (1.08 mL, 7.78 mmol, 1.7 eq.) was added 
and the solution was allowed to stir for 25 min.  Di-t-butyl dicarbonate (1.11 g, 5.33 
mmol, 1.2 eq.) was added to the reaction mixture which was then allowed to stir for 
16 h.  The reaction mixture was quenched with water (75 mL), and diluted with ethyl 
acetate (75 mL).  The phases were separated and the aqueous layer was extracted 
with ethyl acetate (2 × 75 mL).  The combined organic layer was then washed with 
brine (75 mL), dried (Na2SO4) and concentrated in vacuo.  The crude mixture was 
purified by flash column chromatography (0-10% ethyl acetate in petroleum ether) 
giving the intermediate carbamate as a light yellow oil.  This oil was dissolved in 
anhydrous methanol (60 mL).  Ammonium formate (2.58 g, 41.0 mmol, 9.0 eq.) and 
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10% palladium on activated charcoal (200 mg) were added to the solution and heated 
to 35 ºC.  The reaction mixture was allowed to stir for 48 h.  The reaction mixture was 
filtered through celite and washed with ethyl acetate (400 mL).  The filtrate was 
washed with water (400 mL) and the phases were separated.  The aqueous phase 
was extracted with ethyl acetate (2 × 200 mL), the combined organic layer was then 
washed with brine, dried (Na2SO4) and filtered giving the title compound as a light red 
oil (2.19 g, 3.50 mmol, 76%). 
1H NMR (CDCl3, 500 MHz) δ: 7.59-7.57 (4H, m, 4 × C(17)H), 7.35-7.28 (6H, m, 4 × 
C(18)H + 2 × C(19)H), 6.64 (1H, d, J = 7.9 Hz, C(5)H), 6.53 (1H, d, J = 7.4 Hz, C(6)H), 
6.50-6.48 (1H, m, C(4)H), 4.59 (2H, broad s, NH2), 4.29 (2H, s, C(7)H2), 3.91 (2H, t, J 
= 6.7 Hz, C(22)H2), 3.55 (2H, t, J = 6.2 Hz, C(15)H2), 2.98 (2H, broad s, C(11)H2), 1.77 
(1H, apparent septet, J = 6.7 Hz, C(24)H), 1.62 (2H, q, J = 6.7 Hz, C(23)H2), 1.48-1.43 
(2H, m, C(12)H2), 1.40-1.35 (11H, m, C(14)H2 + 3 × C(10)H3), 1.25-1.19 (2H, m, C(13)H2), 
0.97 (9H, s, 3 × C(21)H3), 0.88 (6H, d, J = 6.6 Hz, C(25)H3 + C(26)H3).  13C NMR (CDCl3, 
125 MHz) δ: 156.4 (C(8)), 146.4 (C(3)), 136.2 (C(2)), 135.6 (4 × C(17)), 133.8 (2 × C(16)), 
129.5 (2 × C(19)), 127.6 (4 × C(18)), 123.3 (C(1)), 120.8 (C(6)), 115.8 (C(5)), 110.6 (C(4)), 
79.8 (C(9)), 66.7 (C(22)), 63.8 (C(15)), 47.1(C(7)), 45.2 (C(11)), 38.2 (C(23)), 32.3 (C(12)), 
28.5 (3 × C(10)), 27.3 (C(14)), 26.9 (3 × C(21)), 25.2 (C(24)), 23.1 (C(13)), 22.7 (C(25) + C(26)), 
19.2. (C(20)).  HRMS (CI+) calcd for C38H57O4N2Si [(M+H)+]: m/z 633.4088, found m/z 
633.4082.  νmax (CDCl3)/cm-1: 2929.5 (m), 1670.0 (s), 1472.7 (m), 1237.9 (m). 
(R)-Dimethyl 2-(2-((tert-butoxycarbonyl(5-(tert-butyldiphenyl 
silanyloxy)pentyl)amino)methyl)-6-(isopentoxy)phenylamino)succinate 
 
Aniline 53 (1.90 g, 3.01 mmol. 1.0 eq.) was dissolved in anhydrous dichloromethane 
(30 mL), 2,6- lutidine (0.70 mL, 6.02 mmol, 2.0 eq.) was added and the solution was 
allowed to stir at room temperature for 20 min.  Triflate (S)-20 (1.50 g, 5.10 mmol, 1.7 
eq.) was dissolved in anhydrous dichloromethane (30 mL) and was added dropwise 
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to the solution.  The reaction mixture was heated to 45 ºC and stirred for 48 h.  The 
reaction mixture was then quenched with water (60 mL) and the phases were 
separated.  The aqueous phase was extracted with dichloromethane (60 mL), and 
the combined organic layer was then washed with copper sulfate solution (aq. sat.) 
(3 × 60 mL), dried (Na2SO4), filtered and concentrated in vacuo.  The resulting mixture 
was purified by flash column chromatography (0-10% ethyl acetate in 40-60 
petroleum ethers) giving the desired compound as a clear oil (1.65 g, 2.10 mmol, 
70%). 
1H NMR (CDCl3, 400 MHz, 55 ºC) δ: 7.66-7.64 (4H, m, 4 × C(17)H), 7.42-7.34 (6H, m, 
4 × C(18)H + 2 × C(19)H), 6.84-6.81 (1H, m, C(4)H), 6.77-6.75 (1H, m, C(5)H), 6.68 (1H, 
d, J = 1.6 Hz, C(6)H), 4.62-4.59 (3H, m, C(7)H2 + C(22)H), 4.35 (1H, d, J = 15.4 Hz, NH), 
3.98 (2H, t, J = 6.9 Hz, C(28)H2), 3.65-3.62 (8H, m, C(24)H3 + C(27)H3 + C(15)H2), 3.09-
3.04 (2H, m, C(11)H2), 2.80 (2H, dd, J = 6.6, 3.6 Hz, C(25)H2), 1.83 (1H, n, J = 6.9 Hz, 
C(30)H), 1.71 (2H, q, J = 6.7 Hz, C(29)H2), 1.57-1.45 (13H, m, 3 × C(10)H3 + C(12)H2 + 
C(14)H2), 1.33-1.26 (2H, m, C(13)H2), 1.04 (9H, s, 3 × C(21)H3), 0.97 (6H, d, J = 6.6 Hz, 
C(31)H3 + C(32)H3).  13C NMR (CDCl3, 100 MHz, 55 ºC) δ:  173.2 (C(23)), 171.0 (C(26)), 
156.0 (C(8)), 151.1 (C(3)), 135.5 (4 × C(17)), 134.3 (2 × C(16)), 129.4 (2 × C(19)), 127.5 (4 
× C(18)), 121.4 (C(4) + C(5)), 111.6 (C(6)), 79.5 (C(9)), 67.2 (C(28)), 63.9 (C(15)), 56.5 (C(22)), 
51.7 (C(24)), 51.4 (C(27)), 46.6 (C(7)), 46.0 (C(11)), 38.2 (C(25)), 38.1 (C(14)), 32.3 (C(29)), 
28.4 (3 × C(10)), 27.6 (C(12)), 26.9 (C(31) + C(32)) , 25.2 (C(30)), 23.2 (C(13)), 22.5 (C(20)), 
19.2 (3 × C(21)), (C(1)) unresolved, (C(2)) unresolved.  HRMS (CI+) calcd for 
C44H65N2O8Si [M+H+]: m/z 777.4510, found m/z 777.4505.  νmax (CDCl3)/cm-1: 2953 
(m), 1741 (s), 1672 (s), 1471 (s), 1163 (s).  [α]D: 1.33 (c = 1.0, CHCl3, 25.8 ºC). 
(S)-Dimethyl 2-(2-((tert-butoxycarbonyl(5-(tert-butyldiphenyl 
silanyloxy)pentyl)amino)methyl)-6-(isopentoxy)phenylamino)succinate 
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(S)-51 was synthesised via the method described above (73%).  [α]D: -2.64 (c = 1.0, 
CHCl3, 28.7 ºC) 
(R)-Methyl 2-(9-(isopentyloxy)-4-(5-hydroxypentyl)-3-oxo-2,3,4,5-tetraydro-1H-
benzo-1,4-diazepin-2-yl)acetate 
 
Amine (R)-51 (0.24 g, 0.30 mmol, 1.0 eq.) was dissolved in anhydrous 
dichloromethane (2 mL) and trifluoroacetic acid (2 mL) and the solution was allowed 
to stir for 16 h.  Analysis by thin layer chromatography indicated that the salt had 
formed.  The reaction mixture was concentrated in vacuo, and loaded onto a strong 
cation exchange silica column which was washed with methanol (20 mL) and flushed 
with 7 M ammonia in methanol solution (20 mL).  The ammonia in methanol fraction 
was allowed to stand for two hours before concentration in vacuo, giving the title 
compound as a white solid (0.12 g, 0.28 mmol, 95%).   
1H NMR (CDCl3, 400 MHz) δ: 6.70 (1H, dd, J = 7.4, 1.9 Hz, C(6)H), 6.60-6.54 (2H, m, 
C(7)H + C(8)H), 5.44 (1H, d, J = 16.4 Hz, C(5)H), 5.07 (1H, m, C(2)H), 4.40 (1H, J = 4.6 
Hz, NH), 3.97 (2H, J = 6.5 Hz, C(18)H2), 3.77 (1H, J  = 16.6 Hz, C(5)H), 3.72 (3H, s, 
C(12)H3), 3.50 (4H, m, C(17)H2 + C(13)H2), 3.05 (1H, J = 16.1, 7.6 Hz, C(10)H), 2.67 (1H, 
dd, J = 15.9, 6.3 Hz, C(10)H), 1.81 (1H, apparent septet, J = 6.8 Hz, C(20)H), 1.70-1.64 
(3H, m, C(19)H2 + OH), 1.58-1.44 (4H, m, C(14)H2 + C(16)H2), 1.34-1.22 (2H, m, C(15)H2), 
0.96 (6H, dd, J = 6.6, 1.0 Hz, C(21)H3 + C(22)H3).  13C NMR (CDCl3, 125 MHz) δ: 171.8 
(C(3)), 169.5 (C(11)), 146.6 (C(9)), 135.0 (C(9a)), 121.1 (C(6)), 119.8 (C(5a)), 116.9 (C(7)), 
110.5 (C(8)), 66.9 (C(18)), 62.6 (C(17)), 52.0 (C(12)), 51.5 (C(2)), 51.4 (C(13)), 47.3 (C(5)), 
38.0 (C(19)), 36.2 (C(10)), 32.2 (C(16)), 27.9 (C(14)), 25.2 (C(20)), 22.7 (C(15)), 22.6 (C(21) + 
C(22)). HRMS (CI+) calcd for C22H35O5N2 [M+H+]: m/z 407.2546, found m/z 407.2541.  
M.P. 62-64 ºC.  νmax (CDCl3)/cm-1: 3410.3 (m), 2931.9 (m), 1736.0 (s), 1643.4 (s), 
1373.4 (m). [α]D: 6.79 (c = 1.0, CHCl3, 25.8 ºC). 
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(S)-Methyl 2-(9-(isopentyloxy)-4-(5-hydroxypentyl)-3-oxo-2,3,4,5-tetraydro-1H-
benzo-1,4-diazepin-2-yl)acetate 
 
Alcohol (S)-26 was synthesised via the method described above.  [α]D: -13.97 (c = 
1.0, CHCl3, 24.7 ºC). 
(R)-Methyl 2-(9-(3-methylbutoxy)-4-(5-{[(4-methylbenzene)sulfonyl]oxy}pentyl)-1H-
1,2,3-triazol-1-yl] pentyl)-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
 
Alcohol (R)-20 (0.10 g, 0.25 mmol, 1.0 eq.) was dissolved in dichloromethane (10 
mL).  Triethylamine (0.26 mL, 1.85 mmol, 7.5 eq.) was added to the solution and the 
reaction mixture was allowed to stir for 10 min.  p-Toluenesulfonyl chloride (0.12 g, 
0.63 mmol, 2.5 eq.) was added to reaction mixture which was allowed to stir at room 
temperature for 18 h.  Water (10 mL) was added to the reaction mixture and the 
phases were separated.  The organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo.  The resulting residue was purified by flash column 
chromatography (10-50% ethyl acetate in petroleum ether) giving the title compound 
as a colourless oil (0.93 g, 0.17 mmol, 68%). 
1H NMR (CDCl3, 400 MHz) δ: 7.78 (2H, d, J = 8.3 Hz, 2 × C(19)H), 7.35 (2H, d, J = 8.0 
Hz, 2 × C(20)H), 6.71 (1H, dd, J = 8.0, 1.5 Hz, C(6)H), 6.61-6.54 (2H, m, C(7)H + C(8)H), 
5.42 (1H, d, J = 16.4 Hz, C(5)H), 5.09-5.04 (1H, m, C(2)H), 4.44 (1H, d, J = 4.4 Hz, NH), 
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3.99 (2H, t, J = 6.7 Hz, C(23)H2), 3.93 (2H, t, J = 6.5 Hz, C(17)H2), 3.77-3.74 (1H, m, 
C(5)H), 3.74 (3H, s, C(12)H3), 3.55-3.48 (1H, m, C(13)H), 3.44-3.37 (1H, m, C(13)H), 3.05 
(1H, dd, J = 15.8, 7.4 Hz, C(10)H), 2.68 (1H, dd, J = 15.8, 6.4 Hz, C(10)H), 2.46 (3H, s, 
C(22)H3), 1.83 (1H, apparent septet, J = 6.8 Hz, C(25)H), 1.68 (2H, q, J = 6.5 Hz, C(24)H2), 
1.58 (2H, apparent quintet, J = 7.5 Hz, C(14)H2), 1.48 (2H, apparent quintet, J = 7.5 Hz, 
C(16)H2), 1.35-1.12 (2H, m, C(15)H2), 0.98 (6H, dd, J = 6.6, 0.4 Hz, C(26)H3 + C(27)H3).  
13C NMR (CDCl3, 125 MHz) δ:171.7 (C(3)), 169.4 (C(11)), 146.6 (C(21)), 144.7 (C(9)), 
134.9 (C(18)), 133.2 (C(9a)), 129.8 (2 × C(20)), 127.9 (2 × C(19)), 121.1 (C(6)), 119.8 (C(5a)), 
117.0 (C(7)), 110.5 (C(8)), 70.4 (C(17)), 66.9 (C(23)), 52.0 (C(2)), 51.5 (C(5)), 51.5 (C(12)), 
47.2 (C(13)), 38.0 (C(24)), 36.2 (C(10)), 28.4 (C(14)), 27.6 (C(16)), 25.2 (C(25)), 22.7 (C(26)), 
22.6 (C(27)), 22.5 (C(15)), 21.6 (C(22)).  [α]D: 3.11 (c =0.8, CHCl3, 24.8 ºC).  LRMS (EI+) 
calcd for C29H41O7N2S [(M+H)+]: m/z 561.3, found m/z 561.2.  νmax (CDCl3)/cm-1: 
1736.0 (s), 1658.8 (s), 1589.4 (m), 1450.5 (s), 1172.8 (s).  
(S)-Methyl 2-(9-(3-methylbutoxy)-4-(5-{[(4-methylbenzene)sulfonyl]oxy}pentyl)-1H-
1,2,3-triazol-1-yl] pentyl)-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
 
(S)-47 was synthesised via the method described above.  [α]D: -4.36 (c =1.0, CHCl3, 
26.1 ºC). 
(R)-Methyl 2-(9-(3-methylbutoxy)-4-(5-azidopentyl)-3-oxo-2,3,4,5-tetraydro-1H-
benzo-1,4-diazepin-2-yl)acetate 
 
140 
 
Tosylate (R)-47 (30 mg, 0.05 mmol, 1.0 eq.) was dissolved in dimethylformamide (2 
mL).  Sodium azide (30 mg, 0.50 mmol, 10 eq.) was added to the solution which was 
heated to 70 ºC and stirred for 24 h.  The reaction mixture was diluted with water (10 
mL) and ethyl acetate (15 mL), the phases were separated and the organic layer was 
washed with water (4 × 10 mL).  The organic layer was then dried (Na2SO4), filtered 
and concentrated in vacuo.  The crude mixture was purified by flash column 
chromatography (0-30% EtOAc in petroleum ether) giving the title compound as a 
yellow oil (20 mg, 0.04 mmol, 80 %). 
1H NMR (CDCl3, 500 MHz) δ: 6.63 (1H, dd, J = 7.6, 1.3 Hz, C(6)H), 6.53-6.47 (2H, m, 
C(7)H + C(8)H), 5.37 (1H, d, J = 16.4 Hz, C(5)H), 5.00 (1H, t, J = 6.9 Hz, C(2)H), 4.36 
(1H, broad singlet, NH), 3.91 (2H, t, J = 6.6 Hz, C(18)H2), 3.68 (1H, d, J = 16.6 Hz, 
C(5)H), 3.66 (3H, s, C(12)H3), 3.56-3.50 (1H, m, C(13)H), 3.36-3.31 (1H, m, C(13)H), 3.06 
(2H, t, J = 7.0 Hz, C(17)H2), 2.98 (1H, dd, J = 15.9, 7.4 Hz, C(10)H), 2.60 (1H, dd, J = 
15.8, 6.4 Hz, C(10)H), 1.74 (1H, nonet, J = 6.7 Hz, C(20)H), 1.63-1.58 (2H, m, C(19)H2), 
1.50-1.36 (4H, m, C(14)H2 + C(16)H2), 1.26-1.13 (2H, m, C(15)H2), 0.90 (6H, dd, J = 6.6, 
1.2 Hz, C(21)H3 + C(22)H3).  13C NMR (CDCl3, 125 MHz) δ:171.7 (C(3)), 169.5 (C(11)), 
146.6 (C(9)), 135.0 (C(9a)), 121.1 (C(8)), 119.8 (C(5a)), 116.9 (C(7)), 110.5 (C(6)), 66.9 
(C(18)), 51.9 (C(12)), 51.5 (C(17)), 51.5 (C(2)), 51.2 (C(13)), 47.4 (C(5)), 38.0 (C(19)), 36.2 
(C(10)), 28.4 (C(16)), 21.8 (C(14)), 25.2 (C(20)), 23.8 (C(15)), 22.7 (C(21)), 22.6 (C(22)).  LRMS 
(CI+) calcd for C22H34N5O4 [M+H+]: m/z 432.3, found m/z 432.3.  νmax (CDCl3)/cm-1: 
3421 (w), 2860 (m), 2092 (s), 1735 (s), 1659 (s), 1249 (s).  [α]D: 4.38 (c = 1.0, CHCl3, 
25.1 ºC).   
(S)-Methyl 2-(9-(3-methylbutoxy)-4-(5-azidopentyl)-3-oxo-2,3,4,5-tetraydro-1H-
benzo-1,4-diazepin-2-yl)acetate 
 
(S)-45 was synthesised via the method described above (87%).  [α]D: -.5.59 (c =1.0 , 
26.2 ºC). 
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(R)-Methyl 2-(9-(3-methylbutoxy)-4-(5-[4-(pent-4-yn-1-yl)-1H-1,2,3-triazol-1-yl] 
pentyl)-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
 
Azide (R)-45 (44 mg, 0.10 mmol, 1.0 eq.) was dissolved in THF (0.75 mL) and water 
(0.25 mL).  Copper (II) sulfate (30 mg, 0.12 mmol, 10.0 eq.), sodium ascorbate (48 
mg, 0.24 mmol, 2.4 eq.) and 1,6-heptadiyne (0.12 mL, 1.00 mmol, 10.0 eq.) were 
added to the solution which was heated to 70 °C for 18 h.  The reaction mixture was 
diluted with water (5 mL) and ethyl acetate (5 mL) and the phases were separated.  
The aqueous phase was extracted with ethyl acetate (2 × 5 mL) and the combined 
organic layer was dried (Na2SO4), filtered and concentrated in vacuo onto silica gel.  
Flash column chromatography (50-100% ethyl acetate in petroleum ether) gave the 
title compound as a light yellow oil (40 mg, 0.76 mmol, 76%).  
1H NMR (CDCl3, 500 MHz) δ: 7.22 (1H, s, C(22)H), 6.63 (1H, dd, J = 7.7, 1.4 Hz, C(6)H), 
6.53-6.47 (2H, m, C(7)H + C(8)H), 5.37 (1H, d, J = 16.5 Hz, C(5)H), 5.02-4.98 (1H, m, 
C(2)H), 4.37 (1H, d, J = 4.4 Hz, NH), 4.09 (2H, td, J = 7.1, 3.1 Hz, C(17)H2), 3.91 (2H, t, 
J = 6.5 Hz, C(28)H2), 3.68 (1H, d, J = 16.7 Hz, C(5)H), 3.65 (3H, s, C(12)H3), 3.50 (1H, 
dt, J = 14.0, 7.1 Hz, C(13)H), 3.34 (1H, dt, J = 14.0, 7.2 Hz, C(13)H), 2.97 (1H, dd, J = 
15.9, 7.5 Hz, C(10)H), 2.75 (2H, t, J = 7.4 Hz, C(23)H2), 2.60 (1H, dd, J = 15.7, 6.2 Hz, 
C(10)H), 2.17 (1H, td, J = 6.9, 2.4 Hz, C(25)H2), 1.91 (1H, t, J = 2.6 Hz, C(27)H), 1.83 (2H, 
tt, J = 7.4, 7.2 Hz, C(16)H2), 1.77-1.68 (3H, m, C(30)H + C(24)H2), 1.63-1.58 (2H, m, 
C(29)H2), 1.50-1.44 (2H, m, C(14)H2), 1.21-1.09 (2H, m, C(15)H2), 0.88 (6H, d, J = 6.6 
Hz, C(31)H3 + C(32)H3).  13C NMR (CDCl3, 125 MHz) δ:171.7 (C(3)), 169.5 (C(11)), 146.6 
(C(9) + C(21)), 135.0 (C(9a)), 121.1 (C(8)), 120.8 (C(22)), 119.8 (C(5a)), 116.9 (C(7)), 110.5 
(C(6)), 83.8 (C(26)), 68.9 (C(27)), 66.9 (C(28)), 51.9 (C(12)), 51.5 (C(17)), 51.5 (C(2)), 49.9 
(C(13)), 47.1 (C(5)), 38.0 (C(19)), 36.1 (C(10)), 29.8 (C(23)), 28.0 (C(16)), 27.5 (C(14)), 25.2 
(C(30)), 24.4 (C(24)), 23.4 (C(15)), 22.7 (C(31)), 22.7 (C(32)), 17.8 (C(25)).  HRMS (ESI) calcd 
for C29H41O4N5Na [M+Na+]: m/z 546.3031, found m/z 546.3031.  νmax (CDCl3)/cm-1: 
3291 (m), 2950 (s), 2358 (m), 1617 (s), 1274 (s).  [α]D: 4.19 (c = 1.0, CHCl3, 23.3 ºC). 
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(S)-Methyl 2-(9-(3-methylbutoxy)-4-(5-[4-(pent-4-yn-1-yl)-1H-1,2,3-triazol-1-yl] 
pentyl)-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
 
(S)-114 was synthesised via the method described above (46%).   
(R)-Methyl 2-(9-(3-methylbutoxy)-4-(5-[4-(prop-3-{1-[(R)-Methyl 2-(9-(3-
methylbutoxy)-4-(pentyl)-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-
yl)acetate]-1H-1,2,3-triazol-4-yl }-1-yl)-1H-1,2,3-triazol-1-yl] pentyl)-3-oxo-2,3,4,5-
tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
 
This compound was isolated as a by-product in the synthesis of (R)-114. 
1H NMR (CDCl3, 500 MHz) δ: 7.22 (2H, s, 2 × C(22)H), 6.63 (2H, dd, J = 7.7, 1.1 Hz, 2 
× C(6)H), 6.53-6.47 (4H, m, 2 × C(7)H + 2 × C(8)H), 5.37 (2H, d, J = 16.5 Hz, 2 × C(5)H), 
5.02-4.98 (2H, m, 2 × C(2)H), 4.36 (2H, d, J = 4.4 Hz, 2 × NH), 4.10 (4H, t, J = 7.1 Hz, 
2 × C(17)H2), 3.91 (4H, t, J = 6.7 Hz, 2 × C(25)H2), 3.68 (2H, d, J = 16.7 Hz, 2 × C(5)H), 
3.65 (6H, s, 2 × C(12)H3), 3.50 (2H, dt, J = 7.1, 13.7 Hz, 2 × C(13)H), 3.35 (2H, dt, J = 
6.7,13.7 Hz, 2 × C(13)H), 2.97 (2H, dd, J = 7.4, 15.8 Hz, 2 × C(10)H), 2.69 (4H, br s, 2 
× C(23)H2), 2.60 (2H, dd, J = 15.8, 6.2 Hz, 2 × C(10)H), 1.99-1.96 (2H, m, C(24)H2), 1.76-
1.71 (6H, m, 2 × C(27)H + 2 × C(16)H2), 1.61 (4H, qd, J = 6.5, 1.2 Hz, 2 × C(26)H2), 1.50-
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1.44 (4H, m, 2 × C(14)H2), 1.23-1.10 (4H, m, 2 × C(15)H2), 0.89 (12H, dd, J = 6.6, 1.3 
Hz, 2 × C(28)H3 + 2 × C(29)H3).  13C NMR (CDCl3, 125 MHz) δ: 171.7 (2 × C(3)), 169.5 
(2 × C(11)), 146.6 (2 × C(9) + 2 × C(21)), 135.0 (2 × C(9a)), 121.1 (2 × C(6) + 2 × C(22)), 
119.8 (2 × C(5a)), 117.0 (2 × C(7)), 110.6 (2 × C(8)), 67.0 (2 × C(25)), 51.9 (2 × C(12)), 51.5 
(2 × C(2)),51.5 (2 × C(5)),49.9 (2 × C(17)), 47.2 (2 × C(13)), 38.0 (2 × C(26)), 36.2 (2 × C(10)), 
29.8 (2 × C(16)), 29.2 (C(24)), 27.6 (2 × C(14)), 25.2 (2 × C(27)), 25.0 (2 × C(23)),23.5 (2 × 
C(15)), 22.7 (2 × C(28/29)), 22.6 (2 × C(28/29)).  HRMS (ESI) calcd for C51H70O8N10Na 
[(M+Na)+]: m/z 973.5270, found m/z 973.5234.  νmax (CDCl3)/cm-1: 2928 (s), 2360 (m), 
1647 (s), 1616 (s).  [α]D: -3.29 (c = 1.0, CHCl3, 24.7 ºC). 
(S)-Methyl 2-(9-(3-methylbutoxy)-4-(5-[4-phenyl-1H-1,2,3-triazol-1-yl]pentyl)-3-oxo-
2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
 
Copper (II) chloride (7.0 mg, 0.05 mmol, 1.0 eq.) was suspended in acetonitrile (0.2 
mL), triethylamine (11 µL, 0.08 mmol, 1.5 eq.) was added and the suspension was 
sonicated for 1 min.  Phenylacetylene (5 µL, 0.05 mmol, 1.0 eq.) was added to the 
solution and allowed to stir for 10 min.  Sodium iodide (9 mg, 0.06 mmol, 1.2 eq.) was 
dissolved in water (0.1 mL).  Azide (S)-45 (20 mg, 0.05 mmol, 1.0 eq.) was dissolved 
in acetonitrile (0.2 mL).  The solutions were combined and allowed to stir at room 
temperature for 16 h.  The reaction mixture was concentrated in vacuo onto silica gel 
and purified by flash column chromatography (20-60% EtOAc in petroleum ether) 
giving the title compound as a light brown oil (10 mg, 0.19 mmol, 41%). 
1H NMR (CDCl3, 500 MHz) δ: 7.76 (2H, d, J = 8.5 Hz, 2 × C(26)H), 7.65 (1H, s, C(23)H), 
7.35 (2H, apparent t, J = 7.9 Hz, 2 × C(27)H), 7.25 (1H, t, J = 7.5 Hz, C(28)H), 6.62 (1H, 
dd, J = 7.6, 1.4 Hz, C(6)H), 6.52-6.46 (2H, m, C(7)H + C(8)H), 5.37 (1H, d, J = 16.4 Hz, 
C(5)H), 5.01 (1H, m, C(2)H), 4.36 (1H, d, J = 4.1 Hz, NH), 4.18 (2H, td, J = 7.0, 4.5 Hz, 
C(17)H2), 3.89 (2H, t, J = 6.6 Hz, C(18)H2), 3.68 (1H, d, J = 16.6 Hz, C(5)H), 3.64 (3H, s, 
C(12)H3), 3.53 (1H, dt, J = 13.6, 7.0 Hz, C(13)H), 3.35 (1H, dt, J = 13.7, 6.9 Hz, C(13)H), 
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2.97 (1H, dd, J = 15.8, 7.4 Hz, C(10)H),  2.60 (1H, dd, J = 15.9, 6.3 Hz, C(10)H), 1.84-
1.77 (2H, m, C(16)H2), 1.73 (1H, apparent septet, J = 6.8 Hz, C(20)H), 1.60 (2H, qd, J = 
6.5, 1.6 Hz, C(19)H2), 1.53-1.46 (2H, m, C(14)H2), 1.27-1.18 (2H, m, C(15)H2), 0.88 (6H, 
dd, J = 5.0, 1.7 Hz, C(21)H3 + C(22)H3).  13C NMR (CDCl3, 125 MHz) δ: 171.7 (C(11)), 
169.6 (C(3)), 147.7 (C(24)), 146.6 (C(9)), 135.0 (C(9a)), 130.8 (C(25)), 128.8 (2 × C(26)), 
128.1 (C(28)), 125.7 (2 × C(27)), 121.1 (C(23)), 119.8 (C(5a)), 119.5 (C(6)), 117.0 (C(7)), 
110.6 (C(8)), 67.0 (C(18)), 51.9 (C(12)), 51.5 (C(2)), 51.5 (C(5)), 50.2 (C(17)), 47.1 (C(13)), 
38.0 (C(10/19)), 36.1 (C(10/19)), 29.7 (C(14/16)), 27.5 (C(14/16)),  25.2 (C(20)), 23.4 (C(15)), 22.7 
(C(21)), 22.6 (C(22)).  HRMS (ESI) calcd for C30H39N5NaO4 [(M+Na)+]: m/z 556.2894, 
found m/z 556.2879.  νmax (CDCl3)/cm-1: 2926 (s), 2359 (m), 1734 (s), 1653 (s), 1250 
(s). [α]D: + 18.4 (c = 1.0, CHCl3, 22.7 ºC). 
(S)-Methyl 2-(9-(3-methylbutoxy)-4-(5-[5-iodo-4-phenyl-1H-1,2,3-triazol-1-yl]pentyl)-
3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
 
Copper (I) iodide (14 mg, 0.07 mmol, 1.0 eq.), N-iodosuccinimide (0.017 g, 0.08 
mmol, 1.1 eq.) and triethylamine (0.01 mL, 0.07 mmol, 1.0 eq.) were added to a 
solution of azide (S)-45 (30 mg, 0.07 mmol, 1.0 eq.) in dimethylformamide (1 mL).  
The reaction mixture was allowed to stir at room temperature for 2.5 h at which point 
thin layer chromatography indicated complete consumption of starting material.  The 
reaction mixture was diluted with water (5 mL) and dichloromethane (5 mL) and the 
phases were separated.  The organic layer was washed with water (5 × 10 mL), brine 
(5 mL), dried (Na2SO4) and concentrated in vacuo.  The resulting mixture was purified 
by flash column chromatography giving the title compound as a colourless oil (0.014 
g, 0.02 mmol, 30 %).   
1H NMR (CDCl3, 500 MHz) δ: 7.85 (2H, d, J = 8.5 Hz, 2 × C(26)H ), 7.35 (2H, apparent 
t, J = 7.7 Hz, 2 × C(27)H), 7.32 (1H, t, J = 7.4 Hz, C(28)H), 6.62 (1H, dd, J = 6.7, 2.7 Hz, 
C(6)H), 6.52-6.49 (2H, m, C(7)H + C(8)H), 5.39 (1H, d, J = 16.4 Hz, C(5)H), 5.01 (1H, m, 
145 
 
C(2)H), 4.38 (1H, d, J = 4.1 Hz, NH), 4.23 (2H, t, J = 7.5 Hz, C(17)H2), 3.90 (2H, t, J = 
6.6 Hz, C(18)H2), 3.70 (1H, d, J = 16.6 Hz, C(5)H), 3.66 (3H, s, C(12)H3), 3.56 (1H, dt, J 
= 13.6, 7.0 Hz, C(13)H), 3.35 (1H, dt, J = 13.7, 6.9 Hz, C(13)H), 2.98 (1H, dd, J = 16.0, 
7.5 Hz, C(10)H),  2.61 (1H, dd, J = 15.8, 6.4 Hz, C(10)H), 1.78 (2H, apparent septet, J = 
6.5 Hz, C(16)H2), 1.74 (1H, apparent septet, J = 6.7 Hz, C(20)H), 1.61 (2H, qd, J = 6.6, 
1.3 Hz, C(19)H2), 1.52 (2H, dq, J = 7.5, 7.3 Hz, C(14)H2), 1.30-1.19 (2H, m, C(15)H2),0.89 
(6H, dd, J = 6.6, 1.7 Hz, C(21)H3 + C(22)H3).  13C NMR (CDCl3, 125 MHz) δ: 171.7 (C(11)), 
169.5 (C(3)), 149.7 (C(24)), 146.6 (C(9)), 135.0 (C(9a)), 131.6 (C(23)), 130.4 (C(25)), 128.7 
(2 × C(26) + C(28)), 127.5 (2 × C(27)), 121.1 (C(6)), 119.8 (C(5a)), 117.0 (C(7)), 110.6 (C(8)), 
66.9 (C(18)), 52.0 (C(12)), 51.5 (C(2)), 51.5 (C(5)), 50.5 (C(17)), 47.3 (C(13)), 38.0 (C(10/19)), 
36.2 (C(10/19)), 29.5 (C(14/16)), 27.7 (C(14/16)),  25.2 (C(20)), 23.5 (C(15)), 22.7 (C(21)), 22.6 
(C(22)).  HRMS (ESI) calcd for C30H38IN5NaO4 [(M+Na)+]: m/z 682.1861, found m/z 
682.1847.  νmax (CDCl3)/cm-1: 3405 (m), 2951 (m), 1735 (m), 1658 (s), 1249 (s).  
(S)-Methyl 2-(9-(3-methylbutoxy)-4-[5-(4-{3-[1-(3-{4,4-difluoro-5,7-dimethyl-4-bora-
3a,4a-diaza-s-indacene-3-yl}propyl)-1H-1,2,3-triazol-4-yl]propyl}-1H-1,2,3-triazol-1-
yl)pentyl]-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
 
Alkyne (S)-114 (72 mg, 0.14 mmol, 1.0 eq.) was dissolved in THF (3 mL) and water 
(1 mL).  Azide 109 (46 mg, 0.15 mmol, 1.1 eq.), copper (II) sulfate pentahydrate (27 
mg, 0.17 mmol, 1.2 eq.) and sodium ascorbate (67 mg, 0.34 mmol, 2.4 eq.) were 
added to the solution and the resulting mixture was allowed to stir at 70 °C for 2 h.  
The reaction mixture was concentrated in vacuo and diluted in ethyl acetate (15 mL) 
and water (15 mL) and the phases were separated.  The aqueous phase was 
extracted with EtOAc (10 mL x 2).  The combined organic phases were dried 
(Na2SO4), filtered and concentrated in vacuo.  Preparative thin layer chromatography 
(10% MeOH in EtOAc) gave the title compound as a red/green solid (55 mg, 0.07 
mmol, 48%) 
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1H NMR (CDCl3, 500 MHz) δ: 7.29 (1H, s, C(30)H), 7.20 (1H, s, C(22)H),7.02 (1H, s, 
C(37)H), 6.80 (1H, d, J = 4.1 Hz, C(36)H),6.62 (1H, dd, J = 7.6, 1.8 Hz, C(6)H), 6.52-6.46 
(2H, m, C(7)H + C(8)H), 6.18 (1H, d, J = 4.0 Hz, C(35)H), 6.05 (1H, s, C(39)H), 5.35 (1H, 
d, J = 16.6 Hz, C(5)H), 4.99 (1H, dt, J = 4.9, 6.5 Hz, C(2)H), 4.35 (1H, d, J = 4.4 Hz, 
NH), 4.33 (2H, t, J = 4.4 Hz, CH2), 4.09 (2H, t, J = 7.3 Hz, CH2), 3.90 (2H, t, J = 6.6 
Hz, CH2), 3.67 (1H, d, J = 16.7 Hz, C(5)H), 3.65 (3H, s, C(12)H3), 3.49 (1H, dt, J = 13.7, 
6.9 Hz, C(13)H), 3.33 (1H, dt, J = 13.7, 6.9 Hz, C(13)H), 3.00-2.92 (3H, m, C(10)H + CH2), 
2.68 (2H, t, J = 7.5 Hz, CH2), 2.60 (1H, dd, J = 15.9, 6.3 Hz, C(10)H), 2.47 (3H, s, 
C(47/48)H3), 2.29 (2H, tt, J = 7.5, 7.3, CH2), 2.18 (3H, s, C(47/48)H3), 1.97 (2H, tt, J = 7.6, 
6.5, CH2), 1.78-1.68 (4H, m, 2 × CH2), 1.63-1.58 (2H, m, CH2), 1.46 (2H, tt, J = 7.3, 
7.2, CH2), 1.22-1.13 (3H, m, CH2 + C(44)H), 0.88 (6H, dd, J = 6.6, 1.0, C(45)H3 + C(46)H3).  
13C NMR (CDCl3, 125 MHz): 171.7 (C(11/3)), 169.5 (C(11/3)), 160.4 (ArCq), 156.9 (ArCq), 
147.5 (C(21) + C(26)), 146.6 (ArCq), 144.0 (ArCq), 135.2 (ArCq), 135.0 (ArCq), 133.2 
(ArCq), 128.2 (ArCH), 123.8 (ArCH), 121.1 (ArCH), 120.8 (ArCH), 120.5 (ArCH), 
119.8 (C(5a)), 117.0 (ArCH), 116.7 (ArCH), 110.6 (ArCH), 67.0 (C(42)), 51.9 (C(12)), 51.5 
(C(2)), 51.5 (C(5)), 49.9 (CH2), 49.6 (CH2), 47.2 (CH2), 38.0 (CH2), 36.2 (CH2), 29.8 
(CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.1 (CH2), 27.5 (CH2), 25.7 (CH2), 25.2 
(C(44)), 24.9 (CH2), 23.5 (CH2), 22.7 (C(45/46)), 22.6 (C(45/46)), 14.9 (C(47/48)), 11.3 (C(47/48)). 
HRMS (ESI) calcd for BC43F2H57N10NaO4 [M+Na+]: m/z 849.4523, found m/z 
849.4465.  νmax (CDCl3)/cm-1: 2925 (m), 2361 (w), 1602 (s), 1437 (m), 1138 (s).  [α]D: 
-18.4 (c = 1.0, 23.1 ºC).  λabs,max (MeCN): 503 nm, λem,max (MeCN): 513 nm. 
(R)-Methyl 2-(9-(3-methylbutoxy)-4-[5-(4-{3-[1-(3-{4,4-difluoro-5,7-dimethyl-4-bora-
3a,4a-diaza-s-indacene-3-yl}propyl)-1H-1,2,3-triazol-4-yl]propyl}-1H-1,2,3-triazol-1-
yl)pentyl]-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate 
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MM-IGD-FL1 was synthesised via the method described above.  [α]D: 16.6 (c = 1.0, 
23.2 ºC). 
(R)-Methyl 2-(9-(3-methylbutoxy)-4-(5-aminopentyl)-3-oxo-2,3,4,5-tetraydro-1H-
benzo-1,4-diazepin-2-yl)acetate 
 
Azide (R)-45 (0.15 g, 0.36 mmol, 1.0 eq.), was dissolved in methanol (10 mL) and 10 
% palladium on activated charcoal (20 mg) was added and the reaction mixture was 
stirred at 40 ºC.  Hydrogen gas was allowed to bubble through the reaction mixture 
for 3 h.  The reaction mixture was filtered through celite, washed with methanol (3 × 
10 mL) and the filtrate was concentrated in vacuo giving the title compound as a 
yellow oil (0.14 g, 0.36 mmol, 100%). 
1H NMR (CDCl3, 400 MHz) δ: 6.62 (1H, dd, J = 7.4, 2.0 Hz, C(6)H), 6.53-6.47 (2H, m, 
C(7)H + C(8)H), 5.37 (1H, d, J = 16.4 Hz, C(5)H), 5.03-4.98 (1H, m, C(2)H), 4.35 (1H, d, 
J = 4.5 Hz, NH), 3.90 (2H, t, J = 6.6 Hz, C(18)H2), 3.70 (1H, d, J = 16.6 Hz, C(5)H), 3.66 
(3H, s, C(12)H3), 3.53-3.43 (1H, m, C(13)H), 3.39-3.33 (1H, m, C(13)H), 2.97 (1H, dd, J = 
16.0, 7.4 Hz, C(10)H), 2.60 (1H, dd, J = 15.9, 6.5 Hz, C(10)H), 2.50 (2H, t, J = 6.8 Hz, 
C(17)H2), 1.74 (1H, apparent septet, J = 6.7 Hz, C(20)H), 1.61 (2H, q, J = 6.5 Hz, C(19)H2), 
1.45 (2H, tt, J = 15.0, 7.5 Hz, C(14)H2), 1.35-1.23 (4H, m, C(16)H2 + NH2), 1.20-1.11 (2H, 
m, C(15)H2), 0.89 (6H, dd, J = 6.5, 0.8 Hz, C(21)H3 + C(22)H3).  13C NMR (CDCl3, 100 
MHz) δ: 171.8 (C(3)), 169.4 (C(11)), 146.6 (C(9)), 135.1 (C(9a)), 121.1 (C(6)), 119.9 (C(5a)), 
116.9 (C(7)), 110.5 (C(8)), 66.9 (C(18)), 51.9 (C(12)), 51.6 (C(2)), 51.5 (C(5)), 47.6 (C(13)), 
42.0 (C(17)), 38.0 (C(19)), 36.2 (C(10)), 33.5 (C(16)), 28.1 (C(14)), 25.2 (C(20)), 23.9 (C(15)), 
22.7 (C(21)), 22.6 (C(22)).  HRMS (EI+) calcd for C22H35N3O4 [M+]: m/z 405.2628, found 
m/z 405.2630.  νmax (CDCl3)/cm-1: 3410 (m), 1736 (s), 1658 (s), 1435 (s), 748 (s). [α]D: 
4.32 (c = 1.0, CHCl3, 28.8 ºC). 
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(S)-Methyl 2-(9-(3-methylbutoxy)-4-(5-aminopentyl)-3-oxo-2,3,4,5-tetraydro-1H-
benzo-1,4-diazepin-2-yl)acetate 
  
(S)-45 was synthesised via the method described above (70%). [α]D: - 4.82 (c = 1.0, 
CHCl3, 28.8 ºC). 
(R)-Methyl 2-(9-(3-methylbutoxy)-4-(pentyl-5-[carbamoylethyl-2-{4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diaza-s-indacene-3-yl}])-3-oxo-2,3,4,5-tetraydro-1H-benzo-
1,4-diazepin-2-yl)acetate 
 
BODIPY FL (18 mg, 0.06 mmol, 1.2 eq.) was dissolved in dichloromethane (5 mL).  
O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (23 mg, 
0.06 mmol, 1.2 eq.) and N,N-diisopropylethylamine (22 µL, 0.125 mmol, 2.5 eq.), were 
added to the mixture which was allowed to stir at room temperature for 20 min.  Amine 
(R)-40 (20 mg, 0.05 mmol, 1.0 eq.) was added and the reaction mixture was allowed 
to stir for 16 h.  The reaction mixture was concentrated onto silica gel in vacuo and 
purified by flash column chromatography (0-1% methanol in ethyl acetate) giving the 
title compound as a red/green oil (15 mg, 0.02 mmol, 37%).   
1H NMR (CD3OD, 500 MHz) δ: 7.30 (1H, s, ArH), 6.90-6.89 (1H, m, ArH), 6.59 (1H, 
dd, J = 7.8, 1.2 Hz, C(6)H), 6.52-6.46 (2H, m, C(7)H + C(8)H), 6.20 (1H, d, J = 4.0 Hz, 
149 
 
ArH), 6.09 (1H, br s, ArH), 5.33 (1H, d, J = 16.5 Hz, C(5)H), 4.99 (1H, t, J = 6.8 Hz, 
C(2)H), 3.88 (2H, t, J = 6.5 Hz, C(29)H2), 3.80 (1H, d, J = 16.8 Hz, C(5)H), 3.59 (3H, s, 
C(12)H3), 3.46 (1H, dt, J = 13.5, 6.7 Hz, C(13)H), 3.26 (1H, dt, J = 13.7, 6.7 Hz, C(13)H), 
3.10 (2H, t, J = 7.5 Hz, C(19)H2), 3.00-2.88 (2H, m, C(17)H2), 2.81 (1H, dd, J = 16.2, 7.6 
Hz, C(10)H), 2.58 (1H, dd, J = 16.2, 6.3 Hz, C(10)H), 2.47 (2H, td, J = 7.2, 1.9 Hz, 
C(20)H2), 2.39 (3H, s, C(34/35)H3), 2.16 (3H, s, C(34/35)H3), 1.72 (1H, apparent septet, J = 
6.7 Hz, C(31)H), 1.58-1.54 (2H, m, C(30)H2), 1.43- 1.37 (2H, m, C(14)H2), 1.31-1.19 (2H, 
m, C(16)H2), 1.09-0.97 (2H, m, C(15)H2), 0.86 (6H, d, J = 6.6 Hz, C(32)H3 + C(33)H3). 13C 
NMR (CD3OD, 125 MHz) δ: 174.5 (CO), 173.4 (CO), 172.0 (CO), 161.3 (ArC), 158.5 
(ArC), 148.0 (ArC), 145.8 (ArC), 136.5 (ArC), 136.4 (ArC), 134.9 (ArC), 129.6 (ArCH), 
125.8 (ArCH), 122.5 (ArCH), 121.6 (ArC), 121.3 (ArCH), 118.4 (ArCH), 117.8 (ArCH), 
112.1 (ArCH), 68.1 (C(29)), 52.5 (C(12)), 52.4 (C(2)), 52.2 (C(5)), 40.2 (CH2), 39.2 (CH2), 
36.7 (CH2), 36.0 (CH2), 30.8 (CH2), 29.7 (CH2), 28.8 (CH2), 26.4 (C(31)), 25.7 (CH2), 24.8 
(CH2), 23.1 (C(32/33)), 23.0 (C(32/33)), 14.9 (C(34/35)), 11.2 (C(34/35)).  HRMS (ESI) calcd for 
BC36F2H48N5NaO5 [(M+Na)+]: 702.3645, found: 702.3611.  νmax (CDCl3)/cm-1:2929.0 
(w), 2358.1 (w), 1734.1 (m), 1603.9 (s), 1136.1 (s).  [α]D: +0.120 (c = 1.0, CHCl3, 28.4 
ºC).  λabs,max (MeCN): 504 nm, λem,max (MeCN): 513 nm. 
((S)-Methyl 2-(9-(3-methylbutoxy)-4-(5-amino-(4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene-8-yl)-pentyl)-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-diazepin-2-yl)acetate) 
 
Amine (S)-40 (0.02 g, 0.05 mmol, 1.0 eq.) was added to BODIPY 92 (0.011 g, 0.05 
mmol, 1.0 eq.) in dichloromethane (1 mL) and the reaction mixture was allowed to stir 
at room temperature for 18 h.  The reaction mixture was concentrated onto silica gel 
in vacuo and purified by flash column chromatography (0-60% ethyl acetate in  
petroleum ether).  The desired fractions were concentrated in vacuo and dissolved in 
ethyl acetate (10 mL).  The ethyl acetate solution was washed with water (10 mL), 
brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo giving the title 
compound (10 mg, 0.02 mmol, 40%). 
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1H NMR (CDCl3, 500 MHz) δ: 7.62 (1H, br s, BODIPYH), 7.43-7.38 (3H, m, 3 x 
BODIPYH), 7.05 (1H, br s, BODIPYH), 6.62 (1H, dd, J = 7.6, 1.6 Hz, C(6)H), 6.53-6.48 
(2H, m, C(7)H + C(8)H), 6.44 (1H, br s, BODIPYH), 6.34 (1H, br s, BODIPYH), 5.43 
(1H, d, J = 16.3 Hz, C(5)H), 5.06-5.02 (1H, m, C(2)H), 4.29 (1H, d, J = 4.3 Hz, NH), 
3.88 (2H, t, J = 6.6 Hz, C(23)H2), 3.74 (1H, J = 16.7 Hz, C(5)H), 3.61-3.47 (5H, m, C(12)H3 
+ C(13)H2), 3.04 (1H, dd, J = 16.4, 8.6 Hz, C(10)H), 2.60 (1H, dd, J = 16.4, 5.6 Hz, 
C(10)H), 1.82-1.75 (2H, m, C(17)H2), 1.70 (1H, apparent septet, C(25)H2), 1.62-1.57 (6H, 
m, C(14)H2 + C(16)H2 + C(19)H2), 1.41-1.34 (2H, m, C(15)H2), 0.88 (3H, d, J = 3.8 Hz, 
C(26/27)H3), 0.86 (3H, d, J = 3.8 Hz, C(26/27)H3). 13C NMR (CDCl3, 125 MHz) δ: 171.7 
(C(3/11)), 170.8 (C(3/11)), 149.0 (C(9)), 146.6 (C(9a)), 134.9 (C(18)), 132.3 (2 × C(18a)), 121.1 
(C(6)), 119.4 (C(5a)), 117.2 (C(7)), 116.3 (2 × ArC), 114.3 (2 × ArC), 113.2 (2 × ArC), 
110.7 (C(8)), 67.0 (C(23)), 51.9 (C(12)), 51.7 (C(2)), 51.3 (CH2), 47.7 (CH2), 46.5 (CH2), 
37.8 (CH2), 36.1 (CH2), 29.7 (CH2), 27.6 (CH2), 25.3 (C(25)), 24.1 (CH2), 22.7 (C(26/27)), 
22.6 (C(26/27)).  HRMS (ESI) calcd for BC31F2H40N5NaO5 [(M+Na)+]: 617.3070, found: 
617.3047.  νmax (CDCl3)/cm-1: 2924 (s), 1735 (s), 1643 (s), 1395 (s), 1083 (s).   
3,5-Dimethyl-1H-pyrrole-2-carboxaldehyde[70, 93] 
 
Phosphorous oxychloride (1.02 mL, 11.0 mmol, 1.1 eq.) was added dropwise to 
dimethylformamide (20 mL) at 0 °C and allowed to stir for 10 min and warm to room 
temperature for 30 min.  The reaction mixture was cooled to 0 °C and 2,4-
dimethylpyrrole (1.02 mL, 10.0 mmol, 1.0 eq.) was added.  The reaction mixture was 
heated to 40 °C and allowed to stir for 18 h.  Sodium hydroxide (1 M aq.) was added 
dropwise increasing to pH 11.  The reaction mixture was diluted with ethyl acetate (20 
mL) and brine (20 mL) and the phases were separated.  The organic layer was 
washed with brine (5 × 20 mL), dried (Na2SO4), filtered and concentrated in vacuo 
onto silica gel.  Flash column chromatography (0-20% ethyl acetate in petroleum 
ether) gave the title compound as a colourless oil (1.04 g, 8.3 mmol, 83%).  
1H NMR (CDCl3, 500 MHz) δ: 9.72 (1H, br s, NH), 9.32 (1H, s, C(6)H), 5.76 (1H, br s, 
C(3)H), 2.23 (3H, s, C(7/8)H3), 2.21 (3H, s, C(7/8)H3).  13C NMR (CDCl3, 125 MHz) δC: 
176.0 (C(6)), 138.1 (C(ArQ)), 134.5 (C(ArQ)), 128.8 (C(ArQ)), 112.0 (C(3)), 13.2 (C(7/8)), 10.6 
(C(7/8)). 
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  (E)-Methyl 3-(1H-pyrrol-2-yl)acrylate[70, 93] 
 
Methyl (triphenylphosphoranylidene) acetate (35.1 g, 105 mmol, 2.0 eq.), was 
dissolved in anhydrous dichloromethane (50 mL).  Pyrrole-2-carbaldehyde (90) (5.00 
g, 52.6 mmol, 1.0 eq) was dissolved in dichloromethane (50 mL) and added to the 
solution.  The reaction mixture was allowed to stir for 24 hours before dilution with 
diethyl ether (100 mL) and water (100 mL).  The phases were separated and the 
aqueous layer was extracted with diethyl ether (2 × 50 mL), the combined organic 
layer was washed with brine (100 mL), dried (Na2SO4), and concentrated in vacuo.  
The crude residue was purified by flash column chromatography (20 % ethyl acetate 
in petroleum ether) giving the title compound (5.79 g, 38.3 mmol, 73%). 
1H NMR (CDCl3, 400 MHz): 8.57 (1H, br s, NH), 7.58 (1H, d, J = 16.0 Hz, C(6)H), 6.96-
6.95 (1H, m, ArH), 6.60-6.58 (1H, m, ArH), 6.32-6.30 (1H, m, ArH), 6.00 (1H, d, J = 
16.0 Hz, C(7)H), 3.80 (3H, s, C(9)H3).  13C NMR (CDCl3, 125 MHz): 174.5 (C(8)), 130.9 
(C(5)), 116.8 (C(2)), 108.0 (C(4)), 105.5(C(3)), 51.8 (C(9)), 34.4 (C(6)), 22.6 (C(7)).  
Methyl 3-(1H-pyrrol-2-yl) propanoate[70, 93] 
 
Alkene 87 (0.40 g, 2.60 mmol, 1.0 eq.) was dissolved in anhydrous methanol (15 mL), 
10% palladium on activated charcoal (40 mg) was added.  Hydrogen gas was bubbled 
through the slurry for 5 min and reaction mixture was heated to 40 ºC under a 
hydrogen atmosphere for 2 h.  The mixture was filtered through celite which was then 
washed with methanol (2 × 30 mL).  The methanol portions were then combined and 
concentrated in vacuo giving the title compound (0.40 g, 2.6 mmol, quantitative). 
1H NMR (CDCl3, 400 MHz): 8.57 (1H, br s, NH), 6.71-6.69 (1H, m, ArH), 6.13 (1H, q, 
J = 2.9 Hz, ArH), 5.95-5.93 (1H, m, ArH), 3.72 (3H, s, OC(9)H3), 2.94 (1H, t, J = 6.7 
Hz, C(7)H2CO), 2.67 (1H, t, J = 6.5 Hz, C(6)H2).  13C NMR (CDCl3, 125 MHz):174.5 
(C(8)), 130.9 (C(5)), 116.8 (ArC), 108.0 (ArC), 105.5 (ArC), 51.8 (C(7)), 34.3 (C(9)), 22.6 
(C(6)).  
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Methyl 3-[4,4-Difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
yl]propionate[70]  
 
Pyrrole 88 (0.15 g, 1.0 mmol, 1.0 eq.) and aldehyde 90 were dissolved in 
dichloromethane (6 mL) and cooled to 0 ºC.  Phosphorous oxychloride (0.16 g, 1.10 
mmol, 1.1 eq.) was dissolved in dichloromethane (4 mL) and added to the solution.  
The black reaction mixture was allowed to warm to room temperature and stir for 16 
h.  The reaction mixture was cooled to 0 °C and boron trifluoride diethyl etherate (0.50 
mL, 4.00 mmol, 4.2 eq.) and N,N-diisopropylethylamine (0.73 mL, 3.20 mmol, 4.0 eq.) 
were added.  The reaction mixture was allowed to warm to room temperature and stir 
for 16 hours.  The reaction mixture was diluted with water (20 mL) and then filtered 
through celite and washed with dichloromethane (2 × 20 mL).  The filtrate was 
concentrated in vacuo and purified by flash column chromatography (20% ethyl 
acetate in petroleum ether) giving the title compound as a red solid (0.13 g, 0.42 
mmol, 44%).  
1H NMR (CDCl3, 400 MHz): 7.09 (1H, s, C(8)H), 6.88 (1H, d, J = 4.0 Hz, C(1)H), 6.27 
(1H, d, J = 4.0 Hz, C(2)H), 6.12 (1H, s, C(6)H), 3.71 (3H, s, C(12)H3), 3.30 (2H, t, J = 7.7 
Hz, C(10)H2), 2.79 (2H, t, J = 7.9 Hz, C(9)H2), 2.57 (3H, s, C(13/14)H3), 2.25 (3H, s, 
C(13/14)H3).  13C NMR (CDCl3, 125 MHz):173.0 (C(11)), 160.5 (ArC), 157.0 (ArC), 143.9 
(ArC), 135.2 (ArC), 133.3 (ArC), 128.0 (ArC), 123.8 (ArC), 120.4 (ArC), 116.7 (ArC), 
51.7 (C(12)), 33.3 (C(10)), 24.0 (C(9)), 15.0 (C(13/14)), 11.3 (C(13/14)). 
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3-[4,4-Difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-yl]propionic 
acid[70] 
 
BODIPY 91 (0.10 g, 0.33 mmol, 1.0 eq.) was dissolved in tetrahydrofuran (15 mL).  
Water (10 mL) and 1 M hydrochloric acid (5 mL) were added to the solution and the 
reaction mixture was allowed to stir for 48 h.  The reaction mixture was diluted with 
dichloromethane (20 mL) and the layers were separated.  The aqueous layer was 
extracted with dichloromethane (2 × 20 mL) and the combined organic layer was 
washed with brine (30 mL), dried (Na2SO4), filtered and concentrated in vacuo onto 
silica gel.  The crude mixture was purified by flash column chromatography (2 % 
methanol in dichloromethane) giving the title compound as a dark red/green oil (50 
mg, 0.16 mmol, 50%). 
1H NMR (CD3CN, 500 MHz): 7.40 (1H, s, C(8)H), 7.02 (1H, d, J = 3.8 Hz, C(1)H), 6.35 
(1H, d, J = 3.9 Hz, C(2)H), 6.25 (1H, s, C(6)H), 3.18 (2H, t, J = 7.6 Hz, C(10)H2), 2.73 
(2H, t, J = 7.5 Hz, C(9)H2), 2.53 (3H, s, C(12/13)H3), 2.28 (3H, s, C(12/13)H3).  13C NMR 
(CDCl3, 125 MHz):172.7 (C(11)), 160.3 (ArC), 156.5 (ArC), 144.8 (ArC), 134.8 (ArC), 
132.9 (ArC), 128.1 (ArCH), 124.6 (ArCH), 120.2 (ArCH), 116.0 (ArCH), 31.6 (C(10)), 
23.2 (C(9)), 13.8 (C(12/13)), 10.1 (C(12/13)). 
1H-Pyrrole-2-propanol[74] 
5
6
7
8
OH 105
43
2
NH
1  
Ester 88 (1.20 g, 7.80 mmol, 1.0 eq.) was dissolved in anhydrous diethyl ether (50 
mL), and the solution was cooled to 0 °C.  Lithium aluminium hydride (1 M solution in 
diethyl ether, 12.0 mL, 12.0 mmol, 1.5 eq.) was added dropwise and the resulting 
mixture was allowed to come to room temperature and stir for 16 h giving a thick 
yellow mixture.  The reaction mixture was quenched with 15% sodium hydroxide (aq.) 
(0.5 mL, solution to pH 10).  Water (50 mL) was added to the solution and the phases 
were separated.  The aqueous layer was washed with diethyl ether (2 × 50 mL) and 
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the combined organic layer was dried (Na2SO4), filtered and concentrated in vacuo 
giving the title compound as a colourless oil (0.81 g, 6.5 mmol, 83%).  
1H NMR (CDCl3, 500 MHz) δ: 8.26 (1H, br s, NH), 6.71-6.69 (1H, m, C(2/3/4)H), 6.17-
6.15 (1H, m, C(2/3/4)H), 5.97-5.96 (1H, m, C(2/3/4)H), 3.74 (2H, m, C(8)H2), 2.76 (2H, t, J 
= 7.4 Hz, C(6)H2), 1.91 (2H, tt, J = 7.3, 6.2 Hz, C(7)H2), 1.54 (1H, br s, OH) .  13C NMR 
(CDCl3, 125 MHz) δ: 131.8 (C(5)), 116.4 (C(2/3/4)), 108.3 (C(2/3/4)), 105.2 (C(2/3/4)), 62.3 
(C(8)), 32.2 (C(6)), 24.2 (C(7)). 
2-(3-Tosylpropyl)-1H-pyrrole 
 
Alcohol 105 (0.81 g, 6.5 mmol, 1.0 eq.) was dissolved in anhydrous dichloromethane 
(50 mL).  p-Toluenesulfonyl chloride (3.10 g, 16.2 mmol, 2.5 eq.) and triethylamine 
(6.70 mL, 48.6 mmol, 7.5 eq.) were added to the solution and the reaction mixture 
was allowed  to stir for 48 h.  Water (50 mL) was added to the reaction mixture and 
the phases were separated, the organic phase was washed with brine (50 mL), dried 
(Na2SO4), filtered and concentrated in vacuo onto silica gel.  Flash column 
chromatography was used to purify the crude mixture (0-25% EtOAc in petroleum 
ether) giving the title compound in good yield (1.38 g, 5.0 mmol, 77%). 
1H NMR (CDCl3, 500 MHz): 7.95 (1 H, br s, NH), 7.72-7.71 (2H, d, J = 8.4 Hz, 2 × 
C(10)H), 7.39-7.37 (2H, d, J = 8.4 Hz, 2 × C(11)H), 6.68-6.66 (1H, m, C(2)H), 6.12 (1H, 
apparent quartet, J = 3.0 Hz, C(3)H), 5.86 (1H, br s, C(4)H), 4.08 (2H, t, J = 5.8 Hz, 
C(8)H2), 2.71 (2H, t, J = 7.2 Hz, C(6)H2), 2.49 (3H, s, C(13)H3), 1.97 (2H, tt, J = 7.2, 6.0 
Hz, C(7)H2).13C NMR (CDCl3, 125 MHz): 144.9 (C(12)), 133.1 (C(9)), 130.3 (C(5)), 129.9 
(2 × C(11)), 127.9 (2 × C(10)), 116.6 (C(2)), 108.5 (C(4)),  105.5 (C(3)), 66.6 (C(8)), 29.3 
(C(6)), 23.4 (C(7)), 21.7 (C(13)).  HRMS (ESI) calcd for C14H17NO3S [M+]: 279.0929, 
found: 279.0930.  νmax (CDCl3)/cm-1: 3406 (m), 2960 (m), 2359 (w), 1350 (s), 1173 
(s).   
5-(3-chloropropyl)-1H-pyrrole-2-carbaldehyde 
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Dimethylformamide (1.0 mL) was cooled to 0 °C and phosphorous oxychloride(0.01 
mL, 0.08 mmol, 1.1 eq.) was added dropwise.   The reaction mixture was allowed to 
stir for 20 min.  The reaction mixture was warmed to room temperature and allowed 
to stir for a further 20 min.  The reaction mixture was cooled to 0 °C. Tosylate 106 
(20.0 mg, 0.07 mmol, 1.0 eq.) was dissolved in dimethylformamide and added to the 
reaction mixture which was heated to 50 °C for 18 h.  Water (5 mL) and ethyl acetate 
(5 mL) were added to the reaction mixture and the phases were separated.  The pH 
of the aqueous phase was increased from pH 1 to pH 14 with 15% NaOH (aq.).  The 
aqueous layer was extracted with ethyl acetate (2 × 5 mL) and the combined organic 
layer was washed with brine (5 × 5mL), dried (Na2SO4), filtered, and concentrated in 
vacuo giving the title compound as a waxy oil (8.0 mg, 4.7 mmol, 67%).   
1H NMR (CDCl3, 500 MHz) δ: 9.84 (1H, br s, (NH), 9.32 (1H, s, (C(9)H), 6.85 (1H, dd, 
J = 2.4, 3.8, (C(3)H), 6.06–6.05 (1H, m, (C(2)H), 3.49 (2H, t, J = 6.3 Hz, (C(8)H2), 2.81 
(2H, t, J = 7.4 Hz, (C(6)H2), 2.07 (2H, tt, J = 7.6, 6.4 Hz, (C(7)H2).  13C NMR (CDCl3, 
125 MHz) δ: 178.4 (C(9)), 140.9 (C(1)), 132.2 (C(4)), 122.6 (C(3)), 109.8 (C(2)), 43.8 (C(8)), 
31.7 (C(6)), 24.9 (C(7)).  HRMS (ESI) calcd for C8ClH10NO [M+]: 171.0451, found: 
171.0456.  νmax (CDCl3)/cm-1: 3253.1 (m), 1638.6 (s), 1495.9 (m), 1187.2 (m), 1042.6 
(m).  
3-Tosyl[4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-yl]propane 
 
Pyrrole 106 (0.67 g, 2.40 mmol, 1.0 eq) was dissolved in dichloromethane (20 mL).  
Aldehyde 90 (0.25 g, 2.60 mmol, 1.1 eq) was added and the solution was cooled to 0 
°C and phosphorous oxychloride (0.24 g, 2.60 mmol, 1.1 eq.) was added (light brown 
to greenish brown).  The reaction mixture was allowed to warm to room temperature 
and stir for 4 hours.  N,N-Diisopropylethylamine (1.68 mL, 9.6 mmol, 4.0 eq.) and 
boron trifluoride diethyl etherate (1.20 mL, 10.1 mmol, 4.2 eq.) were added to the 
reaction mixture which was allowed to stir for 24 h.  The reaction mixture was 
concentrated onto silica gel.  Flash column chromatography was used to purify the 
crude mixture (0-35% EtOAc in petroleum ether) giving the title compound as a dark 
red/green oil (0.70 g, 1.6 mmol, 67%). 
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1H NMR (CDCl3, 500 MHz) δ: 7.74-7.72 (2H, br d, J = 8.2 Hz, 2 × C(13)H), 7.28-7.26 
(2H, d, J = 8.0 Hz, 2 × C(14)H), 7.00 (2H, s, C(8)H), 6.79-6.78 (1H, d, J = 3.9 Hz, C(1)H), 
6.12-6.11 (1H, d, J = 4.1 Hz, C(2)H), 6.03 (1H, s, C(6)H), 4.03 (2H, t, J = 6.4 Hz, C(11)H2), 
2.89 (2H, t, J = 7.5 Hz, C(9)H2), 2.47 (3H, s, C(17)H3), 2.37 (3H, s, C(16)H3), 2.17 (3H, s, 
C(18)H3), 2.02 (2H, t, J = 7.7, 6.5 Hz, C(10)H2).  13C NMR (CDCl3, 125 MHz) δ: 160.3 
(C(7a/5)), 157.1 (C(7a/5)), 144.2 (ArC), 143.8 (ArC),  135.2 (ArC), 133.3 (ArC), 133.0 
(ArC), 129.9 (2 × C(13)), 128.1 (ArCH), 128.0 (2 × C(14)), 123.8 (ArCH), 120.4 (ArCH), 
116.8 (ArCH), 69.8 (C(11)), 28.2 (C(9/10)), 24.6 (C(9/10)), 21.6 (C(16)),14.9 (C(17)), 11.3 
(C(18)).  HRMS (ESI) calcd for BC21F2H23N2O3S [(M+Na)+]: 454.1407, found: 454.1419. 
νmax (CDCl3)/cm-1: 2962.8 (s), 2358.1 (m), 1601.9 (s), 1355.0 (m), 1188.2 (m).  
λabs,max (MeCN): 509 nm, λem,max (MeCN): 513 nm. 
2-(3-Azidopropyl)-1H-pyrrole[74] 
 
Alcohol 105 (2.10 g, 16.8 mmol, 1.0 eq.) was dissolved in dichloromethane (60 mL), 
the solution was cooled to 0 °C and triethylamine (4.60 mL, 33.6 mmol, 2.0 eq.) was 
added.  Methanesulfonyl chloride (1.56 mL, 20.2 mmol, 1.2 eq.) was added dropwise 
giving a yellow solution.  The reaction mixture was allowed to warm to room 
temperature before being washed with 1 M hydrochloric acid (50 mL), sodium 
bicarbonate (sat. aq. 50 mL), brine (50 mL), dried (Na2SO4), filtered and concentrated 
in vacuo.  The mesylate was dissolved in dimethyl formamide (60 mL) and sodium 
azide (3.30 g, 50.4 mmol, 3.0 eq.) was added.  The reaction mixture was allowed to 
stir at 70 °C for 16 hours.  The reaction mixture was cooled to room temperature and 
diluted with ethyl acetate (50 mL) and water (50 mL), the phases were separated and 
the aqueous layer was extracted with ethyl acetate (50 mL).  The combined organic 
layer was washed with brine (5 × 50 mL), dried (Na2SO4), filtered, and concentrated 
in vacuo giving the title compound as a colourless oil (1.60 g, 10.6 mmol, 63%). 
1H NMR (CDCl3, 500 MHz) δ: 8.01 (1H, br s, NH), 6.74-6.73 (1H, m, ArH), 6.23-6.21 
(1H, m, ArH), 6.03-6.02 (1H, m, ArH), 3.39 (2H, t, J = 6.6 Hz, C(8)H2), 2.77 (2H, t, J = 
7.5 Hz, C(6)H2), 1.99 (2H, app quint, (dt), J = 7.2, C(7)H2).  13C NMR (CDCl3, 125 MHz) 
δ: 130.8 (C(ArQ)), 116.6 (C(ArQ)), 108.5 (C(Ar)), 105.6 (C(Ar)), 50.7 (C(8)), 28.9 (C(6)), 24.7 
(C(7)).   
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3-Azido[4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-yl]propane[74] 
 
Method 1:  Pyrrole 111 (60 mg, 0.40 mmol, 1.0 eq.) and formylated pyrrole 90 (0.042 
g, 0.44 mmol, 1.1 eq.) were dissolved in dichloromethane (3 mL) and the solution was 
cooled to 0 °C.  Phosphorus oxychloride (0.04 mL, 0.44 mmol, 1.1 eq.) was added to 
the solution dropwise.  The solution was allowed to warm to room temperature and 
stir for 6 h before being cooled to 0 °C.  Boron trifluoride diethyl etherate (0.23 mL, 
1.8 mmol, 4.5 eq.) and N,N-diisopropylethylamine (0.31 mL, 1.8 mmol, 4.5 eq.) were 
added to the dark red solution which was allowed to warm to room temperature and 
stir for 12 h.  The mixture was diluted with water (5 mL) and dichloromethane (5 mL) 
before being filtered through celite and washed with dichloromethane (2 × 5 mL).  The 
combined organic layer was dried (Na2SO4), filtered and concentrated in vacuo.  The 
resulting solid was filtered through a bed of silica gel and washed with 20% ethyl 
acetate in 40-60 petroleum ethers (2 × 20 mL) giving the title compound as a 
red/green oil (0.067 g, 0.22 mmol, 55 %).   
Method 2:  Tosyl BODIPY 108 (77 mg, 0.18 mmol, 1.0 eq.) was dissolved in ethanol 
(5.0 mL).  Sodium azide (60 mg, 0.90 mmol, 5.0 eq.) was added and the reaction 
mixture was heated to 45 °C for 72 h.  The reaction mixture was concentrated in 
vacuo onto silica gel and the reaction mixture was purified by column chromatography 
(0-12.5% ethyl acetate in petroleum ether) giving the title compound as a red/green 
oil (45 mg, 0.15 mmol, 83%). 
1H NMR (CDCl3, 500 MHz) δ: 7.11 (1H, s, C(8)H), 6.92 (1H, d, J = 3.9 Hz, C(1)H), 6.30 
(1H, d, J= 3.9 Hz, C(2)H), 6.13 (1H, s, C(6)H), 3.41 (2H, t, J = 7.0 Hz, C(11)H2), 3.05 (2H, 
t, J = 7.4 Hz, C(9)H2), 2.57 (3H, s, CH3), 2.27 (3H, s, CH3), 2.04 (2H, app quintet, (dt), 
J = 7.8, 7.1 Hz, C(10)H2). 13C NMR (CDCl3, 125 MHz) δ: 160.3 (C(Ar)), 157.8 (C(Ar)), 
143.7 (C(Ar)), 135.1 (C(Ar)), 133.3 (C(Ar)), 128.1 (C(ArH)), 123.7 (C(ArH)), 120.4 (C(ArH)), 
116.6 (C(ArH)), 50.9 (C(11)), 28.1 (C(9)), 25.8 (C(10)), 14.9 (C(12/13)), 11.3 (C(12/13)). 
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3-[4-(pent-4-yn-1-yl)-1H-1,2,3-triazol-1-yl]-1-[4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-
diaza-s-indacene-3-yl]propane 
 
N,N-Diisopropylethylamine (0.05 mL, 0.28 mmol, 4.0 eq.) and copper (I) iodide (6 mg, 
cat.), were added to a solution of 1,6-heptadiyne (0.15 mL, 1.05 mmol, 15.0 eq.) and 
azide 109 (0.22 g, 0.07 mmol, 1.0 eq.) in tetrahydrofuran (10 mL).  The reaction 
mixture was heated to 50 °C and allowed to stir for 72 h.  The reaction mixture was 
concentrated in vacuo onto silica gel and flash column chromatography (10-50% ethyl 
acetate in petroleum ether) gave the title compound as a dark red/green oil (15 mg, 
0.04 mmol, 57%). 
1H NMR (CDCl3, 500 MHz) δ: 7.28 (1H, s, C(16)H), 7.02 (1H, s, C(8)H), 6.81 (1H, d, J 
= 3.9 Hz, C(1)H), 6.18 (1H, d, J = 4.0 Hz, C(2)H), 6.06 (1H, s, C(6)H), 4.36 (2H, t, J = 
7.2 Hz, C(11)H2), 2.95 (2H, t, J = 7.5 Hz, C(9)H2), 2.76 (2H, t, J = 7.6 Hz, C(17)H2), 2.50 
(3H, s, C(22)H3), 2.30 (2H, apparent quintet, J = 7.4 7.4 Hz, C(10)H2), 2.19 (3H, s, 
C(23)H3), 2.77 (2H, td, J = 2.7, 7.0 Hz, C(19)H2), 1.90 (1H, t, J = 2.6 Hz, C(21)H), 1.82 
(2H, apparent quintet, J = 7.2, 7.6 Hz, C(18)H2).  13C NMR (CDCl3, 125 MHz) δ: 160.5 
(C(5)), 156.9 (C(3)), 147.0 (C(15)), 144.0 (C(7a)), 135.2 (C(7)), 133.2 (C(8a)), 128.2 
(C(1)),123.8 (C(8)), 121.1 (C(16)), 120.5 (C(6)), 116.7 (C(2)), 83.9 (C(20)), 68.8 (C(21)), 49.6 
(C(11)), 29.5 (C(10)), 28.0 (C(18)), 25.7 (C(9/17)), 24.5 (C(9/17)), 17.9 (C(19)), 15.0 (C(23)), 11.3 
(C(22)).  HRMS (ESI) calcd for BC21F2H24N5Na [(M+Na)+]: m/z 417.2021, found m/z 
417.2004.  νmax (CDCl3)/cm-1: 2924 (m), 2853 (m), 2362 (m), 1604 (s), 1139 (m).  
λabs,max (MeCN): 503 nm, λem,max (MeCN): 513 nm. 
3-[4-(pent-4-yn-1-yl)-5-iodo-1H-1,2,3-triazol-1-yl]-1-[4,4-difluoro-5,7-dimethyl-4-bora-
3a,4a-diaza-s-indacene-3-yl]propane 
 
This compound was isolated as a red/green oil as a by-product in the synthesis of 
110 (43%). 
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1H NMR (CDCl3, 500 MHz) δ: 7.03 (1H, s, C(8)H), 6.83 (1H, d, J = 4.0 Hz, C(1)H), 6.25 
(1H, d, J = 4.0 Hz, C(2)H), 6.05 (1H, s, C(6)H), 4.36 (2H, dd, J = 7.6, 7.5 Hz, C(11)H2), 
2.99 (2H, t, J = 7.7 Hz, C(9)H2), 2.71 (2H, t, J = 7.6 Hz, C(17)H2), 2.50 (3H, s, C(22)H3), 
2.28 (2H, tt, J = 15.1, 7.7 Hz, C(10)H2), 2.21-2.19 (5H, m, C(19)H2 + C(23)H3), 1.91 (1H, 
t, J = 2.7 Hz, C(21)H), 1.88 (2H, tt, J = 7.3, 7.2 Hz, C(18)H2).  13C NMR (CDCl3, 125 
MHz) δ: 160.5 (C(5)), 156.8 (C(3)), 150.9 (C(15)), 144.0 (C(7a)), 135.3 (C(7)), 133.2 (C(8a)), 
130.9 (C(16)), 128.1 (C(1)), 123.8 (C(8)), 120.5 (C(6)), 116.7 (C(2)), 83.9 (C(20)), 68.9 
(C(21)), 50.2 (C(11)), 29.1 (C(10)), 27.6 (C(18)), 25.6 (C(9)), 25.1 (C(17)), 18.0 (C(19)), 15.0 
(C(23)), 11.3 (C(22)).  HRMS (ESI) calcd for BC21F2H23IN5Na [(M+Na)+]: m/z 543.0988, 
found m/z 543.0970.  νmax (CDCl3)/cm-1: 2925 (s), 2855 (m), 2360 (s), 1734 (w), 2332 
(s).   
3-[4-(1H-1,2,3-triazol-1-yl]-1-[4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene-3-yl]propane)-1H-1,2,3-triazol-1-yl]-1-[4,4-difluoro-5,7-dimethyl-4-bora-
3a,4a-diaza-s-indacene-3-yl]propane 
  
This compound was isolated as a red/green oil as a by-product in the synthesis of 
110. 
1H NMR (CDCl3, 500 MHz): 7.28 (2H, s, 2 × C(16)H), 7.02 (2H, s, 2 × C(8)H), 6.81 (2H, 
d, J = 4.0 Hz, 2 × C(1)H), 6.81 (2H, d, J = 4.0 Hz, 2 × C(2)H), 6.05 (2H, s, 2 × C(6)H), 
4.32 (4H, t, J = 7.2 Hz, 2 × C(11)H2), 2.94 (4H, t, J = 7.5 Hz, 2 × C(9)H2), 2.68 (4H, t, J 
= 7.5 Hz, 2 × C(17)H2), 2.48 (6H, s, 2 × C(19)H3), 2.29 (4H, apparent quintet, J = 7.4, 
7.4 Hz, 2 × C(10)H2), 2.18 (6H, s, 2 × C(20)H3), 1.97 (2H, apparent quintet, J = 7.6 Hz, 
C(18)H2).  13C NMR (CDCl3, 125 MHz): 160.4 (2 × C(5)), 156.9 (2 × C(3)), 147.5 (2 × 
C(15)), 144.0 (2 × C(7a)), 135.2 (2 × C(7)), 133.2 (2 × C(8a)), 128.2 (2 × C(1)), 123.8 (2 × 
C(8)), 121.1 (2 × C(16)), 120.5 (2 × C(6)), 116.7 (2 × C(2)), 49.6 (2 × C(11)), 29.5 (2 × C(10)), 
29.1 (C(18)), 25.7 (2 × C(9/17)), 24.9 (2 × C(9/17)), 14.9 (2 × C(23)), 11.3 (2 × C(22)).  HRMS 
(ESI) calcd for C35H40B2F4N10Na [M+Na]: 721.3452, found: 721.3373.  νmax 
(CDCl3)/cm-1: 2927 (s), 2360 (s), 1717 (m), 1603 (s), 1139 (m). 
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5-(3-Azidopropyl)-1H-pyrrole-2-carbaldehyde 
 
Dimethylformamide (10 mL) was cooled to 0 °C.  Phosphorous oxychloride (4.8 mL, 
50.0 mmol, 15.0 eq.) was added and the solution was allowed to stir at 0 °C for ten 
minutes before being allowed to warm to room temperature and stir for one hour.  The 
solution was cooled to 0 °C and pyrrole 111 (0.50 g, 3.33 mmol, 1.0 eq.) in dimethyl 
formamide (10 mL) was added.  The resulting reaction mixture was allowed to stir at 
40 °C for 18 hours.  Brine (100 mL) and ethyl acetate (100 mL) were added to the 
solution and the phases were separated, the aqueous phase was increased from pH 
2 to pH 11 (3 M NaOH aq.).  The aqueous phase was extracted with ethyl acetate (2 
× 50 mL) and the combined organic layer was washed with brine (5 × 100 mL).  The 
organic layer was dried (Na2SO4), filtered and concentrated onto silica gel.  Flash 
column chromatography was employed to purify to title compound (30% ethyl acetate 
in 40-60 petroleum ethers), giving the desired product as a low temperature melting 
solid (0.41 g, 2.3 mmol, 70%).  
1H NMR (CDCl3, 500 MHz): 10.20 (1H, s, NH), 9.40 (1H, s, C(6)H), 6.95-6.94 (1H, m, 
C(3)H), 6.14-6.13 (1H, m, C(4)H), 3.36 (2H, t, J = 6.6 Hz, C(7)H2), 2.83 (2H, t, J = 7.5 
Hz, C(9)H2), 1.99 (2H, dt, J =  7.7, 6.7 Hz,C(8)H2).13C NMR (CDCl3, 125 MHz) δ: 178.4 
(C(6)), 141.4 (C(2)), 132.2 (C(5)), 122.8 (C(3)), 109.8 (C(4)), 50.5 (C(7)), 28.3 (C(8)), 24.9 
(C(9)).  HRMS (ESI) calcd for C8H10N4O [M +]: m/z 178.0855, found: m/z 178.0856.  
νmax (CDCl3)/cm-1: 3233 (s), 2951 (m), 2167 (m), 2096 (s), 1635 (s).  
5-Azidopropane-3-tosylpropane-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
 
Azide 123 (0.25 g, 1.4 mmol, 1.0 eq.) and tosylate 106 (0.41 g, 1.54 mmol, 1.1 eq.) 
were dissolved in dichloromethane (20 mL) and the solution was cooled to 0 °C.  
Phosphorous oxychloride (0.14 mL, 1.54 mmol, 1.1 eq.) was added and the solution 
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was allowed to stir at room temperature for 18 h.  The reaction mixture was cooled to 
0 °C, N,N-diisopropylethylamine (1.1 mL, 6.16 mmol, 4.0 eq.) and boron trifluoride 
diethyl etherate (0.76 mL, 6.16 mmol, 4.0 eq.) were added and the resulting reaction 
mixture was allowed to warm to room temperature and stir for 18 h.  The reaction 
mixture was concentrated onto silica gel and purified by flash column chromatography 
(0-35% ethyl acetate in petroleum ether) giving the title compound as a red/green oil 
(0.37 g, 0.76 mmol, 54%). 
1H NMR (CDCl3, 500 MHz) δ: 7.73 (2H, d, J = 8.1 Hz, 2 × C(13)H), 7.26 (2H, d, J = 8.0 
Hz, 2 × C(14)H), 7.04 (1H, s, C(8)H), 6.93 (1H, d, J = 4.3 Hz, C(1/7)H), 6.89 (1H, J = 4.1 
Hz, C(1/7)H), 6.27 (1H, d, J = 4.1 Hz, C(2/6)H), 6.20 (1H, d, J = 4.1 Hz, C(2/6)H), 4.04 (2H, 
t, J = 6.3 Hz, C(11/19)H2), 3.32 (2H, t, J = 6.9 Hz, C(11/19)H2), 2.97(2H, t, J = 7.6 Hz, 
C(9/17)H2), 2.92 (2H, t, J = 7.7 Hz, C(9/17)H2), 2.38 (3H, s, C(16)H3), 2.04 (2H, tt, J = 7.8, 
6.4 Hz, C(10/18)H2), 1.95 (2H, apparent quintet, J = 7.9 Hz, C(10/18)H2).  13C NMR (CDCl3, 
125 MHz) δ: 161.3 (C(3/5)), 160.5 (C(3/5)), 144.8 (C(15)), 134.7 (C(12)), 133.0 (C(7a) + C(8a)), 
130.6 (C(2/6)), 130.5 (C(2/6)), 129.9 (2 × C(14)), 127.9 (2 × C(13)),  127.7 (C(8)), 118.5 
(C(1/7)), 118.4 (C(1/7)), 69.6 (C(11)), 50.9 (C(19)), 28.1 (C(9)), 28.0 (C(18)), 26.0 (C(17)), 24.9 
(C(10)), 21.6 (C(16)).  HRMS (ESI) calcd for BC22F2H24N5NaO3S [(M+Na)+]: m/z 
509.1589, found m/z 509.1577.  νmax (CDCl3)/cm-1: 2930 (m), 2096 (s), 1602 (s), 1256 
(s), 1116 (s).  λabs,max (MeCN): 510 nm, λem,max (MeCN): 517 nm. 
3,5-Azidopropane-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
 
This compound was isolated as a red/green oil as a by-product in the synthesis of 
118 (16%). 
1H NMR (CDCl3, 500 MHz): 7.06 (1H, s, C(8)H), 6.93 (2H, d, J = 4.1 Hz, C(1)H + C(7)H), 
6.28 (2H, d, J = 4.1 Hz, C(2)H + C(6)H), 3.33 (4H, t, J = 6.9 Hz, 2 × C(11)H2), 3.00 (4H, 
t, J = 7.8 Hz, 2 × C(9)H2), 1.97 (4H, apparent quintet, J = 7.1 Hz, 2 × C(10)H2).  13C NMR 
(CDCl3, 125 MHz): 161.2 (2 × C(ArQ)), 134.6 (2 × C(ArQ)), 130.5 (2 × C(H)), 127.7 (C(8)), 
118.3 (2 × C(H)), 50.9 (2 × C(11)), 28.0 (2 × C(10)), 26.0 (2 × C(9)).  HRMS calcd for 
BC15F2H17N8Na [(M+Na)+]: m/z 380.1566, found: m/z 380.1551.  νmax (CDCl3): 2930 
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(w), 2095 (s), 2095 (s), 1605 (s), 1252 (m), 1117 (s).  λabs,max (MeCN): 508 nm, 
λem,max (MeCN): 516 nm. 
 
3,5-Tosylpropane-4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene 
  
This compound was isolated as a red/green oil as a by-product in the synthesis of 
118 (29%). 
1H NMR (CDCl3, 500 MHz): 7.72 (4H, d, J = 8.3 Hz, 2 × C(13)H2), 7.27 (4H, d, J = 8.0 
Hz, 2 × C(14)H2), 7.03 (1H, s, C(8)H), 6.89 (2H, d, J = 4.1 Hz, 2 × C(1/2)H), 6.20 (2H, d, 
J = 4.1 Hz, 2 × C(1/2)H), 4.03 (4H, t, J = 6.4 Hz, 2 × C(11)H2), 2.99 (4H, t, J = 7.6 Hz, 2 
× C(9)H2), 2.37 (6H, s, 2 × C(16)H3), 2.02 (4H, tt, J = 7.9, 6.4 Hz, 2 × C(10)H2).  13C NMR 
(CDCl3, 125 MHz): 160.6 (C(3) + C(5)), 144.8 (2 × C(15)), 134.7 (2 × C(12)), 133.0 (C(7a) + 
C(8a)), 130.5 (C(2) + C(6)), 129.9 (4 × C(14)), 127.9 (4 × C(13)), 127.8 (C(8)), 118.6 (C(1) + 
C(7)), 69.6 (2 × C(11)), 28.0 (2 × C(9)), 24.8 (2 × C(10)), 21.6 (2 × C(16)).  HRMS (ESI) 
calcd for BC29F2H31N2NaO6S2 [(M+Na)+]: m/z 638.1613, found m/z 639.1585.  νmax 
(CDCl3)/cm-1: 2925 (m), 2357 (s), 1733 (m), 1607 (s), 1176 (m).  λabs,max (MeCN): 
509 nm, λem,max (MeCN): 518 nm. 
Bis-(1H-pyrrol-2-yl)-methanethione[72] 
 
Pyrrole (5.00 mL, 65.2 mmol, 1.0 eq.) was dissolved in toluene (150 mL) and cooled 
to 0 °C.  Thiophosgene (9.00 mL, 130.4 mmol, 2.0 eq.) was dissolved in diethyl ether 
(150 mL), added to the toluene solution and allowed to stir for 20 min.  Methanol (10% 
aq.) (150 mL) was added and the reaction mixture was allowed to stir for 45 min.  The 
reaction mixture was concentrated in vacuo onto silica gel.  Flash column 
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chromatography (5% toluene and 1% triethylamine in chloroform) gave the title 
compound as a solid (4.90 g, 27.8 mmol, 43%).  
1H NMR (CDCl3, 500 MHz) δ: 9.70 (2 × NH), 7.11-7.10 (2H, m, 2 × ArH), 6.98-6.95 
(2H, m, 2 × ArH), 6.33-6.31 (2H, m Hz, 2 × ArH).  13C NMR (CDCl3, 125 MHz) δ:  
193.2 (C(6)), 138.4 (2 × C(1)), 130.6 (2 × C(2)), 114.8 (2 × C(4/5)), 112.5 (2 × C(4/5)).  
 
8-(Methyl-thio)-BODIPY[72] 
 
Pyrrole 97 (1.09 g, 6.2 mmol, 1.0 eq.) was dissolved in dichloromethane (15 mL) 
giving a red solution.  Methyl iodide (2.3 mL) was added and the reaction mixture was 
allowed to stir at room temperature for 18 h.  Triethylamine (2.6 mL, 18.6 mmol, 3.0 
eq.) was added to the reaction mixture which was allowed to stir for 30 minutes.  
Boron trifluoride diethyl etherate (0.77 mL. 6.2 mmol, 1.0 eq.) was added to the 
reaction mixture which was allowed to stir for 30 min before being concentrated in 
vacuo.  Flash column chromatography (0-10% ethyl acetate and 5% DCM in 
petroleum ether) gave a mixture of compound and triethylamine.  H2O (20 mL) and 
DCM (20 mL) were added to the concentrate and the phases were separated.  The 
organic phase was washed with brine (20 mL), dried (Na2SO4) and filtered giving the 
title compound as a solid in low yield (0.10 g, 0.4 mmol, 6%). 
1H NMR (CDCl3) δ: 7.73 (2H, s, 2 × CH). 7.35-7.40 (2H, d, J = 4.1 Hz, 2 × CH), 6.46 
(2H, d, J = 3.7 Hz, 2 × CH), 2.85 (3H, s, C(9)H3). 13C NMR (CDCl3) δ: 153.8 (C(8)). 
141.4 (2 × CH), 133.8 (C(7a) + C(8a)), 127.6 (2 × CH), 117.8 (2 × CH), 20.5 (C(9)).  
Methyl-[1-[3-(3-methyl-butoxy)-2-nitro-phenyl]-meth-(E)-ylidene]-amine[94] 
 
Aldehyde 18 (1.71 g, 7.2 mmol, 1.0 eq.) was dissolved in heptane (40 mL) and treated 
with methylamine (40 wt. % solution in water, 1.75 mL, 20.2 mmol, 2.8 eq.). The 
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biphasic mixture was stirred vigorously at room temperature for 2 h. Heptane was 
then removed in vacuo, and remaining crude imine 162 was taken directly to the next 
reaction without purification.  
1H NMR (CDCl3, 500 MHz) δ: 8.19 (1H, d, J = 1.5 Hz, C(7)H), 7.49 (1H, d, J = 7.9 Hz, 
ArH), 7.44 (1H, t, J = 8.1 Hz, ArH), 7.10 (1H, d, J = 8.2 Hz, ArH), 4.12 (2H, t, J = 6.6 
Hz, C(9)H2), 3.54 (3H, d, J = 1.6 Hz, C(8)H3), 1.81 (1H, apparent septet, J = 6.7 Hz, 
C(11)H), 1.69 (2H, q, J = 6.7 Hz, C(10)H2), 0.95 (6H, d, J = 6.6 Hz, C(12)H3 + C(13)H3).  
13C NMR (CDCl3, 125 MHz) δ:  156.0 (C(7)), 150.3 (ArCq), 141.4 (ArCq), 130.9 
(ArCH), 128.6 (ArCq), 119.4 (ArCH), 115.1 (ArCH), 68.2 (C(9)), 48.6 (C(8)), 37.5 (C(10)), 
24.9 (C(11)), 22.4 (C(12) + C(13)).  HRMS (CI+) calcd for C13H19N2O3 [M+H+]: m/z 
251.1396, found m/z 251.1397.  
Methyl-[3-(3-methylbutoxy)-2-nitro-benzyl]-amine[94]  
 
Imine 162 (1.80 g, 7.2 mmol, 1.0 eq.) was dissolved in methanol (40 mL), sodium 
borohydride (0.40 g, 10.8 mmol, 1.5 eq.) was added in portions and the reaction 
mixture was stirred at room temperature for 3 h.  The reaction mixture was cooled to 
0 °C, slowly quenched with water (40 mL) and stirred for 20 min.  Ethyl acetate (80 
mL) was added and biphasic mixture was warmed to room temperature. The phases 
were separated and the aqueous layer was extracted with ethyl acetate (2 × 80 mL). 
The combined organic phase was dried (Na2SO4), filtered and concentrated in vacuo 
to give the title compound as an orange liquid (1.72 g, 6.8 mmol, 94%). 
1H NMR (CDCl3, 500 MHz) δ: 7.38 (1H, t, J = 8.0 Hz, ArH), 7.05 (1H, d, J = 7.1 Hz, 
ArH), 6.96 (1H, d, J = 8.3 Hz, ArH), 4.09 (2H, t, J = 6.6 Hz, C(9)H2), 3.72 (2H, s, C(7)H2), 
2.43 (3H, s, C(8)H3), 1.81 (1H, apparent septet, J = 6.8 Hz, C(11)H), 1.68 (2H, q, J = 
6.6 Hz, C(10)H2), 0.95 (6H, d, J = 6.7 Hz, C(12)H3 + C(13)H3 ).13C NMR (CDCl3, 125 MHz) 
δ: 150.4 (ArCq), 141.8 (ArCq), 133.3 (ArCq), 130.8 (ArCH), 121.2 (ArCH), 112.2 
(ArCH), 68.0 (C(9)), 51.3 (C(7)), 37.5 (C(10)), 36.1 (C(8)), 24.9 (C(11)), 22.5 (C(12) + C(13)).  
HRMS (CI+) calcd for C13H21N2O3 [M+H+]: m/z 253.1552, found m/z 253.1551.   
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Methyl-[3-(3-methyl-butoxy)-2-nitro-benzyl]-carbamic acid tert-butyl ester[94]  
 
Amine 8 (4.00 g, 15.9 mmol, 1.0 eq.) was dissolved in dichloromethane (60 mL).  
Triethylamine (4.4 mL, 31.8 mmol, 2.0 eq.) and di-tert-butyl dicarbonate (4.84 g, 22.2 
mmol, 1.4 eq.) were added to the solution which was allowed to stir at room 
temperature for 16 h.  The reaction mixture was concentrated in vacuo onto silica gel 
and purified by flash column chromatography (0-30% ethyl acetate in petroleum 
ether) giving the title compound as an oil (5.61 g, 15.9 mmol, 100%). 
1H NMR (CDCl3, 500 MHz) δ: 7.29 (1H, t, C(5)H), 6.88-6.77 (2H, m, C(4)H + C(6)H), 
4.35-4.32 (2H, m, C(7)H2), 4.00 (2H, t, J = 6.4 Hz, C(12)H2), 2.77-2.71 (3H, m, C(11)H3), 
1.71 (1H, apparent septet, J = 6.7 Hz, C(14)H), 1.58 (2H, dt, J = 6.6, 6.6 Hz, C(13)H2), 
1.42 (3.9H, br s, rotamer of 3 × C(10)H3), 1.35 (5.1H, br s, rotamer of 3 × C(10)H3), 0.86 
(6H, d, J = 6.7 Hz, C(15)H3 + C(16)H3).  13C NMR (CDCl3, 125 MHz) δ: 155.5 (C(3)), 150.4 
(C(8)), 131.6 (C(1)), 131.0 (C(5)), 119.7 (rotamer C(6)), 118.9 (rotamer C(6)), 112.3 (C(4)), 
80.3 (C(9)), 68.0 (C(12)), 48.1 (rotamer C(7)), 47.3 (rotamer C(7)), 37.5 (C(13)), 34.3 (C(11)), 
28.3 (3 × C(10)), 24.9 (C(14)), 22.6 (C(15)), 22.4 (C(16)).  HRMS (ESI) calcd for 
C18H28N2NaO5 [(M+Na)+]: m/z 375.1890, found m/z 375.1891.  νmax (CDCl3)/cm-1: 
2959.9 (m), 1696.5 (s), 1533.5 (s), 1367.6 (s).  
[2-Amino-3-(3-methyl-butoxy)-benzyl]-methyl-carbamic acid tert-butyl ester[94]  
 
Carbamate 10 (3.00 g, 8.50 mmol, 1.0 eq.) was dissolved in anhydrous methanol (30 
mL) and cooled to 0 °C.  10% Palladium on activated charcoal (0.30 g) and 
ammonium formate (5.40 g, 85.0 mmol, 10.0 eq.) were added and the reaction 
mixture was heated to 55 °C for 72 h.  The reaction mixture was filtered through celite 
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and concentrated in vacuo.  The concentrate was dissolved in ethyl acetate (30 mL) 
and washed with water (30 mL), brine (30 mL), filtered and concentrated in vacuo, 
giving the desired compound as a colourless oil (2.74 g, 8.50 mmol, 100%). 
1H NMR (CDCl3, 500 MHz): 6.78 (1H, d, J = 8.7 Hz, C(4/5/6)H), 6.68 (1H, d, J = 6.6 Hz, 
C(4/5/6)H), 6.62 (1H, br s, C(4/5/6)H), 4.69 (1.6H, br s, NH2), 4.38 (2H, s, C(7)H2), 4.20 
(0.4H, br s, NH2), 4.02 (2H, t, J = 6.7 Hz, C(12)H2), 2.77 (3H, s, C(9)H3), 1.88 (1H, m, J 
= 6.7 Hz, C(14)H), 1.73 (2H, dt, J = 6.8, 6.6 Hz, C(13)H2), 1.50 (9H, br s, 3 × C(10)H3), 
0.99 (6H, d, J = 6.7 Hz, C(15)H3 + C(16)H3). 13C NMR (CDCl3, 125 MHz): 156.5 (C(8)), 
146.5 (C(3)), 136.1 (C(2)), 123.3 (C(6)), 120.4 (C(1)), 115.8 (C(5)), 110.6 (C(4)), 79.9 (C(9)), 
66.7 (C(12)), 49.5 (C(7)), 38.2 (C(13)), 33.0 (C(11)), 28.4 (3 × C(10)), 25.2 (C(14)), 22.7 (C(15) 
+ C(16)).  HRMS (ESI) calcd for C18H30N2NaO3 [(M+Na)+]: m/z 345.2149, found m/z 
345.2132.  νmax (CDCl3)/cm-1:  3349 (m), 2951 (m), 1664 (s), 1238 (s), 1128 (s).  
(S)-Dimethyl 2-(2-((tert-butoxycarbonyl(methyl)amino)methyl)-6-
(isopentoxy)phenylamino)succinate[94] 
 
Aniline 12 (1.00 g, 3.2 mmol. 1.0 eq.) was dissolved in anhydrous dichloromethane 
(20 mL), 2,6- lutidine (1.40 mL, 12.4 mmol, 3.9 eq.) was added and the solution was 
allowed to stir at room temperature for 20 min.  Triflate (R)-20 (3.60 g, 12.4 mmol, 3.9 
eq.) was dissolved in anhydrous dichloromethane (30 mL) and was added dropwise 
to the solution.  The reaction mixture was heated to 45 ºC and stirred for 48 h.  The 
reaction mixture was quenched with water (20 mL) and the phases were separated.  
The aqueous phase was extracted with dichloromethane (2 × 20 mL), and the 
combined organic layer was then washed with copper sulfate solution (aq. sat.) (3 × 
20 mL), dried (Na2SO4), filtered and concentrated in vacuo.  The resulting mixture 
was purified by flash column chromatography (0-10% ethyl acetate in petroleum 
ether) giving the desired compound as a clear oil (1.04 g, 2.20 mmol, 71%). 
1H NMR (CDCl3, 500 MHz) δ: 6.77 (1H, br s, C(6)H), 6.70 (1H, d, J = 7.3 Hz, C(4)H), 
6.62 (1H, d, J = 8.5 Hz, C(5)H), 4.81-4.16 (4H, br m, NH + C(7)H2 + C(12)H), 3.91 (2H, t, 
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J = 6.8 Hz, C(18)H2), 3.58 (6H, s, C(14)H3 + C(17)H3), 2.77 (2H, d, J = 5.7 Hz, C(15)H2), 
2.64 (3H, br s, C(11)H3), 1.77 (1H, apparent septet, J = 6.7 Hz, C(20)H), 1.65 (2H, dt, J 
= 6.9, 6.7 Hz, C(19)H2), 1.40 (9H, s, 3 × C(10)H3), 0.90 (6H, dd, J = 6.5, 1.2, C(21)H3 + 
C(22)H3).  13C NMR (CDCl3, 125 MHz) δ:  173.4 (C(16)), 171.2 (C(13)), 156.1 (C(8)), 151.0 
(C(3)), 134.9 (C(2)), 128.2 (C(1)), 122.9 (C(6)), 121.3 (C(5)), 111.6 (C(4)), 79.9 (C(9)), 66.8 
(C(18)), 56.0 (C(12)), 52.0 (C(14/17)), 51.7 (C(14/17)), 48.8 (C(7)), 38.0 (C(15)), 37.9 (C(19)), 
33.3 (C(11)), 28.4 (3 × C(10)), 25.1 (C(20)), 22.7 (C(21/22)), 22.6 (C(21/22)). νmax (CDCl3)/cm-
1:  3329 (w), 2955 (m), 1740 (s), 1694 (s), 1674 (s).  [α]D: -2.20 (c = 1.0, CHCl3, 28.7 
ºC). 
 
(R)-dimethyl 2-(2-((tert-butoxycarbonyl(methyl)amino)methyl)-6-(3-
methylbutoxy)phenylamino)succinate[94]  
 
(R)-14 was synthesised via the method described above (86%).  [α]D: +2.72 (c = 1.0, 
CHCl3, 28.7 ºC). 
(R)-Methyl 2-(9-(3-methylbutoxy)-4-methyl-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-
diazepin-2-yl)acetate[94]  
 
Succinate (R)-14 (1.00 g, 2.10 mmol) was dissolved in dichloromethane (10 mL).  
Trifluoroacetic acid (10 mL) was added to the solution and the reaction mixture was 
allowed to stir at room temperature for 48 h.  The reaction mixture was concentrated 
in vacuo and loaded onto a strong cation exchange column with methanol (10 mL).  
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The column was washed with methanol (3 × 10 mL) and then flushed with 7 M 
ammonia in methanol.  The 7 M ammonia in methanol fractions were allowed to stand 
at room temperature for 4 h before concentration in vacuo giving the desired 
compound as a colourless oil (0.63 g, 1.90 mmol, 90%).   
1H NMR (500 MHz, CHCl3) δ: 6.63 (1H, dd, J = 7.5, 1.8 Hz, C(6)H), 6.52-6.47 (2H, m, 
C(7)H + C(8)H), 5.39 (1H, d, J = 16.3 Hz, C(5)H), 5.01-4.99 (1H, m, C(2)H), 4.35 (1H, br 
s, NH), 3.94-3.86 (2H, m, C(14)H2), 3.65 (3H, s, C(12)H3), 3.63 (1H, d, J = 17.5 Hz,  
C(5)H), 2.99 (3H, s, C(13)H3), 2.97 (1H, dd, J = 8.3, 7.5 Hz, C(10)H), 2.61 (1H, dd, J = 
15.8, 6.3 Hz, C(10)H), 1.73 (1H, apparent septet, J = 6.8 Hz, C(16)H), 1.60 (2H, dt, J = 
6.7, 6.6 Hz, C(15)H2), 0.88 (6H, d, J = 6.7 Hz, C(17)H3 + C(18)H3).  13C NMR (125 MHz, 
CDCl3) δ: 171.7 (C(7)), 169.5 (C(3)), 146.6 (C(9)), 135.0 (C(9a)), 121.3 (C(6)), 119.3 (C(5a)), 
116.8 (C(7)), 110.7 (C(8)), 66.9 (C(14)), 53.1 (C(5)), 52.0 (C(12)), 51.5 (C(2)), 38.0 (C(15)), 
36.3 (C(10)), 34.6 (C(13)), 25.2 (C(10)), 22.6 (C(17) + C(18)).  HRMS (ESI) calcd for 
C18H26N2NaO4 [M+Na+]: m/z 357.1785, found m/z 357.1794.  [α]D: 9.32 (c = 1%, 
CHCl3, 28.7 ºC). 
(R)-Methyl 2-(9-(3-methylbutoxy)-4-methyl-3-oxo-2,3,4,5-tetraydro-1H-benzo-1,4-
diazepin-2-yl)acetate[94]  
 
(S)-2 was synthesised via the method described above (88%). [α]D: -7.84 (c = 1%, 
CHCl3, 28.8 ºC). 
2-2-2-(t-Butyldiphenylsiloxy)ethoxy-ethoxy-ethanol[95] 
 
This compound was isolated as a by-product in the synthesis of 149. 
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1H NMR (CDCl3, 500 MHz) δ: 7.61-7.60 (4H, m, 4 × C(8)H), 7.35-7.28 (6H, m, 2 × 
C(10)H + 4 × C(9)H), 3.73 (2H, t, J = 5.4 Hz, CH2), 3.56-3.49 (8H, m, 4 × CH2), 2.73 
(2H, t, J = 5.5 Hz, CH2), 2.40 (1H, br s, OH), 0.97 (9H, s, 3 × CH3).  13C NMR (CDCl3, 
125 MHz) δ: 135.6 (4 × C(8)), 133.7 (2 × C(7)), 129.6 (2 × C(10)), 127.6 (4 × C(9)), 72.4 
(CH2), 70.7 (CH2), 70.5 (CH2), 70.5 (CH2), 63.4 (CH2), 49.2 (CH2), 26.8 (3 × C(12)), 
19.2 (C(11)).  
2-[2-(2-Azidoethoxy)ethoxy]ethan-1-ol[96] 
 
Triethylene glycol (1.80 mL, 13.3 mmol, 2.8 eq.) was dissolved in tetrahydrofuran (25 
mL) and cooled to 0 °C.  Methanesulfonyl chloride (0.37 mL, 4.8 mmol, 1.0 eq.) and 
triethylamine (1.38 mL, 10.0 mmol, 2.1 eq.) were added to the solution which was 
allowed to stir at 0 °C for 10 min and concentrated in vacuo.  Ethanol (25 mL) and 
sodium azide (0.62 g, 9.60 mmol, 2.0 eq.) were added to the concentrate and the 
reaction mixture was allowed to stir at 70 °C for 18 h.  The reaction mixture was 
concentrated onto silica and purified by flash column chromatography (20-80% ethyl 
acetate in petroleum ether) giving the title compound as a colourless oil (0.55 g, 3.10 
mmol, 65%).   
1H NMR (500 MHz, CDCl3) δ:  3.66-3.60 (8H, m, 4 × CH2), 3.54-3.52 (2H, m, C(6)H2), 
3.33 (2H, m, C(1)H2), 2.97 (1H, br s, OH).  13C NMR (125 MHz, CDCl3) δ: 72.5 (CH2), 
70.5 (CH2), 70.3 (CH2), 69.9 (CH2), 61.5 (C(6)), 50.6 (C(1)). 
 
2,2,2-(tert-Butyldiphenylsiloxy)ethoxy-ethoxy-ethylamine 
 
Alcohol 157 (0.55 g, 3.10 mmol, 1.0 eq.) and t-butyldiphenylsilylchloride (2.0 mL, 7.80 
mmol, 2.5 mmol) , were dissolved in dichloromethane (20 mL) and cooled to 0 °C.  
Triethylamine (3.2 mL, 23.3 mmol, 7.5 eq.) was added and the reaction mixture was 
allowed to warm to room temperature and stir for 48 h giving a red solution.  Water 
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(20 mL) and dichloromethane (20 mL) were added to the solution and the phases 
were separated.  The aqueous layer was extracted with dichloromethane (2 × 20 mL) 
and the combined organic layers were washed with brine (20 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo onto silica gel.  The mixture was filtered through 
a plug of silica and washed with 10% ethyl acetate in petroleum ether.  The resulting 
mixture was dissolved in methanol (20 mL).  Ammonium formate (2.00 g, 31 mmol, 
10.0 eq.) and 10% palladium on activated charcoal (60 mg) were added and the 
reaction mixture was allowed to stir at room temperature 16 h.  The reaction mixture 
was filtered through celite and purified by flash column chromatography (0-100% ethyl 
acetate in petroleum ether, then 5 % triethylamine in 95 % ethyl acetate followed by 
100% methanol).  The methanol fraction was concentrated in vacuo and filtered 
through cotton wool with 100% ethyl acetate (40 mL) giving the desired compound a 
colourless oil (0.66 g, 1.70 mmol, 55%). 
1H NMR (500 MHz, CHCl3) δ: 7.61-7.59 (4H, m, 4 × C(8)H), 7.37-7.28 (6H, m, 4 × C(9)H 
+ 2 × C(10)H), 3.75 (2H, t, J = 6.5 Hz, C(6)H2), 3.59-3.57 (2H, m, CH2), 3.55-3.52 (4H, 
m, 2 × CH2), 3.42 (2H, t, J = 5.2 Hz, C(2)H2), 2.78 (2H, br s, C(1)H2), 1.20 (2H, br s, 
NH2), 0.98 (9H, s, 3 × C(12)H3).  13C NMR (125 MHz, CDCl3) δ: 135.6 (4 × C(8)), 133.7 
(2 × C(7)), 129.4 (2 × C(10)), 127.6 (4 × C(9)), 73.6 (CH2), 72.5 (CH2), 70.8 (CH2), 70.4 
(CH2), 63.5 (CH2), 41.9 (C(1)), 26.8 (3 × C(12)), 19.2 (C(11)).  νmax (CDCl3)/cm-1: 2930.0 
(m), 2856.7 (m), 1589.4 (m), 1361.8 (m), 1105.2 (s). HRMS (CI+) calcd for 
C22H34NO3Si [(M+H)+] calcd: m/z 388.2308, found: m/z 388.2308. 
 
2,2,2-(tert-Butyldiphenylsilanyloxy)ethoxy-ethoxy-ethyl-[3-(3-methylbutoxy)-2-nitro-
benzyl]-amine  
 
Aldehyde 18 (0.17 g, 0.7 mmol, 1.0 eq.) and amine 149 (0.32 g, 0.8 mmol, 1.1 eq.) 
were dissolved in heptane (10 mL).  Sodium cyanoborohydride (0.07 g, 1.1 mmol, 1.5 
eq.) was added and the reaction mixture was heated to 80 °C for 18 h.  The reaction 
mixture was concentrated in vacuo onto silica and the mixture was purified by flash 
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column chromatography (100% ethyl acetate) giving the title compound as a 
colourless oil (0.30 g, 0.49 mmol, 70%). 
1H NMR (500 MHz, CDCl3) δ: 7.61-7.59 (4H, m, 4 × C(15)H), 7.36-7.28 (6H, m, 4 × 
C(16)H + 2 × C(17)H), 7.25 (1H, t, J = 7.9 Hz, C(5)H), 6.96 (1H, d, J = 7.8 Hz, C(4/6)H), 
6.82 (1H, d, J = 8.2 Hz, C(4/6)H), 3.98 (2H, t, J = 6.6Hz, CH2), 3.75 (2H, t, J = 5.1 Hz, 
CH2), 3.64 (2H, s, C(7)H2), 3.59-3.56 (4H, m, 2 × CH2), 3.50-3.48 (2H, t, J = 5.1 Hz, 
CH2), 2.68 (2H, t, J = 5.2 Hz, C(8)H2), 1.70 (1H, apparent septet, J = 6.8 Hz, C(22)H), 
1.57 (2H, q, J = 6.6 Hz, C(21)H2), 0.97 (9H, s, 3 × C(19)H3), 0.95 (6H, d, J = 6.7 Hz, 
C(23)H3 + C(24)H3).  13C NMR (125 MHz, CDCl3) δ: 150.3 (C(3)), 141.5 (C(2)), 135.6 (4 × 
C(15)), 133.7 (2 × C(14)), 133.6 (C(1)), 130.8 (C(5)), 129.6 (2 × C(17)), 127.6 (4 × C(16)), 
121.0 (C(4)), 112.1 (C(6)), 72.5 (CH2), 70.7 (CH2), 70.5 (CH2), 70.4 (CH2), 67.9 (C(20)), 
63.5 (C(13)), 49.0 (C(7)), 48.6 (C(8)), 37.6 (C(21)), 26.8 (C(19)), 24.9 (C(22)), 22.5 (C(24) + 
C(25)), 19.2 (C(18)).  HRMS calcd for C34H49N2O6Si ([M+H]+): 609.3354, found: 
609.3332.  νmax (CDCl3)/cm-1: 2930 (m), 1585 (m), 1584 (m), 1533 (s), 1112 (s).   
 
2,2,2-(tert-Butyldiphenylsilanyloxy)ethoxy-ethoxy-ethyl-3-(3-methyl-butoxy)-2-nitro-
benzyl]-carbamic acid tert-butyl ester  
 
Amine 158 (0.30 g, 0.49 mmol, 1.0 eq.) was dissolved in dichloromethane (10 mL).  
Triethylamine (0.14 mmol, 0.98 mmol, 2.0 eq.) and di-tert-butyl dicarbonate (0.43 g, 
2.0 mmol, 4.0 eq.) were added and allowed to stir at room temperature for 48 h.  The 
reaction mixture was concentrated in vacuo onto silica gel.  The mixture was purified 
by flash column chromatography (0-20% ethyl acetate in petroleum ether) giving the 
title compound as a light brown oil (0.28 g, 0.39 mmol, 80%).   
1H NMR (500 MHz, CDCl3) δ: 7.66-7.63 (4H, m, 4 × C(18)H), 7.32-7.19 (7H, m, 4 × 
C(19)H + 2 × C(20)H + ArC(4/5/6)H), 6.81-6.76 (2H, m, 2 × ArC(4/5/6)H), 4.44-4.40 (2H, m, 
C(7)H2), 3.95-3.94 (2H, m, C(23)H2), 3.72 (2H, t, J = 5.2 Hz, CH2), 3.52-3.49 (5H, m, 
contains two rotamers: 5H of several CH2), 3.43 (3H, br s, contains two rotamers: 3H 
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of several CH2), 3.33 (1H, br s, rotamer: 56% of CH2 (1H)), 3.22 (1H, br s, rotamer: 
44% of CH2 (1H)), 1.68 (1H, apparent septet, J = 6.7 Hz, C(25)H), 1.55 (2H, dt, J = 6.6, 
6.5 Hz, C(24)H2), 1.38 (4H, br s, rotamer: 44% of 3 × C(10)H3 (4H)), 1.27 (5H, br s, 
rotamer: 56% of 3 × C(10)H3 (5H)), 0.95 (9H, s, 3 × C(24)H3), 0.82 (6H, d, J = 6.6 Hz, 
C(26)H3 + C(27)H3).  13C NMR (125 MHz, CDCl3) δ: 155.7 + 155.3 (rotamers C(8)), 150.4 
+ 150.3 (rotamers C(3)), 141.+ 140.7 (rotamers C(2)), 135.6 (4 × C(18)), 133.7 (2 × C(17)), 
132.4 + 131.9 (rotamers C(1)), 131.0 + 130.8 (rotamers C(4/5/6)),  129.6 (2 × C(20)), 127.7 
(4 × C(19)), 119.8 + 119.0 (rotamers C(4/5/6)),  112.2 + 112.0 (rotamers C(4/5/6)), 80.3 + 
80.2 (rotamers C(9)), 72.5 (C(13/14/15/16)), 70.8 + 70.7 (rotamers C(12)), 70.5 + 70.4 
(rotamers C(11)), 67.9 (C(23)), 67.7 (C(13/14/15/16)), 63.5 (C(13/14/15/16)), 47.5 (C(13/14/15/16)), 
46.7 + 46.5 (rotamers C(7)), 37.5 (C(24)), 28.4 + 28.2 (rotamer 3 × C(10)), 26.9 (3 × C(22)), 
24.8 (C(25)), 22.5 (C(26) + C(27)), 19.2 (C(21)). HRMS (ESI) calcd for C29H56N2NaO8Si 
[(M+Na)+]: m/z 731.3698, found m/z 731.3669.  νmax (CDCl3): 2957 (s), 1697 (s), 1533 
(s), 1142 (s),1113 (s).  
 [2-Amino-3-(3-methyl-butoxy)-benzyl]- 2,2,2-(tert-butyldiphenylsilanyloxy)ethoxy-
ethoxy-ethyl-carbamic acid tert-butyl ester 
 
Carbamate 164 (0.18 g, 0.25 mmol, 1.0 eq.) dissolved in methanol (10 mL).  10 % 
Palladium on activated charcoal (18 mg) and NH4CO2 (0.16 g, 2.5 mmol, 10.0 eq.) 
were added to the solution which was heated to 60 °C and allowed to stir for 15 h.  
The reaction mixture was filtered through celite, washed with methanol (2 × 10 mL), 
concentrated in vacuo, giving a crude product which was taken onto.subsequent 
steps with no purification (0.11 g, 0.16mmol, 64%). 
1H NMR (500 MHz, CDCl3) δ: 7.61-7.59 (4H, m, 4 × C(18)H), 7.35-7.28 (6H, m, 4 × 
C(19)H + 2 × C(20)H), 6.64 (1H, dd, J = 8.0, 1.0 Hz, C(4/5/6)H) 6.61 (1H, d, J = 7.6 Hz, 
C(4/5/6)H), 6.48 (1H, br s, C(4/5/6)H), 4.39 (2H, s, C(7)H2), 3.91 (2H, t, J = 6.7 Hz, C(23)H2), 
3.73 (2H, t, J = 5.2 Hz, C(13/14/15/16)H2), 3.56-3.52 (4H, m, 2 × C(13/14/15/16)H2), 3.47-3.44 
(4H, m, C(12)H2 + C(13/14/15/16)H2), 3.19 (2H, br s, C(11)H2), 1.76 (1H, apparent septet, J 
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= 6.8 Hz, C(25)H), 1.62 (2H, q, J = 6.8 Hz, C(24)H2), 1.38 (9H, br s, 3 × C(10)H3), 0.97 
(9H, s, 3 × C(22)H3), 0.88 (6H, d, J = 6.6 Hz, C(26)H3 + C(27)H3).  13C NMR (125 MHz, 
CDCl3) δ: 156.2 (C(8)), 146.4 (C(3)), 136.2 (C(2)), 136.2 (4 × C(18)), 133.7 (2 × C(17)), 
129.6 (4 × C(20)), 127.7 (4 × C(19)), 123.6 (C(6)), 120.7 (C(1)), 115.9 (C(5)), 110.6 (C(4)), 
80.0 (C(9)), 72.5 (CH2), 70.8 (CH2), 70.5 (CH2), 69.6 (CH2), 66.7 (C(23)), 63.5 (CH2), 
48.1 (C(7)), 44.7 (C(11)), 38.2 (C(24)), 28.5 (C(10)), 26.8 (3 × C(22)), 25.2 (C(25)), 22.7 (C(26) 
+ C(27)), 19.2 (C(21)).  HRMS (ESI) calcd for C39H58N2NaO6Si [(M+Na)+]: m/z 701.3956, 
found m/z 701.3925.  νmax (CDCl3)/cm-1: 2957.0 (m), 2359.0 (m), 1674.3 (s), 1473.7 
(m), 1111.0 (s). 
(S)-Dimethyl 2-(2-((tert-butoxycarbonyl(2,2,2-(tert-butyldiphenylsilanyloxy)ethoxy-
ethoxy-ethyl)amino)methyl)-6-(3-methylbutoxy)phenylamino)succinate 
  
Aniline 147 was dissolved in dichloromethane (10 mL) and cooled to -78 °C, 2,6-
lutidine (0.06 mL, 0.53 mmol, 1.9 eq.) was added to the solution.  Triflate (R)-20 (80 
mg, 0.28 mmol, 1.7 eq.) was added in dichloromethane (5 mL), the reaction mixture 
was heated to 40 °C and allowed to stir for 18 h.  The reaction mixture was allowed 
to cool to room temperature and copper sulfate (aq. sat. 15 mL) was added and the 
phases were separated.  The organic phase was washed with copper sulfate (2 × 15 
mL), brine, dried (Na2SO4), filtered and concentrated in vacuo onto silica gel.  Flash 
column chromatography was used to purify the resulting mixture (0-30% ethyl acetate 
in petroleum ether) giving the title compound as a colourless oil (115 mg, 0.14 mmol, 
36%).  
1H NMR (CDCl3, 500 MHz) δ: 7.61-7.59 (4H, m, 4 × C(18)H), 7.35-7.27 (6H, m, 2 × 
C(20)H + 4 × C(19)H), 6.70-6.64 (3H, m, C(4)H + C(5)H + C(6)H), 4.81-4.69 (3H, m, C(23)H 
+ C(6)H2), 4.30-4.27 (1H, m, NH), 3.90 (2H, t, J = 6.8 Hz, C(29)H2), 3.73 (2H, t, J = 5.4 
Hz, C(16)H2), 3.61-3.45 (14H, m, C(25)H3 + C(28)H3 + C(12)H2 + C(13)H2 + C(14)H2 + C(15)H2), 
3.24-3.15 (2H, m, C(11)H2), 2.77-2.76 (2H, m, C(26)H2), 1.76 (1H, apparent septet, J = 
6.5 Hz, C(31)H), 1.68-1.65 (2H, m, C(30)H2), 1.38 (9H, s, 3 × C(10)H3), 0.97 (9H, s, 3 × 
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C(22)H3), 0.89 (6H, dd, J = 6.5, 1.3 Hz, C(32)H3 + C(33)H3).  13C NMR (CDCl3, 125 MHz) 
δ: 173.4 (C(24/27)), 171.2 (C(24/27)), 155.9 (C(8)), 150.8 (C(3)), 135.6 (4 × C(18)), 133.7 (2 
× C(17)), 129.6 (2 × C(20)), 127.6 (4 × C(19)), 122.9 (C(6)), 121.1 (C(5)), 111.7 (C(4)), 80.0 
(C(9)), 77.2 (CH2), 72.5 (CH2), 70.7 (CH2), 70.4 (CH2), 69.4 (CH2), 66.9 (CH2), 63.4 
(CH2), 56.1 (C(23)), 52.0 (C(25/28)), 51.7 (C(25/28)), 47.6 (CH2), 44.9 (CH2), 38.1 (CH2), 
28.4 (3 × C(10)), 26.8 (3 × C(22)), 25.2 (C(31)), 22.7 (C(32/33)), 22.6 (C(32/33)), 19.2 (C(21)), 
C(1) and C(2) are unresolved.  HRMS (ESI) calcd for C45H65N2NaO10Si [(M+Na)+]: m/z 
845.4379, found m/z, 845.4339.  νmax (CDCl3)/cm-1: 2954 (m), 1741 (s), 1691 (s), 1463 
(m), 1111 (s).  [α]D: +17.2 (c =1.0, CHCl3, 22.8 ºC).   
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5.3 Biology General Information 
Dulbecco’s Phosphate Buffered Saline (0.0095 M (PO4) without Ca and Mg) (PBS).  
FBS, DPBS, Trypsin-EDTA, Glutamine, DMEM from Lonza.  Corning T75 vented 
culture flasks from Fisher.  Human Dermal Fibroblasts, neonatal (HDFn) from 
Invitrogen.  Images taken with Nikon Eclipse TS100 and Euromex CMEX DC 5000. 
 
5.4 General Protocols for Splitting and Maintaining Human Fibroblast Cultures 
5.4.1 Composition of Media and Buffers 
Dulbecco’s  Modified Eagle’s Media with 1 g/L Glucose (DMEM).   
cDMEM: DMEM + Glutamine + Penicillin-Streptomycin + Fetal bovine serum  
sfDMEM:  DMEM + Glutamine + Penicillin-Streptomycin + 0.1% bovine serum 
albumin. 
 
5.4.2 Changing media: 
The media (cDMEM) and DPBS were heated to 37oC in water bath for about 15 
minutes before use.  The used media was removed from the cells. The flask was tilted 
and the cells were washed with 5 ml DPBS.  Fresh media was added to the cells (10 
mL to T75 flask, 5 ml to T25 flask).  The cells were incubated at 37 °C and the media 
was changed every two days.    
 
5.4.3 Splitting flasks of cells: 
The media was removed and the cells were washed with warmed DPBS (2 × 5 mL).  
The cells were treated with trypsin (1 mL) and incubated at 37 °C for 5 minutes.  The 
cells were removed from the base of the flask through physical perturbation and 
suspended in media (9 mL).  The cells were transferred to a universal and centrifuged  
at 800 rpm for 5 mins.  The supernatant was removed and the cells were suspended 
in media (4 mL).  An aliquot of the cell media suspension (1 mL) was added to a T75 
flask and media (9 mL) was added.  The flask was incubated at 37 °C.   
 
5.5 HDFn Scrape Wounds General Procedure 
 
Cells seeded in cDMEM (1.5 × 105 cells/mL) into 12 well plate and allowed to attach 
for 72 hours.  Media removed and cells washed with PBS (5 mL).  sfDMEM (0.25 mL) 
added to each well and cells incubated for 1 hour.  Treatment solutions (4 solutions x 
3 wells) made from appropriate stock.  Diameter scrapes made in each well with 
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sterile, yellow pipette tip (600 µM). Media removed, cells washed with PBS and 
treated with appropriate medium (0.25-0.5 mL).  Image captured of scrape in each 
well (× 100 magnification).  Cells allowed to incubate for 24 hours, solutions made 
from stock, media replaced.  Images captured at 24 hours.  Repeated for 48 and 72 
hours time periods.   
 
5.6 RNA Extraction Protocol 
Reagent Preparation:  
β-Mercaptoethanol was added to Buffer RLT giving 10 μL/1 ml. 
Buffer RPE is supplied as a concentrate, ethanol (96–100%) (4 volumes) was added 
to Buffer RPE to obtain a working solution.   
DNase I (1500 Kunitz units) was dissolved in RNase free water (550 μL).  
 
Procedure:   
The media was completely aspirated from the cell culture flask.  The cells were 
disrupted through the addition of Buffer RLT (350 μL) to the cell-culture dish.  The 
resulting lysate was collected with a rubber policeman.  The lysate was transferred 
into a microcentrifuge tube by pipette. The lysate was passed through a 0.9 mm 
diameter needle fitted to an RNase-free syringe five times. 70% Ethanol (350 μL) was 
added to the homogenized lysate, and mixed well by pipetting.  The sample was 
transferred to an RNeasy spin column in a 2 ml collection tube and centrifuged for 15 
s at ≥8000 x g (≥10,000 rpm), the flow-through was discarded.  Buffer RW1 (350 μL) 
was added to the RNeasy spin column. The column was centrifuged for 15 s at ≥8000 
x g (≥10,000 rpm) to wash the spin column membrane and the flow-through was 
discarded   
 
DNase I stock solution (10 μL) was added to Buffer RDD (70 μL) and the tube was 
gently inverted to allow solvation.  DNase I incubation mix (80 μL) was added directly 
to the RNeasy spin column membrane, and allowed to stand at room temperature for 
15 min.  Buffer RW1 (350 μL) was added to the RNeasy spin column, which was then 
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) and the flow through was discarded.  
Buffer RPE (500 μL) was added to the RNeasy spin column which was centrifuged 
for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane.  The flow-
through was discarded.  Buffer RPE (500 μL) was added to the RNeasy spin column 
which was centrifuged for 2min at ≥8000 x g (≥10,000 rpm) to wash the spin column 
177 
 
membrane.  The RNeasy spin column was placed in a new 2 ml collection tube,and 
the old collection tube was discarded with the flow-through. The RNeasy spin column 
was centrifuged at full speed for 1 min and the RNeasy spin column was placed in a 
new 1.5 ml collection tube.  RNase-free water (30–50 μL) was added directly to the 
spin column membrane and the spin column was centrifuged for 1 min at ≥8000 x g 
(≥10,000 rpm) eluting the RNA.  
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6.0 Appendices  
 
Appendix 6.1: Serum Free vs Complete DMEM Scratch Assay Results 
 
Well 1  
Wound Area 
Remaining (%) 
Well 2  
Wound Area 
Remaining (%) 
Well 3  
Wound Area 
Remaining (%) 
Time (hr) Complete Media Control 
0. 100.0 100.00 100.00 
24. 80.40 45.90 72.10 
48. 53.30 36.50 47.50 
72. 0.00 51.85 38.04 
 Complete Media + Compound 
0. 100.00 100.00 100.00 
24. 81.10 97.80 36.90 
48. 84.90 83.50 42.00 
72. 33.34 0.00 0.00 
 Serum Free Media Control 
0. 100.00 100.00 100.00 
24. 65.30 90.40 92.80 
48. 68.90 101.20 77.10 
72. 69.89 71.76 66.32 
 Serum Free Media + Compound 
0. 100.00 100.00 100.00 
24. 95.80 88.70 61.70 
48. 79.00 90.70 61.30 
72. 0.00 72.79 0.00 
  
   
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Appendix 6.2:  Determination of Optimal Dose ((S)-Methyl  IGD Peptidomimetic 
((S)-2))) 
Time (hr) Control Wound Area Remaining (%) 
0. 100 100 100 100 100 100 100 100 100 
24. 68 77 65 65 83 63 44 80 67 
48. 47 61 46 55 59   32 66 47 
72. 37 32 42 37 47   10 30 23 
 S IGD 0.1 Wound Area Remaining (%) 
0. 100 100 100 100 100 100 100 100 100 
24. 55 66 79 49 63 87 54 49 46 
48. 26 38 56 36 52 56 40 43 39 
72. 22 57 60 46 40 64 29 26 19 
 S IGD 1 Wound Area Remaining (%) 
0. 100 100 100 100 100 100 100 100 100 
24. 73 60 64 83 77 72 69 62 52 
48. 64 43 29 52 59 49 36 42 34 
72. 48 41 46 35 40 21 25 28 23 
 S IGD 10 Wound Area Remaining (%) 
0. 100 100 100 100 100 100 100 100 100 
24. 56 74 63 71 54 90 63 54 63 
48. 50 48 29 41 37 68 40 24 32 
72. 65 39 59 39 39 51 27 29 15 
  
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Appendix 6.3:  Determination of Optimal Dose ((R)-Methyl IGD Peptidomimetic 
((R)-2)) 
Time (hr) Control Wound Area Remaining (%) 
0. 100 100 100 100 100 100 100 100 100 
24. 61. 65 59 59 65 60 69 60 59 
48. 48 37 50 40 56   52 48 44 
72. 38 42 35 46 39   39 20 27 
 R IGD 0.1 Wound Area Remaining (%) 
0. 100 100 100 100 100   100 100 100 
24. 65 59 56 57 43   64 60 47 
48. 41 37 42 36 38   40 60 44 
72. 49 35 32 27 28   25 13 17 
 R IGD 1 Wound Area Remaining (%) 
0. 100 100   100   100 100 100 100 
24. 59 66   62   52 51 56 54 
48. 39 45   53   49 27 37 37 
72. 30 34   19.   33 18 23 5 
 R IGD 10 Wound Area Remaining (%) 
0. 100 100 100 100 100 100 100 100 100 
24. 71 61 68 62 67 63 59 66 56 
48. 45 44 60 37 52 54 46 44 49 
72. 36 32 44 27 45 48 25 45 24 
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Appendix 6.4:  High Resolution Magic Angle Spinning NMR of Solid Supported 
IGD Peptidomimetic. 
All high-resolution magic-angle spinning (HRMAS) NMR experiments were recorded 
at room temperature on a Bruker Avance 700 spectrometer operating at 700.26 MHz 
for 1H, using a 4 mm H-X solid-state NMR probe from Bruker. About 1-2 mg of sample 
was placed at the center of the HRMAS rotor and covered with 2-3 drops of 
deuterated CDCl3 before sealed. The sample was spun at a spinning frequency of 
10000 Hz. A 5.0 μs 90° pulse and a recycle time of 2 s were used. The 1H HRMAS 
spectrum was obtained with a spectral width of 5580 Hz and 32 scans. 
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Appendix 6.5: Absorption and Emission Spectra 
6.5.1:  Absorption and Emission Spectra for Difunctionalised BODIPYs  
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Appendix 6.5.2:  Absorption and Emission Spectra for IGD peptidomimetic BODIPYs 
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Appendix 6.5.3:  Absorption and Emission Spectra for Novel BODIPYs 
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Appendix 6.6: Genes Investigated in qRT-PCR Array 
Relevance to 
Cell Motility Genes Investigated in Human Cell Motility RT-qPCR Array 
Chemotaxis FGF2 (BFGF), ITGB2, MAPK1 (ERK2), MYH10, MYH9, PLAUR (UPAR), PLD1, PRKCA, RAC2, TGFB1, VEGFA, WASF2, WIPF1. 
Receptors EGFR (ERBB1), IGF1R, ITGA4 (CD49D), ITGB1, ITGB2, ITGB3, MET, PLAUR (UPAR), RHO. 
Growth 
Factors 
 
CSF1 (MCSF), EGF, FGF2 (BFGF), HGF, IGF1, TGFB1, VEGFA. 
Rho Family 
GTPases 
RHO Signaling: ACTR2, ACTR3, ARHGDIA, LIMK1, MSN, MYL9, MYLK, PLCG1, 
PLD1, PRKCA, PTEN, PTPN1 (PTP1B), RHO, RHOA, RHOB, RHOC, RND3, 
ROCK1, VIM. 
RAC Signaling: ACTR2, ACTR3, BAIAP2, CFL1, CRK, PAK1, PAK4, PLD1, 
PRKCA, RAC1, RAC2, STAT3, WASF1, WASF2, WASL. 
CDC42 Signaling: ACTR2, ACTR3, CDC42, PFN1, WASF1, WASF2, WASL. 
Cell 
Adhesion 
Molecules 
Cell-Cell Adhesion: DPP4, EGFR (ERBB1), EZR, ITGA4 (CD49D), ITGB1, ITGB2, 
MSN, MYH9, ROCK1, TGFB1. 
Cell-Extracellular Matrix (ECM) Adhesion: ACTN1, ACTN3, CSF1 (MCSF), ILK, 
ITGB1, ITGB2, ITGB3, MMP14, PTEN, PTK2B (PYK2), PXN, RASA1, RHOA. 
Focal Adhesions: ACTN1, ACTN3, ARHGEF7, BCAR1, CAPN1, CAPN2, CAV1, 
ENAH, ILK, ITGB1, MYL9, PTK2 (FAK), PTK2B (PYK2), PXN, TLN1, VASP, VCL. 
Leukocyte Adhesion & Rolling: EZR, ITGA4 (CD49D), ITGB1, ITGB2, MSN, 
ROCK1. 
Integrin 
Signaling BCAR1, ILK, ITGA4 (CD49D), ITGB1, ITGB2, ITGB3, MYH9, PTK2 (FAK). 
Cellular 
Projections 
Filopodia: BAIAP2, CDC42, DIAPH1, EGFR (ERBB1), ENAH, EZR, MSN, RDX, 
SVIL, VASP. 
Lamellipodia: CTTN, DPP4, EGFR (ERBB1), ENAH, FAP, PIK3CA (p110-alpha), 
PLD1, PTK2 (FAK), PXN, RDX, SVIL, VASP, VCL, WASF1, WASF2, WASL.. 
Stress Fibers: ACTN4, DIAPH1, MYH10, MYH9, RHOA, RHOB, RHOC 
Membrane Blebs: ACTN1, ACTN3, ACTN4, EZR, MYH10, MYH9, MYLK, RND3, 
ROCK1. 
Invasive Projections: ACTR2, ACTR3, ARF6, CDC42, CFL1, CTTN, DPP4, EGF, 
EZR, FAP, MMP14, MMP2, MMP9, MSN, MYH9, PLAUR (UPAR), RAC2, RASA1, 
SH3PXD2A, SRC, SVIL, TGFB1, VEGFA, WASL, WIPF1. 
Growth Cones: ARHGEF7, CDC42, CFL1, PTK2B (PYK2).. 
Membrane Ruffles: ACTR2, ACTR3, ARF6, BAIAP2, BCAR1, CTTN, DIAPH1, 
EZR, ITGB1, MYH9, RAC1, RAC2, RDX, RHOA, TLN1, WASF2 
Cell Polarity CDC42, CFL1, EZR, IGF1R, ILK, MYH9. 
Proteases & 
Protease 
Inhibitors 
AKT1, CAPN1, CAPN2, DPP4, FAP, HGF, MMP14, MMP2, MMP9, MYH9, 
PLAUR (UPAR), TIMP2. 
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